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ABSTRACT 
Mitochondrial dynamics in hematopoietic stem cells 
Mariana Justino Lage de Almeida 
 
Hematopoietic stem cells (HSCs) take on the extraordinary role of sustaining life-long 
production of blood cells. Despite their indisputable therapeutic potential, HSC biology is 
poorly understood, and the field remains limited by the inability to maintain, expand, or 
generate HSCs in vitro. The aim of this study was to elucidate a particular gap in our 
understanding of the organellar cell biology of HSCs, specifically the role and function of 
the mitochondria. Several signaling pathways and biological processes converge onto the 
mitochondria, yet these organelles were found to be largely dispensable in HSCs on the 
basis of their predominantly glycolytic metabolism and reports of low mitochondrial 
content. 
 
Our studies show that MitoTracker Green (MTG), a frequently used fluorescent dye to 
measure mitochondrial mass in hematopoietic populations, is effluxed by HSCs resulting 
in their systematic and deceptive enrichment in the subset of cells with the lowest MTG 
fluorescence. Using dye-independent methods we discovered that HSCs have elevated 
mitochondrial content despite their reliance on glycolysis for ATP production. Moreover, 
mechanisms of mitochondrial quality control and clearance by autophagy appear to be 
comparatively lower in HSCs than in any other hematopoietic population we analyzed, 
suggesting HSCs maintain their mitochondria over time.  
 
To investigate the function of mitochondria in HSCs we generated mice with disruption of 
mitofusins (MFN) 1 and 2. These proteins are key mediators of mitochondrial fusion, a 
process that in coordination with mitochondrial fission regulates mitochondrial size, 
number, and function. Mice with deletion of Mfn1 and Mfn2 (DKO) die perinatally, are pale 
in appearance and their HSCs show complete loss of regenerative capacity. Several 
processes linked to dysfunctional mitochondrial fusion and known to be tightly regulated 
in HSCs are altered in these mutants, including mitochondrial morphology, mitochondrial 
mass, proliferation, and altered metabolism. Interestingly, one allele of Mfn1 is sufficient 
to rescue the hematopoietic function and lethality of DKO mice, while one allele of Mfn2 
only rescues myeloid reconstitution. 
 
Taken together, our findings highlight the importance and complexity of mitochondrial 
function and dynamics in HSCs and have contributed to the recently increased 
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1. Introduction: Principles of hematopoiesis and hematopoietic stem cells 
 Overview  
Hematopoiesis is the process by which the cellular components of the blood are produced. 
These include highly diverse cell-types with specialized functions in innate and acquired 
immunity (leukocytes), tissue oxygenation (erythrocytes) and blood clotting 
(megakaryocytes/platelets)1. Leukocytes, or white blood cells, are a heterogenous 
population that include lymphocytes, granulocytes and monocytes. Lymphocytes (B, T and 
NK cells) belong to the lymphoid lineage of blood cells whereas the remaining leukocytes 
together with red blood cells and platelets comprise the myeloid lineage. The production 
and maturation of lymphoid and myeloid cells takes place in the bone marrow (BM), liver, 
spleen, thymus and lymph nodes collectively forming the hematopoietic system. 
 
Mature effector cells have a defined life span that is significantly shorter than the lifespan 
of the organism. Their continuous life-long replenishment relies on a rare BM population 
of self-renewing and multipotent cells – the hematopoietic stem cells (HSCs)2. These two 
properties are fundamental to the definition and function of HSCs. Self-renewal ensures 
the pool of HSCs does not exhaust over time while multipotency enables HSC 
differentiation into all mature blood cell lineages3. The roadmap of HSC differentiation is 
highly complex and is often revised by the discovery of new hematopoietic populations 
and distinct paths of differentiation4.  
 
Due to their unique properties, HSCs have widespread therapeutic application in a variety 
of malignant and non-malignant hematopoietic disorders5. Since the 1950s, when their 
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therapeutic potential was first demonstrated6, considerable research efforts have been 
made to identify the network of intrinsic and extrinsic factors that regulate this rare 
population of stem cells. Despite significant progress and promising results, the field 
remains incapable to support robust ex vivo expansion of HSCs, a limitation that has 




 Clinical application of HSCs and its challenges 
Thousands of HSCTs are performed annually to reestablish normal hematopoietic function 
in patients with primary immunodeficiencies, hemoglobinopathies, and blood 
malignancies5,7. HSCs can be isolated from BM, mobilized peripheral blood (PB), and cord 
blood (CB). The source and purification strategy of HSCs is decided on a case-by-case 
basis to minimize the development of rejection and graft versus host disease (GVHD), a 
major cause of transplant morbidity and mortality8. To reduce the risk of these conditions 
developing in patients, donor and recipient are HLA (human leukocyte antigen) -matched, 
immune effector cells are excluded from the donor sample9 and/or the patient’s immune 
system is continuously suppressed. However, there are extensive challenges associated 
with HSCT: the availability of suitable donors is limited, the exclusion of donor cells 
correlates with poorer prognosis in certain malignancies, and chronic immune suppression 
of recipients contributes to morbidity8.  
 
An attractive alternative is the use of the patient’s own HSCs, termed autologous HSCT, 
where the patient HSCs are collected and transplanted back after chemotherapy. The full 
potential of this approach resides in its combination with ex vivo genetic manipulation 
techniques. However, the clinical application of such therapy is limited by the reduced 
number of HSCs that can be obtained from human sources, the inefficient human HSC 
purification protocols and the inability to significantly expand HSCs ex vivo.  
 
Enormous effort has been put into developing an in vitro system in which HSC self-renewal 
is enhanced and differentiation is blocked, without altering HSC properties that might 
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render them unsafe. This was initially attempted by generation of immortalized cell lines, 
but their clinical use was discouraged due to abnormal and uncontrolled proliferation. The 
use of small molecules such as SR-110, UM17111, and PGE212 , and Notch ligands13 has 
been reported to increase HSC expansion ex vivo. Nevertheless, expansion methods 
remain insufficient to produce the necessary number of HSCs and are associated with 
epigenetic changes driven by DNA methylation, loss of proliferation and engraftment 
capacity compared to unexpanded HSCs from the same donor14. 
 
A more unconventional direction of therapy is to differentiate human pluripotent stem cells 
into transplantable HSCs. Although this is yet to be accomplished, promising studies have 
showed that direct reprograming of human fibroblasts15, human hematopoietic 
progenitors16 and, more recently, human endothelium10 into HSCs could be achievable 
through exogenous expression of transcription factors. In 2008 Ledran and colleagues led 
the discovery of an alternative technique to generate stem-cell derived HSCs by co-
culturing human embryonic stem cells (ESCs) with stromal cells derived from the 
hematopoietic niche17. The possibility of having an unlimited source of patient-specific 
HSCs would drastically expand the scope, potential, and safety of HSC therapy. 
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 Experimental approaches to studying HSCs 
 Immunophenotypical analysis and isolation of HSCs 
The frequency of mouse HSCs in the BM is approximately 1 in 105 nucleated cells18 and 
there are no known morphological features that can distinguish HSCs from other cells. 
Fluorescence-activated cell sorting (FACS) is the only method that can prospectively 
identify and purify putative HSCs based on the expression, or lack thereof, of cell surface 
antigens. Most purification strategies begin by excluding pan-markers of lineage-restricted 
populations of B cells (B220, CD19), T cells (CD3, CD4, CD8), erythrocytes (Ter119) and 
granulocytes/monocytes (Gr1, Mac1). In addition to being negative for lineage markers 
(Lin-), HSCs are enriched in the heterogenous population of cells expressing cKit19 and 
Sca1(LSK)20 and can be further refined by their side population profile based on efflux of 
Hoechst 3334221 or, more frequently, by the combined lack of expression of CD3422, Flt323 
and the SLAM markers CD150 and CD4824. The combined use of CD150+CD48-CD41- 
enriches murine HSCs to approximately 1 in 224. The expression profile of surface markers 
used to isolate murine HSCs should be carefully considered depending on the HSC 
developmental stage. For example, unlike adult BM HSC, FL HSCs express Mac1 and 
Flt325,26. 
 
The enrichment strategy used to isolate mouse HSCs does not translate to humans. First, 
there is no human homolog to Sca1. Second, in contrary to mouse HSCs, human HSCs 
do not express CD15027 and are positive for Flt328 and CD34. In fact, CD34 is the most 
frequently used positive marker of human stem and progenitor cells. The human CD34+ 
population is still markedly heterogenous and includes subsets with different reconstitution 
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potentials. The CD34+ subset with the known highest regenerative capacity can be purified 
by the surface marker expression profile of CD38-CD45RA-CD90+CD49F+ 29,30. Yet, HSC 
activity is found in only 1 in 10 cells of this subset29, presenting a great limitation to their 
research30. 
 
While phenotypic analysis is a convenient and fast approach to identify and isolate 
populations of interest, it does not reflect HSC function. Furthermore, it is unclear how 
mutations and aging might alter expression profiles, highlighting the importance of 
functional studies in characterizing HSCs. 
 
 In vitro assays 
In vitro assays are a cost-effective and convenient way to preliminary assess HSC and 
progenitor function. The colony forming cell (CFC) assay tests the ability of a fixed number 
of cells to form colonies in a semisolid medium supplemented with cytokines after 
approximately 14 days. The number and morphology of the colonies reflect the ability of 
the input cells to differentiate and proliferate. Since CFC assays do not test self-renewal 
capacity, more time-consuming culture assays have been developed for that purpose: the 
cobblestone area-forming cells (CAFC) assay and long-term culture initiating cell (LTC-IC) 
assay31. Both experiments are initiated by co-culturing hematopoietic cells with an 
adherent stromal cell feeder layer to provide appropriate signals for HSC survival in vitro. 
After 4 weeks, the presence of HSCs in the initial sample is tested by performing a CFC 
assay (LTC-IC assay) or monitoring the formation of cobblestone areas (CAFC assay), 
which are phase-dark areas of proliferating cells underneath the stromal cells. These 
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experiments are fast and convenient screening tools in human studies or studies that 
would otherwise require a substantial number of animals. However, their predictive value 
of HSC function is limited. 
 
 Repopulation assays 
In long-term in vivo repopulation assays the test, or donor cells, are transplanted into 
lethally irradiated hosts, or recipients. Donor and recipient express different alleles of the 
surface marker CD45 (CD45.1 only, CD45.2 only or both) which can be specifically 
recognized by antibodies. At various timepoints after transplantation PB is collected from 
the recipient mice and donor-derived cells are analyzed by FACS for their overall presence 
(chimerism) and lineage (typically myeloid, B and T cells). Classically, a population is 
considered to include LT-HSCs when multi-lineage donor cells can be found in recipient 
mice after 16 weeks32. A modification of this assay is the competitive repopulation assay 
in which the donor/test cells are transplanted together with a specific number of whole BM 
from a second mouse (competitor) into the recipient mouse33. Depending on the 
experimental design, this strategy can allow for a direct comparison between the two 
populations. In cases where donor cells exhibit impaired regenerative capacity or are 
purified HSCs, the competitor BM supplies recipients with mature blood cells to ensure 
their survival. Competitive transplantation assays were the gold standard for determining 
HSC function, but it is becoming increasingly appreciated that the long-term repopulation 
capacity of HSCs can only truly be measured via serial transplantation. This experiment 
consists of harvesting the BM from primary recipients and transplanting it into lethally 
irradiated secondary recipients and, potentially, from secondary recipients into tertiary 
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hosts. Only the most primitive HSCs will yield long-term and multi-lineage repopulation in 
tertiary recipient mice. 
 
 Single cell transplantation 
In this variation of competitive repopulation assays putative HSCs are single-cell sorted 
and transplanted with competitor BM into lethally irradiated recipients. This experimental 
approach has shown that individual HSCs can have distinct lineage contributions and has 
been essential in uncovering HSC heterogeneity (section 1.7).  
 
 Limited dilution assay 
Limited dilution assays (LDA) were developed to determine the frequency of HSCs activity 
in a test sample2. In a variation of competitive repopulation assays, donor cells are injected 
into recipient mice at a minimum of three different known doses. After 16 weeks, the 
number of recipients with no donor cells in the periphery is determined for each dose and 
fit into a Poisson distribution. For reliable predictions donor chimerism should not be 
undetectable in all the recipient mice of any given dose and the threshold for what 
constitutes a recipient with “absent donor chimerism” should follow the field standards and 
be maintained constant over independent experiments. 
 
 Mouse models to study hematopoiesis 
Mouse models have been integral to the advancement of the hematopoietic field and 
served as the most common source of HSCs in our studies. The list of mice with genetic 
deletions or mutations is exhaustive and specific mutants will be referenced to in other 
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sections when relevant. In this section we focus on the technical aspects of mouse models 
that have significantly expanded our ability to study HSC function in vivo. 
 
A major advance in the field came from the application of the Cre recombinase technology 
to spatially and temporally control the expression of a gene in mice. Crossing of Cre-mice 
with other transgenic mice containing the gene of interest flanked by LoxP sites (floxed) 
results in excision of the floxed gene segment in Cre-expressing cells.34,35. The Cre-LoxP 
system can be used to control the deletion or expression of a gene of interest by 
engineering the Loxp sites to flank a gene sequence or a stop codon inserted upstream, 
respectively. To control when or where Cre-mediated excision takes place different 
regulatory strategies are used to modulate Cre expression. The two most common 
models for timed Cre-expression in hematopoietic studies are Mx1-driven Cre 
expression36 and the Cre-ERT fusion system37, which induce and activate Cre upon 
administration of interferon and estrogen analogues, respectively. Cre-independent 
inducible systems such as the tetracycline regulatory system have been used in 
hematopoietic studies38,39, although less frequently. The use of inducible models should 
include appropriate controls to monitor spontaneous Cre activity and the possible 
confounding effects of inducer molecules. To drive constitutive and selective expression 
of Cre in the hematopoietic compartment the murine Vav1 oncogene promoter typically 
used40,41. However, Vav expression is only detectable starting at E11.542 and hence, 
different conditional mouse models are used to study earlier embryonic stages43. 
Moreover, the specificity to blood cells is not complete as Vav-Cre mice express the 
recombinase in endothelial cells, ovaries and testes44. In addition to tissue-specific drivers 
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of Cre, the use of cell-type specific regulatory elements have proved useful in studies 
investigating specific hematopoietic populations and HSC niche cells (section 1.6.2.)44.  
 
A major obstacle to assess the multilineage potential of HSCs in vivo has been the lack 
of expression of CD45 in erythrocytes and platelets. As a consequence, these abundant 
and essential blood cells are typically unaccounted for in classical repopulation assays. 
In 2013 Hamanaka and colleagues generated a CD45.1 transgenic mouse line stably 
expressing Kusabira Orange (KuO) in all hematopoietic-lineage elements including 
erythrocytes and platelets45. KuO mice are healthy and exhibit normal hematopoiesis and 
may prove extremely useful for functional in vivo studies in the future. 
  
While HSC function has been widely investigated in transplantation, less is known about 
the physiological role of HSCs in unperturbed hematopoiesis. The discovery of HSC-
specific markers and the advance in mouse genetics have allowed for the implementation 
of lineage tracing systems in mice. In recent years different inducible systems of HSC 
labeling have been developed but no consensus has yet been reached46,47,48,49 (section 
1.7.5). Nonetheless, these mouse models are beginning to shed light on fundamental 
questions in developmental immunology. 
 
Finally, engraftment of human cells will not occur in standard mouse strains due to 
immunological rejection. The development of immunodeficient murine models, incapable 
of mounting a robust immune response, has allowed human HSC research to evolve from 
in vitro assays to in vivo models, improving the ability to predict the clinical outcome of 
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HSCT. NSG mice are the most commonly used strain to test human HSC function in vivo. 
These mice were generated in a non-obese diabetic (NOD)/severe combined 
immunodeficiency (SCID) background by introducing a complete null mutation of the Il2rg 
gene50. These mutations render NSG mice severely immunocompromised and permissive 
to engraftment and hematopoietic reconstitution by human CD34+ cells. More recently, 
similar strains were generated to overcome NSG sensitivity to radiation51 and the 
misrepresentation of human-derived cell-types52, further expanding the application scope 
of humanized mice.  
 
The development and widespread adoption of these methodologies and tools have made 
HSCs the most well studied tissue stem cells. In general, research to date in the field has 
focused on understanding the cell-extrinsic and -intrinsic mechanisms that regulate HSC 
development and function.  
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 The anatomic locations of HSC development 
The original pool of HSCs is formed during embryogenesis through a process involving 
colonization of several anatomic sites throughout development and up until birth. Because 
efforts to generate HSCs in vitro have thus far proven unsuccessful, the understanding of 
the developmental path that gives rise to definitive HSCs in vivo has become an important 
area of research.  
 
Embryonic hematopoiesis begins with the specification of mesoderm to hematopoietic and 
vascular fates53, subsequently generating mesodermal precursor cells that migrate to the 
yolk sac to initiate red blood cell production (primitive hematopoiesis). The earliest report 
of blood cells is found in the yolk sac blood islands at E8.2554. At E9.5 myeloerythroid 
progenitors colonize the fetal liver (FL) via the first vascular connections, marking the 
beginning of definitive erythropoiesis. The first developing HSCs are generated at E8.5 at 
a different location, in the ventral wall of the dorsal aorta in the aorta/gonad/mesonephros 
(AGM) region55-57. These primitive HSCs (pre-HSCs) undergo a maturation process before 
they can reconstitute the hematopoietic system of an adult host. It is not until E10.5 that 
the first transplantable HSCs emerge from pre-HSCs in the AGM region, marking the 
beginning of definitive hematopoiesis55. By E11, when vasculature has developed, HSCs 
are present in all hematopoietic regions of the embryo: the yolk sac, AGM, placenta, and 
FL. After E12.5 the FL serves as the main hematopoietic organ where HSCs undergo 
expansion to supply the organism with enough HSCs for post-natal life and 
differentiation58. Beginning at E17.5 HSCs can be found in the developing bones59, which 
become the predominant site of hematopoiesis throughout life.   
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 Intrinsic regulation of HSCs 
 Cell cycle 
During fetal life, HSCs are actively cycling to provide the growing embryo with blood cells 
and to expand the HSC pool60. After birth, HSCs continue to cycle until 4 weeks of age, at 
which point approximately only 5% of BM HSCs are actively in cell cycle60. From then on, 
under physiological conditions, BM HSCs primarily reside in G0 60,61. While quiescence is 
believed to promote HSC longevity and function, entry in cell cycle is necessary for self-
renewal and differentiation. Label-retention studies have showed that the regenerative 
capacity of BM HSCs decreases with the number of times they divide62. Using a pulse 
histone 2B-green fluorescent protein label Bernitz et al identified a population of LT-HSCs 
that lose their potential by the fifth symmetric division63, highlighting the importance of tight 
regulation of HSC quiescence. Moreover, abnormal cell cycle regulation of HSCs is 
associated with degraded HSC function and hematological malignancies64. 
 
The intrinsic regulation of cell cycle in HSCs relies on the activation and inhibition of 
cyclins, the mediators of cell cycle entry and progression. The cyclin D-Cdk4/6 complex 
controls the progression of G1 and is thought to be an important determinant of HSC cell 
cycle activity, since HSCs are mostly found in G0. Indeed, several proteins from the INK4 
family of antagonists of the cyclin D-Cdk4/6 complex can modulate HSC proliferation. 
Increased expression levels of the antagonists p16 and p19 completely inhibited HSC 
entry in cell cycle preventing their self-renewal and system homeostasis65. On the other 
hand, expression of the G1-phase inhibitor p18 was necessary to restrict HSC entry in cell 
cycle66. Inhibition of the cyclin E-Cdk2 complex, which regulates S phase progression, by 
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the antagonist p57 has also been shown to impact HSC quiescence67. These data show 
that expression of these antagonists in HSCs is properly balanced to regulate their 
quiescence and proliferation64.  
 
 Cell division 
Cell division is strongly associated with determination of cell fate in HSCs: symmetric 
divisions results in two HSCs (self-renewal) whereas asymmetric divisions generate one 
daughter cell that begins differentiating and loses self-renewal capacity (differentiation) 
68. The properties of the daughter cells are determined by the unequal distribution and 
inheritance of cell fate determinants, such as the regulator of the Notch signaling pathway, 
Numb69. Notch signaling, along with other pathways (section 1.6.1.), can tip the balance 
between self-renewal and differentiation in HSCs3,70, indicating unequal distribution of 
modulators of key HSCs regulatory pathways amongst daughter cells may be a 
mechanism by which cell fate is determined during cell division.  
 
The possible mechanisms of asymmetric division remain unclear71. In 2014 Zimdahl and 
colleagues discovered that the dynein binding protein LIS1 determines the proper 
orientation of the mitotic spindle to promote asymmetric segregation of cellular 
components69. Lis1-/-HSCs exhibited defects in the spindle position and altered 
segregation of factors like Numb in the daughter cells. As a result of limited self-renewal, 
the pool of Lis1-/-HSCs was depleted and mice were bloodless, indicating the orientation 
of the cell division plane can determine self-renewal.  
15 
 
Dysregulation of the balance between self-renewal and differentiation division is thought 
to drive the hematopoietic abnormalities observed in various in vivo models as well as in 
human leukemogenesis72.  
 
 Regulation of gene expression by transcription factors 
HSC fate decisions are associated with changes in gene expression controlled by a 
network of transcription factors (TFs)73. Discovering the TFs that drive the HSC 
transcription program is of great interest as combinatorial expression of these proteins 
may allow for the generation of de novo HSCs74. The list of TFs which have been linked 
to HSC cell fate is extensive and therefore only a few are discussed in this section. 
 
HSC specification is dependent on ETV2 for the formation of the hemangioblast from 
mesoderm75 and SCL for commitment to hemogenic endothelium76. Subsequent lineage 
specification to definitive HSCs is largely driven by RUNX177 and repressed by HOXA378. 
The expression of SOX17 in definitive fetal HSCs appears to drive the process of HSC 
expansion during embryonic development. SOX17 expression is exclusive to fetal and 
neonatal HSCs and its loss correlates with a decrease in cycling, impaired reconstitution 
ability and the acquisition of the surface marker profile of adult HSCs79.  
 
Transcription regulation plays a major role in HSC homeostasis for the lifetime of an 
organism. In addition to its role in HSC ontogeny, SCL is highly expressed in HSCs and 
regulates quiescence by inhibiting progression into G180. SCL can form multifactor 
complexes with other TFs like GATA2 which, among other roles, inhibits cell cycle entry 
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of murine and human HSCs81,82. Hox genes are another important set of TFs involved in 
HSC maintenance83 and are preferentially expressed in HSCs and progenitors84. 
Overexpression of several Hox genes expands HSCs ex vivo, in particular HOXB4 which 
induces symmetric self-renewal divisions that results in a 1000-fold expansion of mouse 
HSCs85.  
 
Our lab has contributed to the discovery of PRDM16, deletion of which is linked to an 
increase in apoptosis, cell cycle, HSC depletion and loss of regenerative capacity in FL 
and BM HSCs86,87,88,89. Regulation of HSCs by PRDM16 is in part mediated by induction 
of mitofusin 2 (Mfn2) expression which is necessary to maintain HSCs with extensive 
lymphoid potential (section 5.1.4.). Abnormal expression and mutations in PRDM1690-92 
and other key HSCs TFs such as EVI193 and PU.194 are closely associated with 
leukemogenesis.  
 
 Regulation of gene expression by epigenetics 
Epigenetic modifications regulate transcription by altering DNA accessibility and chromatin 
structure. Several DNA and histone modifications have been shown to modulate essential 
cellular functions of HSCs. The DNA methyltransferases DNMT3a95, DNMT3b96 and 
DNMT197 as well as the methylcytosine dioxygenase TET298 regulate HSC self-renewal. 
 
The lysine acetyltransferases CBP99, p300100 and MOZ101 and the lysine 
methyltransferases MLL1102 are essential histone modifiers for HSC self-renewal. MLL1 
induces expression of the transcription factors EVI1 and PRDM16103. Two repressive 
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complexes PCR1 and PCR2 with histone ubiquitin ligase and methyltransferase activity, 
respectively, repress cell cycle activation by silencing cyclin antagonists such as p16, and 
are essential to maintain HSCs104,105. 
 
The role for epigenetics in regulating HSC maintenance is further supported by the 
detection of epigenetic alterations in hematological disease106,107. Mutations in DNMT3a 
and TET2 have been reported to predispose HSCs to malignant transformation (pre-
leukemic stem cells) in humans108 and mouse models98,109. Mutant HSCs display abnormal 
expansion and can become fully transformed with the acquisition of additional driver 
mutations. Therefore, dysregulation of HSC epigenetics can have an initiating role in the 
development of malignancy.  
 
In summary, whereas self-renewal and multilineage potential are the unique properties 
that place HSCs at the apex of the hematopoietic hierarchy, their tight regulation is 
necessary for an equilibrium between exhaustion and malignant expansion. In addition to 
cell-intrinsic mechanisms, HSC quiescence, self-renewal and differentiation are regulated 







 Extrinsic regulation of HSCs: the hematopoietic niche 
 Growth factors and signaling pathways  
Several external factors have been shown to promote HSC maintenance and self-renewal 
in vivo and ex-vivo by modulation of the intrinsic regulatory mechanisms previously 
described. Depending on the developmental stage a growth factor may be essential or 
dispensable for normal HSC function. The best studied are the stem cell factor (SCF), the 
CXCL12/SDF1, thrombopoietin (TPO) and angiopoietin-1 (Ang-1) for which HSCs 
express receptors (KIT, CXCR4, MPL and TIE2, respectively). Genetic ablation of these 
cytokines or their receptors results in abnormal adult HSC function110,111. In addition, 
specific molecules from the conserved signaling pathways Bmp, Notch, Wnt, Hedgehog 
and Vegf are required for HSC specification during development112. These pathways have 
been shown to act upstream of key regulators of HSC ontogeny such as ETV2113 and 
RUNX1114 to establish HSC fate. In addition, HSC entry in cell cycle can be induced by 
extrinsic factors produced during infection or injury to promote rapid replenishment of 
blood cells. These include interferon (IFN)α115, IFNγ116 and tumor necrosis factor 
(TNF)α117. Despite the identification of these extrinsic factors, their individual or combined 
use has not yet led to the expansion or generation of engraftable HSCs. 
 
 Cellular components 
Label of HSCs in stained BM sections revealed the majority of HSCs are in close 
association with the vascular endothelium24,47,118-122. The cellular components of the HSC 
niche have been largely identified by inducing cell-type specific Cre-mediated excision of 
molecules known to be required for HSC maintenance in vivo but not produced by HSCs. 
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Specific deletion of Scf and Cxcl12 in a variety of cell-types revealed perivascular stromal 
cells (marked by Leptin receptor, Nestin-GFP, or Prx1), and endothelial cells (marked by 
TIE2) were the main physiological source of these molecules in the adult HSC niche123-
126. In addition, immune cell types have been identified as extrinsic regulators of HSCs 
including BM macrophages, which promote retention in the niche127 and regulatory T cells, 
which generate an immune privileged site128. Interestingly, the sympathetic nervous 
system promotes HSC retention by inducing CXCL12 production in stromal cells129,130,131. 
More recently, it was discovered that the physiological source of TPO in the HSC niche is 
generated in the liver132. These findings demonstrate that the origin of key niche elements 
can expand beyond the cell types in physical proximity to HSCs.  
  
Similarities between the adult and embryonic HSC environments include the interaction 
with the surrounding perivascular niche133 and possibly the reliance on stromal cells. Fetal 
HSCs can be transiently maintained when co-cultured with stromal cell lines derived from 
AGM. In addition, studies indicate hepatic progenitors134 and perivascular stromal cells135 
may be a source of important factors for HSC maintenance in the FL. It has been proposed 
that a FL population of cells positive for CD3 help support HSCs through insulin-like growth 
factor 2 (IGF2)- and angiopoietin-like protein-dependent mechanisms136. Despite 
overwhelming interest in better understating the embryonic niche that supports HSC 






 Hypoxia  
The complexity of the HSC niche is likely not limited to its cell types and the cytokine 
microenvironment. Several lines of evidence indicate that oxygen levels in the BM can 
influence HSC homeostasis. First, progenitor and stem cells are better maintained in 
hypoxic conditions in vitro137. Second, staining with hypoxic markers such as pimonidazole 
indicates that the regions of BM with lower oxygen tension are enriched in quiescent and 
functionally superior HSCs138. These findings were further supported by direct 
measurement of oxygen concentration in live animals that found the peri-sinusoidal region 
of the BM to be the most hypoxic region139. Third, the idea of a hypoxic niche is consistent 
with the observation that quiescent HSCs are sensitive to an increase in levels of reactive 
oxygen species140 and are predominantly glycolytic, a metabolic state promoted in hypoxic 
conditions. 
 
However, a direct role for hypoxia as an extrinsic factor of stemness regulation remains a 
topic of debate141. The measurements of low oxygen tension obtained by high resolution 
microscopy correlated with cellularity and may simply reflect oxygen consumption139. 
Moreover, HSCs stained more intensely for pimonidazole regardless of their location120, 
indicating the use of oxygen probes may reflect the cellular metabolic status rather than 
oxygen levels of the surrounding niche142. Finally, genetic evidence indicates that the 
glycolytic metabolism of HSCs may be hardwired rather than hypoxia-driven142. Deletion 
of hypoxia-inducible factors (HIFs), TFs that are activated in hypoxic cells and drive 
specific transcriptional programs only caused a subtle loss of HSC function and minimal 
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changes in expression of glycolytic enzymes143-145. Future studies will be needed to 





 The hematopoietic hierarchy and HSC heterogeneity 
Defining the differentiation roadmap of stem cells, progenitors and mature cells has been 
a fundamental goal of the hematopoietic field for decades. It is anticipated that 
understanding the relationship between different hematopoietic populations will guide 
investigators into the molecular mechanisms that drive differentiation. The early model of 
the hematopoietic hierarchy assumed HSCs were a homogenous population that 
differentiated into progenitors and mature cells in a strict, step-wise manner. However, this 
traditional model has been significantly revised by advances in single-cell resolution 
techniques and genetic barcoding, which unveiled a previously unknown heterogeneity 
and plasticity of hematopoietic differentiation. In the next sections we review the premises 
of the past model in the light of recent findings. 
 
 Classical model of hematopoiesis 
In the classical hierarchy model (Fig. 1), the HSC population gives rise to a population with 
multilineage potential but reduced self-renewal capacity, the multipotent progenitors 
(MPPs), which subsequently generates a segregation of lymphoid and myeloid lineages 
by giving rise to common lymphoid (CLPs) and myeloid progenitors (CMPs). Next, CLPs 
produce lymphocytes while CMPs further differentiate into megakaryocyte/erythrocyte 








 Identification of new hematopoietic populations 
In the last decade it became apparent that the identification of the top hierarchical 
populations based on expression of surface markers included functionally distinct cell-
types. Long-term in vivo functional assays identified HSCs with distinct self-renewal 
capacity which were classified as long-term (LT), intermediate-term (IT) and short-term 
(ST) HSCs24,146,147. Similarly, functional and lineage tracing assays revealed great 
heterogeneity in the MPP population in regard to immunophenotype, cell cycle status and 
multilineage potential. Based on these parameters MPPs have been resolved into the 
lymphoid-primed MPPs148, MPP1, MPP2, MPP3 and MPP4149,150. 
 
Figure 1. Classical model of hematopoiesis. HSCs sit at the top of the hematopoietic hierarchy due to 
their multilineage potential and self-renewal capacity. HSCs give rise to the MPPs which further differentiate 
in CMPs and CLPs to generate a lymphoid/myeloid lineage segregation. CMPs give rise to MEPs and 
GMPs to generate myeloid cells while CLPs produce lymphocytes. HSC: hematopoietic stem cell, MPP: 
multipotential progenitor, CMP: common myeloid progenitor, MEP: megakaryocyte/erythrocyte progenitor, 
GMP: granulocyte/macrophage progenitor, CLP: common lymphoid progenitor, NK: natural killer cell, B: B 
lymphocytes and T: T lymphocytes. 
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 Lineage specification at the HSC stage 
Independent studies and experimental approaches have shown megakaryocytes and 
platelets can be generated directly from HSCs, bypassing three successive progenitor 
differentiation steps (MPPs, CMPs, MEPs)30,49,151. These studies directly contradicted the 
step-wise model of the classical hematopoietic hierarchy. 
 
 Lineage-biased differentiation of HSCs 
Traditionally, HSCs were thought to be a homogenous population of stem cells that 
generated the different hematopoietic lineages through unbiased, or balanced, multi-
lineage differentiation. Studies of HSC heterogeneity based on expression of different 
proteins revealed different subsets of HSCs exhibited different lineage potentials152-155. 
Based on these observations nomenclature systems were created to classify HSCs 
according to their potential. HSCs that generate similar numbers of myeloid and lymphoid 
cells are referred to as “balanced” or β-HSCs, while HSCs with biased lineage output are 
termed “myeloid-biased” (or α-HSCs), “lymphoid-biased” (or γ/δ-HSCs), and “platelet-
biased” HSCs155. Based on the expression of CD150 it is possible to enrich for HSCs with 
extensive lymphoid potential (CD150Low HSCs) and myeloid-dominant HSCs (CD150High 
HSCs)153,156. However, it was not until single-cell in vivo assays and labeling experiments 
were performed that it was definitively shown that individual HSCs were heterogenous in 
their lineage output. Perhaps the most striking example of the lineage-restricted cell fate 
is a class of HSCs that will efficiently replenish hosts with megakaryocytes and platelets 
but no other lineages151. Different factors, such as the niche, epigenetics, and organelles, 
have been proposed to play a role in HSC heterogeneity and bias HSC lineage output157. 
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Our lab has identified a mitochondrial protein (Mitofusin 2) that is necessary for 
maintenance of CD150LowHSCs but not CD150High HSCs89. Interestingly, recent findings 
indicate HSC lineage bias may be predetermined when HSCs first emerge in the dorsal 
aorta of the AGM158. 
 
 HSCs contribution in unperturbed and stressed hematopoiesis 
Based on transplantation data, HSCs were thought to be the major source of blood cells 
in mammalian organisms. However, less was known about the physiological role of HSCs 
in steady-state hematopoiesis. In recent years different inducible systems of HSC labeling 
have been developed to address this question but the results obtained from monitoring 
label progression have not reached a consensus. Induction of genetic labeling of HSCs 
have reached different conclusions depending on the HSC marker used46,47. Studies 
employing an inducible transposon tagging approach indicated that steady-state 
hematopoiesis is predominantly sustained by progenitors, rather than by HSCs48,49. These 
findings indicate the weight given to HSCs in the classical hematopoietic hierarchy might 
not accurately represent the course of native hematopoiesis and it remains an outstanding 
question. Nevertheless, it is widely established that HSCs are the only cells in the 





HSC function and development are regulated by a highly complex and cooperative 
network of intrinsic and extrinsic mechanisms. Numerous proteins, pathways, cells and 
environmental cues have been shown to participate in this network, but to date no single 
factor or set of factors has supported significant maintenance, expansion, or development 
of HSCs ex vivo or in vitro. This shortcoming has proved cumbersome for the 
advancement of HSC-based therapy and warrants additional research. While considerable 
effort has been made to identify the individual elements that regulate HSCs, less is known 
about the biological processes that govern these cells. Our studies aimed to elucidate a 




2. Introduction: Mitochondria and cellular health  
 Overview 
Mitochondria are ubiquitous, semi-autonomous organelles that originated from an ancient 
α-proteobacterium approximately 2 billion years ago159. Reminiscent of their ancestors, 
mitochondria have maintained a double membrane structure and part of their own 
genome160. They are present in the cytosol of all nucleated eukaryotic cells and have long 
been considered the cell’s powerhouse given their central role in ATP synthesis. 
 
While originally relegated to its role in energy production, today it has been established 
that mitochondria can impact virtually any cellular process. These organelles house 
enzymes involved in the biosynthesis of several macromolecules including lipids, 
nucleotides and iron-sulfur clusters while also facilitating the degradation of other 
molecules by fatty acid β-oxidation and the Krebs cycle161. Beyond metabolism, 
mitochondria integrate pathways of diverse biological processes such as cell death, 
calcium homeostasis, inflammation and gene expression161. 
 
Mitochondria are remarkably heterogenous, with cell-specific morphology and dynamics 
that allow them to fulfill specialized functions to maintain cellular homeostasis and 
coordinate cellular adaptation to stressful conditions. Consistent with a multifunctional role, 
mitochondrial dysfunction has emerged as a key factor in various pathological conditions 
including metabolic diseases, cancer metabolism and neurodegeneration162.  
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 Mitochondrial architecture 
 Mitochondrial DNA 
Unlike other organelles, mitochondria harbor their own DNA (mtDNA) which is a double 
stranded circular molecule of approximately 16.5Kb in most multicellular organisms163. 
mtDNA does not have introns and, with the exception of the non-coding regulatory 
fragment (D-loop), it is entirely transcribed from both strands163. The mitochondrial 
genome contains 37 genes encoding 13 proteins of the electron transport chain (ETC), 
two ribosomal RNAs 12S and 16S and 22 transfer RNAs. The remaining mitochondrial 
proteins are nuclear-encoded and imported to mitochondria164. These include the mtDNA 
replication, transcription and translation machinery including mitochondrial polymerases 
and helicases. Hundreds to thousands of mtDNA are present in a single cell, an amount 
that is predicted to significantly exceed the ETC protein requirements. 
 
Unlike nDNA, mtDNA is not associated with histones, it is instead compacted into a DNA-
protein structure termed nucleoid. The mtDNA-binding protein transcription factor A 
(TFAM) is the major component and initiator of mtDNA packaging. TFAM was initially 
identified as a mtDNA transcription factor but it has become clear that its ability to bend, 
wrap and unwind DNA is crucial to package mtDNA165,166. In addition to TFAM, the 
mitochondrial nucleoid is composed of a set of DNA-binding proteins involved in mtDNA 
replication and transcription, as well as components of signaling pathways that control 




mtDNA mutations have been linked to various diseases (section 2.5.4)169 and have been 
reported to occur more frequently than in nDNA170. Potential explanations for this 
phenomenon have implicated exposure to ROS generated from the ETC, replication-
associated DNA lesions, and less diverse and efficient DNA repair systems (base excision 
repair and microhomology end joining pathways)171,172. However, recent studies have 
detected enzymes in the mitochondria that are involved in more sophisticated DNA-repair 
systems such as homologous recombination and non-homologous end joining, indicating 
mtDNA repair mechanisms might be more complex than previously thought171. 
 
 Mitochondrial membranes and structure 
Mitochondria are separated from the cytoplasm by the outer mitochondrial membrane 
(OMM) which is porous and permeable to ions and small uncharged molecules through a 
large number of porins, referred to as VDACs (voltage-dependent anion channels). Larger 
molecules are imported by mitochondrial translocases. Other major components of the 
OMM include the import complexes of proteins and lipids, components of the apoptotic 
pathway and components of the mitochondrial fission and fusion machinery (section 2.4) 
164,173. 
 
Between the OMM and the inner mitochondrial membrane (IMM) there is an approximate 
20nM of intermembrane space (IMS)174. This compartment has been implicated in 
coordinating mitochondrial function with extracellular processes including exchange of 
molecules with the cytosol and initiation of apoptotic cascades175. 
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The IMM separates the intermembrane space from the matrix and forms invaginations that 
extend into the matrix to form regions termed cristae. In contrast to the OMM, IMM is a 
tight barrier to ions and molecules, the vast majority of which are transported across by 
specific transporters. As a result, while there is no membrane potential across the OMM, 
the IMM has an electrochemical potential of about 180mV and is the site where oxidative 
phosphorylation takes place176,177. Interestingly, the protein composition of IMM varies in 
the boundary regions compared to the cristae. Whereas transport protein complexes are 
enriched in the boundary membrane, the oxidative phosphorylation complexes 
preferentially localize to the cristae177. 
 
The matrix is the innermost compartment of mitochondria and is the region where DNA 
replication, transcription, protein biosynthesis and several other enzymatic reactions take 
place. The pH is higher in the matrix (≈7.9) compared to the inter membrane space (≈6.9) 
and this pH gradient drives ATP synthesis via the ETC178.  
 
 Mitochondrial translocases 
The mitochondrial genome encodes only approximately 1% of the total mitochondrial 
proteome179. mRNAs in the mitochondria are translated by mitochondrial ribosomes in the 
matrix while the remaining proteins are encoded by nuclear genes and synthesized as 
precursors on cytosolic ribosomes180. The nuclear-encoded mitochondrial proteins 
possess targeting signals that direct them to the mitochondria where appropriate protein 
complexes recognize and import them179. 
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Proteins containing a cleavable mitochondrial targeting sequence (MTS) at the amino-
terminal are transported via the classical route of mitochondrial protein import. Briefly, 
through protein-protein interactions involving the MTS, unfolded pre-proteins are 
translocated through a channel composed by proteins of the OMM translocase (TOM 
complex) and directed to the inner membrane translocase (TIM23 complex)164. The matrix 
heat shock protein Hsp70 is thought to bind the proteins upon exit from the TIM23 channel 
and pull them into the matrix179. Following translocation, pre-proteins can take a variety of 
routes depending on their final location164 but in most cases they are processed by a 
peptidase (MPP) that cleaves the MTS and are subsequently folded into their native 
conformation by chaperones179. Proteins containing an internal mitochondrial targeting 
sequence are bound by cytosolic chaperones to prevent cytosolic aggregation and are 
directed to the TOM complex. All OMM, most IMM and several IMS proteins follow this 





 Mitochondrial functions  
 ATP synthesis 
ATP is produced by two main pathways: glycolysis in the cytosol and oxidative 
phosphorylation in the mitochondria. Oxidative phosphorylation generates ATP through a 
cascade of redox reactions organized in large protein complexes embedded in the IMM, 
collectively known as the ETC composed of: Complex I (NADH:ubiquinone 
oxidoreductase), complex II (succinate dehydrogenase) complex III 
(ubiquinone:cytochrome c oxidoreductase), complex IV (cytochrome c oxidase), and 
complex V (ATP synthase). In addition, two electron carriers mediate electron transfer to 
Complex III and Complex IV – the membrane integrated ubiquinone and the soluble 
cytochrome c, respectively181. 
 
Oxidative phosphorylation is initiated when NADH and FADH2, as produced from the 
oxidation of organic fuels in the mitochondrial matrix, donate electrons to Complex I and 
Complex II, respectively. Electrons are then transported through Complex III and to 
Complex IV where oxygen serves as the final electron acceptor. The transport of electrons 
allows complexes I, III and IV to pump protons from the matrix to the IMS generating an 
electrochemical proton gradient across the IMM. Ultimately, this creates a proton drive 
force used by Complex V to phosphorylate ADP and produce ATP181. 
 
 Production of reactive oxygen species 
Oxygen-derived free radicals are collectively referred to as reactive oxygen species (ROS) 
and include superoxide anion radicals (●O2-), hydroxyl radicals (HO●) and hydrogen 
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peroxide (H2O2)182. Production of ROS begins with reduction of molecular oxygen by a 
single electron to generate ●O2-. Mitochondria are the major intracellular source of ROS 
because the vast majority of electrons escape from mitochondrial redox carriers, in 
particular from complex I and complex III of the ETC183. The most potent ROS is thought 
to be HO●184 and can be generated through 1) conversion of ●O2- into H2O2 
(spontaneously or via the mitochondrial superoxide dismutases) and subsequent 
conversion to HO● via the Fe2+-dependent Fenton reaction or 2) interaction of H2O2 and 
●O2- via the Haber-Weiss mechanism185.  
 
The level of mitochondrial ROS is influenced by environmental factors such as hypoxia, 
nutrient availability, and local cytokines milieu as well as by changes in mitochondrial 
membrane potential186. ROS can cause oxidative damage by reacting with residues in 
DNA, proteins and lipids, thereby impacting cellular function. Several ROS clearance 
mechanisms have been described in the mitochondria including conversion of ●O2- to 
H2O2 by superoxide dismutase and further enzymatic degradation to water187. Beyond 
toxicity, ROS also participate in cell signaling and have been shown to be important 
chemical messengers in activating transcription factors such as NF-kB188 to promote a 
stress response and HIF-1α189 to promote adaptation to a hypoxic niche.  
 
 Lipid metabolism and the Krebs cycle 
Although most lipid synthesis occurs in the endoplasmic reticulum (ER), mitochondria play 
an essential role in the biosynthesis of important lipids such as the unique mitochondrial 
membrane phospholipid cardiolipin and the membrane lipid ubiquinone, an essential 
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electron carrier in the ETC190. In addition to their biosynthetic role, mitochondria are the 
site of fatty acid β-oxidation, a degradation process that generates acetyl-CoA and the 
reducing equivalents NADH and FADH2 which are subsequently integrated in the Krebs 
cycle and the ETC, respectively164. The Krebs cycle, also known as tricarboxylic acid 
(TCA) cycle, occurs entirely in the mitochondria wherein via a series of enzymatic 
reactions the acetyl group of acetyl-CoA is oxidized to two molecules of CO2 and reducing 
equivalents of NADH and FADH2191. Acetyl-CoA can be produced not only from fatty-acid 
β-oxidation but also from degradation of glucose and amino acids, making the Krebs cycle 
the converging point of other metabolic pathways191. In addition, several biosynthetic 
precursors of other pathways are generated in the Krebs cycle including succinyl-CoA 
(heme synthesis) and α-ketoglutarate (glutamate synthesis)164.  
 
 Iron-sulfur clusters 
Iron-sulfur (Fe-S) clusters are common cofactors necessary for the function of 
mitochondrial, cytosolic and nuclear proteins involved in essential biological processes 
such as DNA replication, DNA repair, Krebs cycle and ETC. The biogenesis of Fe-S 
clusters is a multistep and complex process involving highly conserved enzymes192 that 
was previously thought to reside exclusively in the mitochondria. However, several 
enzymes involved in Fe-S biosynthesis have been found in the cytosol and nucleus192. 
 
 Immunity 
Components of the mitochondria have been indirectly or directly linked to immune 
functions. Macrophage activation and T cell differentiation is associated with a metabolic 
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shift in the TCA cycle, oxidative phosphorylation and fatty acid oxidation193,194. Although 
these metabolic changes are transcriptionally regulated they exemplify a mechanism by 
which mitochondrial function can modulate the activity of immune cells.  
 
Several mitochondrial alarmins or damage-associated molecular patterns (DAMPs) have 
been identified and include proteins, lipids and mtDNA195. These molecules are typically 
shielded from host recognition but upon cellular stress, infection or injury they can be 
exposed and engage with pattern recognition receptors (PRRs) to trigger an immune 
response. mtDNA is becoming increasingly recognized as an agonist of the innate immune 
system as it displays several unique features that may be identified as foreign by the 
immune system. These include a distinct methylation signature, frequent oxidative 
damage modifications and formation of distinct nucleic acid species during transcription 
and replication such as double stranded mRNA196. Indeed, mtDNA released into the 
cytosol due to loss of mitochondrial membrane integrity or cellular damage can engage 
with endosomal and cytosolic PRRs to trigger pro-inflammatory and type I interferon 
responses196.  
 
Mitochondria can directly mediate an anti-viral response against RNA viruses via the OMM 
MAVS (mitochondrial antiviral signaling) protein197. When viral dsRNA is detected in the 
cytosol it engages with receptors like RIG-I (retinoic acid inducible gene I). Subsequently, 
MAVS acts as an adaptor between the viral RNA-bound immune receptors and immune 
effectors to trigger an intracellular signaling cascade that activates the TFs NF-κB and 
interferon regulatory factor 3 (IRF-3). These proinflammatory factors then coordinate and 
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drive the expression of proinflammatory cytokines and interferon, respectively. Seth and 
colleagues showed that silencing of MAVS by RNA interference prevents activation of NF-
κB and IRF3 causing increased viral replication whereas overexpression of MAVS boosts 
antiviral immunity197. More recently, Zhou and colleagues showed activation of the NLRP3 
inflammasome is dependent on mitochondrial function198. 
 
 Calcium homeostasis 
Intracellular Ca2+ is regulated by the influx of extracellular Ca2+ though the plasma 
membrane, the Ca2+ release from intracellular stores (mainly the Golgi and the ER) and 
by extrusion of cytosolic Ca2+ by the plasma membrane Ca2+ ATPase (PMCA) pump199. 
Release of Ca2+ from the ER can go directly to the cytosol or to juxtaposed organelles 
such as mitochondria which act as intracellular Ca2+ buffers200.  
 
Import of Ca2+ across the OMM occurs through VDACs201 while traffic across IMM occurs 
mainly via the mitochondria calcium uniporter (MCU) and is dependent on the 
electrochemical gradient202. MCU has low Ca2+ affinity and its activation is triggered by 
microdomains of high Ca2+ at the contact sites with the ER and the sarcoendoplasmic 
reticulum, also known as the mitochondria associated membranes (MAMs). Release of 
Ca2+ from the mitochondria is mediated by the ion exchanger NCLX, (Na+-Ca2+-Li+) and a 
less well known H+/Ca2+ antiporter 203,204. 
 
Intramitochondrial Ca2+ plays important roles in mitochondrial and cellular homeostasis. 
First, it favors ATP production by activating the TCA dehydrogenases, Complex V205, and 
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the pyruvate dehydrogenase which is required to convert pyruvate to acetyl-CoA206. 
Second, accumulation of mitochondrial Ca2+ can initiate progression of cell death by 
causing sustained opening of the large mitochondrial permeability transition pore 
(mPTP)207 and subsequent dissipation of membrane potential, matrix swelling and OMM 
rupture208.  
 
 Cell death 
Mitochondria play a central role in regulation of cell death by apoptosis and necrosis161. 
Exposure to apoptotic stimuli such as oxidative stress or intracellular Ca2+ overload 
promotes the homo-oligomerization of the pro-apoptotic factors Bax and Bak in the OMM 
to form pores and increase membrane permeabilization209. As a result, proapoptotic 
molecules exit the mitochondria into the cytosol to trigger apoptosis signaling. The best 
described of these molecules is cytochrome C which has an ETC-independent function in 
promoting cell death210. In the cytosol, cytochrome C binds to APAF-1 to recruit and 
activate caspase 9, triggering the caspase cascade. Ultimately, the effectors caspase 3 




Epigenetic changes regulate gene expression by altering the chromatin structure into an 
open and transcriptionally active conformation or into a condensed and transcriptionally 
repressed conformation211. This process is mediated mostly by histone modifications 
(acetylation, methylation, phosphorylation, ubiquitylation, etc) and DNA methylation212. 
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Mitochondria provide intermediate metabolites used to generate the acetyl and methyl 
epigenetic markers used in acetylation and methylation reactions, respectively 213,214. The 
acetyl group is generated by conversion of citrate produced in the TCA and exported to 
the cytosol. The methyl group is generated from the S-adenosyl methionine (SAM) 
precursor which is generated in the cytosol and sustained by mitochondrial metabolism. 
Moreover, histone deacetylases which remove the acetyl groups from histones, use NAD+ 
as a cofactor, although the extent to which mitochondrial NAD+ is used remains unclear212. 
Interestingly, mitochondrial stress can cause chromatin reorganization to promote 
transcription activation of the UPRmt genes and restore mitochondrial homeostasis, 




 Mitochondrial dynamics 
Mitochondria are often depicted as static and isolated entities, but they form a highly 
dynamic network that undergoes continuous remodeling as a result of movement, fusion 
and fission (mitochondrial dynamics). Mitochondrial fusion is the process by which two 
mitochondria merge and their contents combine, while mitochondrial fission is the division 
of one mitochondrion into two daughter organelles215. Changes in the balance between 
fusion and fission take place in physiological processes such as the cell cycle, apoptosis 
and mitochondrial quality control as well as in response to changes in the cellular 
environment215,216. Both fusion and fission involve a series of steps dependent on the 
activity of large GTPases from the Dynamin family, deletion of which causes embryonic 
lethality in mice217,218,219. 
 
 Mitochondrial fission 
Mitochondrial fission occurs by constriction and scission of the mitochondrial membrane 
at sites marked by mitochondria-ER contacts that initiate pre-constriction of the OMM by 
actin assembly and contraction220. The GTPase Dynamin-related/-like protein (DRP1) is 
recruited to these sites by the receptors mitochondrial fission factor (MFF) and the 
mitochondrial dynamins MiD51 and MiD49 where it oligomerizes to form a ring-like 
structure that further increases constriction221,222. Subsequently, the Dynamin 2 (DNMT2) 
is specifically recruited to these regions to terminate scission and generate two daughter 
mitochondria223. The mechanisms that lead to IMM constriction are poorly understood and 
there are no known molecules specifically involved in this process221. Mitochondrial 
fragmentation is linked to mitochondrial dysfunction as it is often observed during cell 
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death224. Moreover, increased mitochondrial fission promotes equal segregation of 
mitochondria among daughter cells during G2/M and facilitates mitochondrial motility and 
quality control224. 
 
 Mitochondrial fusion  
Mitochondrial fusion is a sequential two-step process by which the OMM and the IMM of 
two mitochondria fuse. OMM fusion is mediated by the homologue GTPases mitofusin 1 
and 2 (MFN1 and MFN2) which are inserted in the OMM and accumulate at contact areas 
between two mitochondria to establish homo or heterotypic complexes221. These protein-
protein interactions mediate the tethering of the OMMs of two adjacent mitochondria, 
increasing their contact surface area which subsequently fuses due to conformational 
changes induced by GTP hydrolysis221. The exact mechanism and domains of MFN1 and 
MFN2 that mediate fusion remain unclear and are matter of great debate in the field today 
as new mitofusin topologies are proposed225. IMM fusion occurs after OMM and is 
mediated by OPA1 and the mitochondrial membrane lipid cardiolipin in a MFN1-dependent 
process226. OPA1 is inserted in the IMM and contains sites for proteolytical cleavage by 
the membrane-bound metalloproteases OMA1 and YME1L which regulate the abundance 
of long OPA1 (L-OPA1) and short OPA1 (S-OPA1) isoforms. The fusion activity and 
purpose of OPA1 isoforms remain elusive but the current understanding is that L-OPA is 
sufficient to drive fusion227 and drives IMM fusion by interacting with the mitochondrial 




Fused mitochondrial networks are associated with stimulation of oxidative phosphorylation 
and TCA activity228,229, protection against phagophore engulfment during autophagy 
triggered by nutrient starvation230 and compensation of temporary mitochondrial 
dysregulation231. 
 
 Mitochondrial motility 
Mitochondrial motility is the mechanical process by which these organelles can be 
distributed within cells to match energy demands and to ensure proper inheritance during 
cell division232,233. This process appears particularly important in highly polarized cells 
such as neurons 232.  
 
Different mechanisms of mitochondrial transport have been identified but generally 
mitochondrial transport has been shown to involve the interaction between microtubules 
and motor proteins associated with mitochondria via adaptor proteins232. The Miro-Milton 
complex (MIRO1/2-TRAK1/2 in mammalian cells) is the most well-characterized adaptor 
complex234. Miro is an OMM Rho GTPase that binds to Milton which in turn binds to 
microtubule motor proteins235,236. Afterwards, kinesin and dynein motor proteins transport 
mitochondria toward microtubule plus (anterograde movement) and minus ends 
(retrograde movement), respectively236.  
 
The extent of mitochondrial motility has been proposed to be modulated by several 
mechanisms including regulation of the adaptor proteins, the number of active motors 
driving movement and the interaction with other organelles236. Interestingly, Ca2+ 
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concentrations can cause conformational changes in Miro and alter its interactions with 




 Mitochondrial health and disease 
Maintenance of a healthy population of mitochondria is essential for cellular homeostasis 
and survival. Mitochondrial networks are maintained by regular cycles of degradation and 
biogenesis which together coordinate the elimination of dysfunctional mitochondria and 
the biogenesis of new organelles (mitochondrial turnover). These processes occur via 
various mechanisms that are commonly referred to as mechanisms of mitochondrial 
quality control. Impairment of these mechanisms has been shown to cause accumulation 
of mitochondria with increased ROS production and reduced ATP production, as well as 
increased membrane permeability which may lead to the release of pro-apoptotic factors 
and immunogenic mitochondrial components into the cytosol237. 
 
 Mitochondrial degradation  
In response to mitochondrial damage and dysfunction several quality control pathways 
can be activated. In physiological conditions, mitochondrial chaperons and proteases 
monitor and degrade proteins238,239. If proteins are unfolded, damaged, or in excess, the 
mitochondrial unfolded protein stress response pathway (UPRmt) is activated to protect 
mitochondria from proteotoxicity240. This response involves the activation of a 
transcriptional program to induce expression of nuclear-encoded mitochondrial 
chaperones and other genes to restore cellular homeostasis while repressing translation 
and import of additional mitochondrial proteins240. In addition, the most terminal response 
to mitochondrial dysfunction is the specific targeting of damaged organelles to degradation 
by autophagy (mitophagy)241. The best-characterized pathway of mitophagy is dependent 
on the recruitment of the E3 ubiquitin ligase Parkin from the cytosol to the mitochondria242 
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and it is extensively discussed in section 4.1.3. The turnover rate of mitochondrial 
components may be asynchronous depending on their redistribution by fusion and fission 
events as well as the mechanisms by which they are degraded. Of note, these pathways 
are frequently studied under extreme stress conditions and their physiological relevance 
is a matter of debate.  
 
 Mitochondrial biogenesis 
The expression of mitochondrial nuclear-encoded proteins is largely controlled by the 
transcription factor proliferator-activated receptor gamma coactivator-1aplha (PGC-1α). It 
controls the expression of nuclear respiratory factors 1 and 2 (Nrf1 and Nrf2) and Tfam, 
key modulators of mitochondrial biogenesis243. Overexpression of PGC-1α leads to 
upregulation of more than 100 genes that are involved in fatty acid β-oxidation, TCA, 
oxidative phosphorylation, mitochondrial translocases and mitochondrial ribosomal 
machinery and its expression levels correlates with expression of ETC enzymes244. In 
addition to directly control gene expression, PGC-1α can interact with other transcriptions 
factors like PPARs and ERRs to further promote mitochondrial biogenesis243. 
 
PGC-1α activity is regulated at the transcriptional and translational levels. 
Transcriptionally, PGC-1α is proposed to be activated by calcineurin A, the 
Ca2+/calmodulin-dependent protein kinase IV245, the p38 mitogen-activated protein kinase 
(p38 MAPK) and the AMP-dependent kinase237. Some of these factors are upregulated by 
PGC-1α resulting in a positive loop that allows PGC-1α to drive its own expression246. 
Translationally, the most well-described post-translational modifications are 
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phosphorylation by AMPK, p38 MAPK and Akt, and acetylation by GCN5237,247. Whereas 
phosphorylation can activate or repress PGC-1α transcriptional activity depending on the 
residue, acetylation of PGC-1α is described to be only repressive237.  
 
 Coordination between mitochondrial degradation and biogenesis 
The link between mitochondrial biogenesis and degradation ensures mitochondrial content 
is maintained over time. Cunningham and colleagues showed the nutrient sensor and 
master regulator of autophagy mammalian target of rapamycin (mTOR) activates 
mitochondrial biogenesis by activating PGC-1α248. More recently, the key mitophagy 
regulator Parkin was shown to also modulate mitochondrial biogenesis via its E3 ubiquitin 
ligase activity. Using mice with genetic deletion of Parkin (Park2), Stevens showed Parkin 
is necessary for ubiquitination and subsequent proteasomal degradation of the PGC-1α 
repressor PARIS (Parkin-interacting substrate)249.  
 
 Mitochondrial dysfunction and disease 
Mitochondrial diseases are genetic disorders caused by mutations in mtDNA genes 
(primary disorders) or nuclear genes that encode mitochondrial proteins (secondary 
disorders) such as structural components, ETC complexes and replication, transcription 
or translation machinery162. They can manifest in any tissue at any age and with a wide 
range of symptoms. Mitochondrial syndromes can be caused by mutations in a variety of 
genes. For example, Leigh syndrome has been linked to mutations in more than 75 
different genes250. As a result, mitochondrial diseases are difficult to diagnose or predict 
inheritance patterns. Nevertheless, adult primary mitochondrial disorders are estimated at 
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9.6 cases per 100,000 individuals and secondary mitochondrial disorders at 2.9 cases per 
100,000 individuals, with prevalence estimates varying geographically251. 
 
The severity of primary mtDNA-related disorders is variable, partially depending on the 
ratios of mutated to wild-type mtDNA copies present in the same cell (heteroplasmy). 
Pathogenic mtDNA mutations include point mutations as well as large-scale deletions that 
can remove up to 10Kb of the genome. Mitochondrial disorders are predominantly 
associated with defects in oxidative energy metabolism and accompanied by a reduction 
in cellular oxygen consumption, decreased ATP synthesis and, less often, in an 
overproduction of ROS181. The clinical presentations of mitochondrial diseases include 
hearing loss, exercise intolerance, cardiomyopathy, liver failure and diabetes mellitus251. 
More recently mtDNA mutations have been associated with ageing and cancer but 
causality has not been established252. 
 
Mutations in mitochondrial proteases and chaperones are linked to progressive 
neurological disorders253 while impairment of Parkin-mediated mitophagy is associated 
with the development of hereditary Parkinson’s disease and has been implicated in both 
Alzheimer’s and Huntington’s disease254,255. Several clinical syndromes due to mutations 
in genes encoding fission and fusion machinery components have been described221. For 
example, Charcot-Marie-Tooth disease is directly linked to mutations in MFN2 while 
mutations in OPA1 genes are known for the development of the most common optic 
neuropathy256. These findings show that deterioration of mitochondrial quality control 




Finally, alterations in mitochondrial function can be modulated to contribute to disease 
progression. Cancer cells exhibit several distinct biological hallmarks that transform 
normal cells into tumor cells. More than 60 years ago it was recognized that cancer cells 
display a metabolic reprogramming to increase glycolytic metabolism in the presence of 
oxygen (Warburg effect) 257. Mitochondrial fragmentation is frequently observed during this 
switch. In liver, colorectal and lung cancers, this reduction in mitochondrial length was 
linked to reduced levels of MFN2 expression258. These findings indicate that cancer cells 
may obtain a competitive advantage from modulation of metabolism and MFN2 
expression. Other bioenergetic alterations have been reported to accompany malignant 
transformation such as increase in glycolysis and TCA cycle in cells with loss or mutation 
of p53259. However, there is not a single bioenergetic transition common to all types of 
cancer and the full extent of the role of mitochondrial function in this disease context 
remains unknown. 
 
In summary, the connection between mitochondrial dysfunction and the pathogenesis of 




  Conclusions 
Although classic studies have demonstrated the critical role of mitochondria in providing 
energy for the cell, the diverse functions of this organelle in cellular metabolism and stress 
responses continue to emerge in a variety of cell types. It has become clear that 
mitochondria do not operate independently but instead integrate multiple signals to 
influence cellular signaling, gene expression and even cell fate. The regulatory biology of 
mitochondria still remains largely unknown and it will be an attractive research area for 
many years to come. Our studies aimed to elucidate if and how these organelles modulate 




3. Mitochondrial content in HSCs 
Data presented in this chapter were published by Cell Stem Cell in December of 2017 
entitled “Dye-independent methods reveal elevated mitochondrial mass in hematopoietic 
stem cells”  by De Almeida MJ, Luchsinger LL, Corrigan DJ, Williams LJ and Snoeck HW 
PMID:29198942 
 
 Background  
Classical assays for measurement of mitochondrial content are time-consuming, 
expensive, or are not feasible to perform in a rare cell-type such as HSCs. The use of flow 
cytometry for analysis of mitochondrial fluorescent probes overcame the limitations of 
traditional methodologies and has become widely used in HSCs. Based on this 
experimental approach, numerous publications have claimed mitochondrial content to be 
reduced in HSCs compared to other hematopoietic populations260-266. However, these 
studies did not take the differential efflux capabilities of hematopoietic populations into 
account. This oversight may have led to erroneous fluorescence readings and 
misinterpretation of a basic aspect of HSC biology. In the next section we review the 
functional data that has supported the idea of low mitochondrial content in HSCs and 
contributed to the dismissal of a major role for this organelle. In addition, we provide an 
overview of the unique dye efflux capacity of HSCs and an outline of methodologies to 






 Mitochondrial respiration is detrimental for adult HSCs 
The detection of low mitochondrial mass in BM HSCs was a secondary finding in studies 
focused on investigating processes and pathways associated with mitochondrial function, 
in particular its role in ATP production by oxidative phosphorylation. In these studies, it 
was consistently observed that genetic mutations that triggered an increase in oxidative 
metabolism in HSCs, also caused a reduction in HSC function and maintenance in adult 
mice. This phenotype was observed in association with a dysregulation in a variety of 
cellular contexts including increased mTOR activity (Tsc1-/-HSCs)267, defective autophagy 
(Atg7-/-, Atg12-/-, fip200-/- HSCs)268-270, increased mitochondrial unfolded protein response 
(Sirt7-/-HSCs)261, enhanced TCA flux (Pdk2/4-/-HSCs)264, and enhanced mitochondrial 
metabolism (Mtch2-/-HSCs, Src3-/-HSCs)271,272. In agreement with this observation, mass 
spectrometry analysis of WT HSCs detected a metabolic profile reflective of a predominant 
glycolytic metabolism264. 
 
The abnormal increase in oxidative phosphorylation in the mutant HSCs correlated with 
an increase in differentiation-associated phenotypes such as increase in ATP production 
and loss of quiescence. This finding led to the discovery that the metabolic state of HSCs 
was a key determinant of cell-fate. In addition, oxidative HSCs displayed an increase in 
DNA-damaging ROS, to which HSCs are highly sensitive273. Since mitochondria are the 
major source of ROS as a byproduct of mitochondrial respiration, it is thought the 
predominantly glycolytic metabolism of HSCs may be a protection mechanism from ROS 
and DNA damage. This notion was further supported by two observations. First, quiescent 
HSCs have low energetic requirements that would be met by glycolytic ATP. Second, 
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although controversial, the hypoxic nature of the HSC niche is reported by some to 
promote glycolysis in HSCs (section 1.6.3.). 
 
In summary, increased mitochondrial respiration disrupts the delicate balance between 
quiescence, self-renewal and differentiation of BM HSCs. This observation together with 
reports of low mitochondrial content in HSCs established the dogma that low mitochondrial 
content and activity were required for HSC homeostasis and discouraged the field from 
investigating ATP-independent functions of mitochondria. Recent studies, including our 
own, have reevaluated these presumptions and will be further discussed in the result and 
discussion sections of this chapter. 
 
 Dye-efflux in HSCs 
More than two decades ago, it was shown that significant enrichment of murine HSCs 
could be performed solely based on dual-wavelength flow cytometric analysis of BM 
stained with the fluorescent DNA-binding dye Hoechst 33342. HSCs were found in the 
rare dim fluorescent cells termed side population (SP) which was enriched by 1000-fold 
for reconstitution activity in vivo274. The ability of HSCs to efflux Hoechst 33342 is a 
property shared with other murine stem cell populations including neural275 and retinal 
stem cells276. In addition, SP cells were detected in Hoechst-stained hematopoietic tissues 
from multiple species including swine BM, rhesus macaque BM, and human BM and 
CB277. Efflux of the mitochondrial dye rhodamine-123 (Rh-123) could also discriminate the 
population of HSCs in murine BM278 and human BM and CB279. Therefore, high efflux 




The molecular mechanism underlying this phenotype has been investigated by both 
chemical and genetic approaches. Treatment with pump inhibitors verapamil, cyclosporin 
A or reserpine have been shown to prevent efflux of Hoechst 33342 and the mitochondrial-
dyes Rho-123, JC-1 and nonyl acridine orange (NAO) in HSCs274,278. Regulation of dye-
efflux in HSCs has been attributed to two members of the ATP-binding cassette (ABC) 
super family of transporter proteins: multidrug resistance mutation 1 (MDR1) and breast 
cancer resistance protein 1 (BCRP1). Genetic ablation of Bcrp1, but not the mouse 
homologues Mdr1a and Mdr1b, resulted in depletion of HSCs from the Hoechst 33342 
SP280. On the other hand, Mdr1a/1b-/- cells completely lacked the capacity to expel 
Rho123281. These studies showed HSCs were able to molecularly distinguish dyes 
through expression of transporters with different substrate affinities. Although steady-state 
hematopoiesis progresses normally in Mdr1a/1b-/- and Bcrp1-/- mice, BCRP1-deficient 
HSCs were killed in the presence of the chemotherapeutic drug mitoxantrone at a dose 
that did not affect WT HSCs280. This result indicated that the high efflux capacity of HSCs 
may have evolved to provide protection from toxic agents.  
 
 Quantification of mitochondrial content  
Measurement of mitochondrial content and mitochondrial activity are distinct mitochondrial 
readouts that often correlate in cells with a predominantly oxidative metabolism. Thus, 
inferring mitochondrial mass from quantification of mitochondrial respiration might be 
misleading in BM HSCs, which heavily rely on a glycolytic metabolism. Estimation of 
mitochondrial content regardless of their bioenergetic state can be done by visualization-
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based approaches, quantification of mitochondrial components, and measurement of 
fluorescence intensity in cells with fluorescently-labeled mitochondria.  
 
Classically, mitochondrial content can be assessed by transmission electron microscopy 
(TEM) of ultrathin slices. While this technique allows for powerful magnification of 
mitochondrial structure, it is expensive and time-consuming. An alternative approach is to 
target mitochondria-specific proteins by immunofluorescence or to fluorescently label 
mitochondria. This can be accomplished by the use of fluorescent probes or genetic 
expression of fluorescent proteins targeted to the mitochondria. These experiments 
provide invaluable knowledge into the morphology of mitochondria but are highly 
influenced by the process of acquisition. Moreover, HSCs are small, round, non-adherent 
cells and hence, difficult to image. Image acquisition is often done in a single plan view 
from a reduced number of cells, which is likely insufficient to observe the complete 
mitochondrial network. 
 
Quantification of mitochondrial content by targeting of unique mitochondrial components 
is frequently presented as the ratio of a mitochondrial protein, lipid or DNA, relative to a 
cytosolic or nuclear component. Protein studies are traditionally performed by western 
blot, lipid quantification by chromatography-based methods, and targeting of mtDNA by 
qPCR. Of those, only qPCR is feasible to be routinely performed on purified HSCs. 
 
Quantification of mitochondrial fluorescence can be done after staining cells with the non-
potentiometric mitochondrial dyes MTG and NAO. In contrast to other mitochondrial 
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probes, MTG and NAO are reported to associate with mitochondrial lipids and label 
mitochondria regardless of membrane potential282,283, although some controversy exists 
in respect to MTG284. Mitochondrial fluorescence intensity can also be measured in cells 
isolated from transgenic mice with exogenous expression of fluorescent proteins 
specifically targeted to the mitochondria285,286. Although these approaches are fast, 
convenient and amenable to both microscopy and flow cytometry, possible confounding 
factors should be taken into consideration. First, mitochondrial dyes can be toxic if used 
at high concentrations. Second, the expression of fluorescent proteins in the transgenic 
mice is artificial and constitutively driven by exogenous promoters. The possibility of 
different fluorescent intensities being the result of a cell-type specific promotor activity 
cannot be excluded until verified.  
 
In summary, the methodologies available to measure mitochondrial mass require careful 
optimization and control of confounding variables. Importantly, conclusions regarding the 
mitochondrial content of a population should only be drawn from the combinatorial use of 
independent techniques.  
 
 Project rationale 
Reports of low mitochondrial content in HSCs have been largely based on staining with 
mitochondrial dyes. However, the ability of HSCs to efficiently efflux dyes has been 
recognized for decades and even exploited in isolation methods. Hence, we hypothesized 
the reduced fluorescence intensity of mitochondrial probes in HSCs was a result of efflux. 
In this study, we have tested this hypothesis and employed dye-independent methods to 
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determine mitochondrial content in HSCs. We aimed to definitively clarify a basic aspect 





 Mitotracker Green is effluxed by HSCs 
Reports of low mitochondrial content in hematopoietic stem cells (HSCs) have historically 
relied on flow cytometry analysis after staining with mitochondrial dyes, such as 
Mitotracker Green (MTG)260-266,287,288. MTG is a fluorescent dye readily taken up by live 
cells where it is sequestered in the mitochondria. The quantity of MTG fluorescence in a 
cell is commonly interpreted as an indicator of mitochondrial content. As previously done 
by others, we stained bone marrow (BM) from WT mice with MTG and analyzed MTG-
fluorescence intensity. This experiment was performed in HSCs, multipotential progenitors 
(MPPs), committed myeloid progenitors (CMPs, comprising myeloid, erythroid and 
Figure 1. MTG fluorescence in hematopoietic populations. A. Gating strategy in MTG-stained 
BM to differentiate HSCs (LSKCD48-Flt3-CD150+), MPPs (LSKCD48+Flt3+), CMP (Lin-cKit+Sca1-), 
CLP (Lin-cKitloSca1loIL7Rα+Flt3+), and Lin+. Boxed regions represent final gates for each population. 
B. MTG Mean fluorescence intensity (MFI) normalized to HSCs (n=4, mean±sem). C. 
Representative histogram of fractionation of BM based on MTG fluorescence. D. HSC frequency in 
MTGLo , MTGHi and total BM (n=6, mean±sem). 
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megakaryocyte progenitors), common lymphoid progenitors (CLPs) and lineage positive 
(Lin+) cells.  
 
Each hematopoietic population was identified based on its cell surface maker profile: 
HSCs (Lin-cKit+Sca1+CD48-Flt3-CD150+), MPPs (Lin-cKit+Sca1+CD48+Flt3+), CMPs (Lin-
cKit+Sca1-), CLPs (Lin-cKitloSca1loIL7Rα+Flt3+) and lastly Lin+, which express markers of 
terminally differentiated cells (Fig. 1A). Mean fluorescence intensity (MFI) of MTG+ cells 
was significantly lower in HSCs and MPPs than in more differentiated populations (Fig. 
1B). Moreover, HSCs were enriched in the BM fraction with lowest MTG intensity (MTGLo) 
and highly depleted in the fraction with highest MTG intensity (MTGHi) (Fig. 1C and D). 
These results would suggest mitochondrial content was reduced in HSCs, thus 
reproducing previous studies. 
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However, more than two decades ago, pivotal work showed HSCs can be identified and 
isolated by flow cytometry based on their ability to efflux Hoechst274. Subsequent studies 
showed that deletion or inhibition of ABC transporters Mdr1 and Bcrp1 by verapamil (VP) 
prevented dye efflux and, as a consequence, increased Hoechst signal in HSCs280,281. 
We hypothesized low MTG-fluorescence in HSCs may be a consequence of dye efflux. 
Staining of BM in the absence and presence of VP caused a slight shift in overall 
fluorescence (Fig. 2A) without affecting HSC frequency in total BM (Fig. 2B). However, 
MTG-fluorescence in HSCs increased significantly in the presence of VP, causing HSCs 
to become nearly undetectable in the MTG-VPLo fraction (Fig. 2C and 2D). Importantly, 
the same level of enrichment previously observed in the MTGLo fraction was now detected 
in the MTG-VPHi fraction (Fig. 2D).  
Figure 2. MTG fluorescence of HSCs in the presence of verapamil. A. Histogram of MTG 
fluorescence in whole BM stained in the absence or presence of verapamil (VP). B. HSC frequency in 
total whole BM stained in the presence and absence of VP (n=4, mean±sem). C. Representative flow 
plot of the location of HSCs (black) in MTG-stained BM in the absence or presence of VP. D. Frequency 
of HSCs in MTGHi and MTGLo fractions stained in the absence or presence of VP (n=6, mean±sem).  
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Inhibition of efflux by VP led to an increase in dye retention in HSCs, MPPs, CMPs and 
CLPs (Fig. 3A). Stem cells had an average 6-fold increase in MTG MFI, which was 
significantly higher than in committed progenitors (Fig. 3B). The extent to which VP 
affected each hematopoietic population correlated with the mRNA levels of ABC 
transporters Mdr1a/b and Bcrp1, all of which were preferentially expressed in HSCs (Fig. 
3C).  
 
Figure 3. Effect of verapamil in MTG retention. A. Histogram of MTG fluorescence in each 
population stained in the absence (grey) or presence (green) of VP. B. Effect of VP in MTG MFI (n=4, 
mean±sem). C. relative mRNA levels of Mdr1a/b and Bcrp1 in sorted BM hematopoietic populations 
(n=3, mean±sem).  
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To assess presence of HSC function in MTGHi and MTGLo fractions, we performed 
competitive repopulation assays using BM cells sorted solely based on MTG fluorescence 
(Fig. 4A and 4D). After 16 weeks, the percentage of donor-derived cells in the peripheral 
blood (PB) of recipient mice reflected our previous analysis of phenotypic HSCs. Stem cell 
activity was significantly higher in the MTGLo fraction and shifted to the MTG-VPHi fraction 
in the presence of VP (Fig. 4B, C, E and F). If MTG accurately reports mitochondrial 
content if efflux is inhibited, these results strongly pointed to high mitochondrial mass in 
HSCs. 
 
Altogether our data determined MTG was a flawed quantitative tool to assess 
mitochondrial content in hematopoietic populations due to different efflux capacities. To 
Figure 4. HSC activity in vivo based on MTG fluorescence. A. Schematic of isolation of MTG-stained 
BM cells for competitive transplants in the absence or D. presence of VP. B. Percentage of CD45.1 
donor cells derived from MTG-stained BM in the absence or E. presence of VP in the PB of recipient 
mice 16 weeks post transplantation (n≥15 mean±sem, from three independent transplants). C. 
Representative flow plots of the CD45.1 population derived from MTG-stained donor BM in the absence 
or F. presence of VP. 
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definitively determine the relative mitochondrial content of HSCs in the hematopoietic 
system, we turned to the use of dye-independent methods, employing distinct techniques 
and targeting different mitochondrial components.  
 
 HSCs exhibit higher mtDNA:nDNA ration than lineage-committed 
populations 
Mitochondria harbor their own genome which exclusively encodes 37 genes. To determine 
mitochondrial content using a quantitative technique, we performed qPCR on cell 
lysates289 targeting single copy mitochondria-encoded genes (Cytb, Nd1) and nuclear-
encoded genes (Actb, Cypd). Each amplicon was confirmed by sequencing (not shown) 
and the primer efficiency for each target was calculated to be between 96-103% (Fig.5A). 
Moreover, cell number inferred from beta-actin standard curve mirrored the real cell input 
(Fig. 5B). Finally, we obtained equal relative mtDNA:nDNA ratios from independent 
amplification of the two mitochondrial-encoded genes (Fig. 5C). After careful validation, 
Figure 5. Validation of qPCR assay for determination of mtDNA:nDNA ratio. A. standard curve of 
nuclear-encoded genes (black) and mitochondrial-encoded genes (green) from DNA vectors containing 
the target. B. inputted and inferred HSC number based on Actb Ct values and standard curve. C. Relative 
mtDNA:nDNA ratio in HSCs targeting either Cytb or Nd1 as mitochondrial genes and Actb, normalized 
to Cytb (n=1). 
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the relative mtDNA:nDNA ration in hematopoietic populations was calculated based on 
Cytb and Actb amplification.  
 
We had previously questioned whether VP improved the use of MTG as an indicator of 
mitochondrial content in populations that can efflux this dye. We therefore sought to 
determine the relative ratio of mtDNA:nDNA in MTGHi and MTGLo fractions within total 
MTG-stained BM and within the heterogeneous CMP population of MTG-stained BM. 
Indeed, in the absence of VP, MTG fluorescence intensity did not parallel mtDNA content 
per cell in neither BM nor CMPs (Fig. 6A and 6B). In the presence of verapamil MTG_VPLo 
cells displayed on average lower mtDNA:nDNA ratio than MTG_VPHi cells (Fig. 6A and 
6B). However, only in CMPs did this difference reach statistical significance which leads 
us to question if MTG stain is truly informative for relative measurement of mitochondrial 
content in hematopoietic populations.  
 
Figure 6. Relative mtDNA:nDNA in MTGHi and MTGLo fractions. A. Relative mtDNA:nDNA in MTGLo 
and MTGHi fractions isolated from MTG-stained BM (n≥4, mean±sem) and B. MTG-stained CMPs in 
the absence (left) or presence (right) of VP (n≥3, mean±sem) 
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Using the mtDNA assay, two additional experiments were performed to compare 
mitochondrial content in HSCs and their progeny. First, we performed the assay in the 
populations of interest directly after cell isolation by flow cytometry (Fig. 7A). Second, we 
collected samples over time from ex vivo HSC cultures, where HSC differentiation and 
exhaustion inevitably occur (Fig. 7B). In both experimental settings we found that 
mitochondrial content was highest in HSCs and progressively decreased with 
differentiation.  
In a collaborative study, Map17 expressing HSCs were sorted from induced Map17-CreER 
mice (Fig. 8A). This population of stem cells was shown to contribute to multi-lineage 
differentiation in steady state and is thought to occupy a top position in the differentiation 
Figure 7. Relative mtDNA:nDNA in HSCs and more differentiated populations. A. Relative 
mtDNA:nDNA in sorted hematopoietic populations. HSC, MPP, CMP, CLP, and Lin+ were isolated as 
previously described. Macrophages (Mac1+), T cells (CD3+) and B cells (CD19+) (n≥4 mean±sem). B. 
Relative mtDNA:nDNA of ex vivo HSC cultures over time (n≥3 mean±sem). 
Figure 8. Relative mtDNA:nDNA in Map17+HSCs. A. Flow cytometry plots of the gating strategy to 
purify Map17+HSCs in Map17-Cre ER mice. B. Relative mtDNA:nDNA in sorted hematopoietic 
populations (n≥3, mean±sem).  
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hierarchy47. Distinction of HSCs based on Map17 expression reproduced the results 
obtained in bulk HSCs. Map17+HSCs exhibited increased mitochondrial content compared 
to committed progenitors (Fig. 8B). Regardless of Map17 expression, the two subsets of 
HSCs displayed a high ratio of mtDNA:nDNA, indicating high mitochondrial content may 
be a general feature of HSCs.  
 
 HSCs contain more TFAM punctae than lineage-committed populations  
Mitochondrial genomes are packaged into compact units termed the nucleoids (section 
2.2.1). For independent validation of mtDNA measurements by qPCR, we performed 
immunofluorescence assays targeting the major mtDNA binding and packaging factor -
mitochondrial transcription factor A (TFAM). Confocal images showed the expected 
punctae pattern for TFAM in mitochondria, as marked by staining of the OMM translocase 
protein TOM20 (Fig. 9A). Importantly, although we observed variability within each 
population, the average number of nucleoids was significantly higher in HSCs and MPPs 
compared to CMPs, CLPs, and terminally differentiated cells Lin+ (Fig. 9B), thus confirming 
Figure 9. Mitochondrial nucleoids in hematopoietic populations. A. Representative confocal images 
of (top) mitochondrial nucleoids visualized with immunostaining for TFAM and (bottom) mitochondria 
visualized with immunostaining for TOM20 (scale bar, 5μM). B. Quantification of mitochondrial nucleoids 
(mean, n≥17 cells, pooled from 3 independent experiments). 
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our previous findings and indicating higher mitochondrial mass in more primitive 
hematopoietic populations. 
 
 Mitochondria reporter mouse confirms high mitochondrial content in HSCs 
To visualize mitochondria in an antibody-independent manner, we acquired mice with Cre-
dependent fluorescently labeled mitochondria286. Through E2a-Cre mediated excision of 
a stop codon downstream of the CAG promoter, we induced ubiquitous and constitutive 
expression of the fluorescent protein Dendra2 fused to the COX8A mitochondria targeting 
sequence (MitoDendra2) (Fig. 10A)89. First, we visually confirmed the presence of a large 
mitochondrial network in fixed HSCs isolated from the MitoDendra2 mice (Fig. 10B). We 
subsequently isolated MitoDendra2-BM sub-populations based on fluorescence intensity 
Figure 10. Validation of MitoDendra2 mice as a reporter of mitochondrial content. A. Schematic 
representation of the Rosa26 locus in MitoDendra2 mice. B. Representative microscopy images of fixed 
hematopoietic cells purified from mitoDendra2 mice. C. (left) Representative histogram of isolation of BM 
fractions based on MitoDendra2 fluorescence and (right) respective relative mtDNA:nDNA ratio in each 
fraction (n≥3, mean±sem). D. Relative mtDNA:nDNA in GFPLo and GFPHi fractions of BM from an 
untargeted CAG-GFP mouse (n=1, mean±sd).  
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and determined mitochondrial content by qPCR in each fraction. Unlike BM isolated from 
CAG-GFP mice, fractionation of MitoDendra2 fluorescence levels positively correlated 
with mitochondrial content (Fig. 10C and 10D). MitoDendra2 fluorescence is therefore a 
reliable quantitative tool for measuring mitochondrial content in hematopoietic populations. 
 
The intensity of MitoDendra2 fluorescence was significantly higher in HSCs and immediate 
progenitors MPPs (Fig. 11A and 11B). Analysis of HSCs by surface markers showed stem 
cells were nearly absent in the bottom 10% of MitoDendra2 fluorescence (Dendra2Lo) and 





Figure 11. MitoDendra2 fluorescence in hematopoietic populations. A. Representative MitoDendra2 
fluorescence histogram. B. MitoDendra2 mean fluorescence intensity (MFI) normalized to HSCs (n=3, 




In long-term competitive repopulation assays, MitoDendra2Hi donor cells efficiently 
reconstituted recipient mice (Fig. 12A and 12B). In contrast, the percentage of 
MitoDendra2Lo donor-derived cells in the periphery was below 3% in all recipient mice (Fig. 
12B and 12C). In serial transplantation of BM cells isolated from primary recipients, 
MitoDendra2Hi, but not MitoDendra2Lo, cells were able to reconstitute secondary recipients 
(Fig. 12D). Considering these results, we concluded the multi-lineage potential and self-
renewal capacity distinctive of HSCs is present in the BM fraction with the highest 
mitochondrial content. 
Figure 12. HSC activity in vivo based on MitoDendra2 fluorescence. A. Schematic of isolation of 
MitoDendra2+ BM cells for competitive transplantation. B. Representative flow plots of donor gating 
strategy in the PB of recipient mice. C. Donor contribution of MitoDendra2 fractions in primary recipient 
mice (n=10 mean±sem, from two independent transplants). D. (left) Timeline of secondary transplants 
and (right) Donor contribution of MitoDendra2 fractions in secondary recipient mice (n=9 mean±sem, 




 Mitochondrial content analysis in human HSCs reveals similarities and 
distinctions to mouse 
Human studies using MTG have reported low mitochondrial mass in the CD34+ 
HSC/progenitor compartment of cord blood (CB)262. We investigated if low fluorescence 
of MTG in human(h) HSCs would also be reverted by verapamil (VP). Human CB was 
stained with MTG in the absence and presence of VP and MTG-fluorescence determined 
in hHSCs (Lin-CD45RA-CD38-CD34+CD90+), hMPPs (Lin-CD45RA-CD38-CD34+CD90-), 
committed progenitors hMPs(Lin-CD45RA-CD38+CD34+), and hLin+ (Fig. 13A). As 
hypothesized, MTG fluorescence in hHSCs increased when efflux was inhibited (Fig. 13B) 
by approximately 6-fold (Fig. 13C and D), similarly to mouse HSCs. Treatment with VP 
Figure 13. MTG fluorescence in human CB hematopoietic populations. A. Gating strategy in MTG-
stained CB to purify hHSCs (Lin-CD45RA-CD38-CD34+CD90+), MPPs (Lin-CD45RA-CD38-CD34+CD90-
), hMP (Lin-CD45RA-CD38+CD34+), and Lin+. Boxed regions represent final gates for each population. 
B. Representative flow plot of the location of HSCs (black) in MTG-stained CB in the absence or presence 
of VP. C. Histogram of MTG fluorescence in each population stained in the absence (grey) or presence 
(green) of VP. D. Effect of VP on MTG MFI (n=5, mean±sem). E. Frequency of hHSCs in MTG fractions 
stained in the absence (left) or presence (right) of VP (n=5, mean±sem). 
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decreased the frequency of hHSCs in the MTGLo fraction, but not to the extent we 
observed in the mouse (Fig. 13E). In contrast to mouse HSCs, the majority of hHSCs 
presented an intermediate MTG fluorescence and were almost undetectable in the MTG-
VPHi fraction. These results did not entirely reproduce our mouse studies but still showed 
that hHSCs exhibited low MTG fluorescence due to efflux and, therefore, their 
mitochondrial content might be higher than previously thought.  
 
We investigated if the differences observed between the two sources of HSCs reflected 
variation between species (mouse vs human) or, alternatively, differences between 
developmental stages (BM vs CB). To do so, we compared the mtDNA:nDNA between 
hematopoietic populations isolated from human CB and the developmentally closer mouse 
Figure 14. Relative mtDNA:nDNA in human and mouse hematopoietic cells in early developmental 
stages. A. standard curve of the nuclear-encoded gene (black) and the mitochondrial-encoded gene 
(green) from human gDNA. B. Relative mtDNA:nDNA in human hematopoietic populations sorted from 
CB as previously described (n≥4, mean±sem). C. Gating strategy to purify hematopoietic populations of 
interest from mouse FL. HSCs (LSKCD48-Mac1+CD150+), MPPs (LSKCD48+), CMP (Lin-cKit+Sca1-), and 
Lin+. Boxed regions represent final gates for each population. D. Relative mtDNA:nDNA in mouse 
hematopoietic populations sorted from FL (n=3, mean±sem). 
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fetal liver (FL) from E14 embryos. In human cells mitochondrial content was calculated 
based on amplification of the nuclear encoded gene beta-2-microglobulin (B2m) and of 
the mitochondrial tRNALeu encoded in the mitochondrial genome (Fig. 14A). As suggested 
by the MTG-VP experiments, mitochondrial content in hHSCs was not significantly higher 
or lower than other CB populations (Fig. 14B). Mouse FL HSCs (Lin-cKit+Sca1+CD48-
Mac1+CD150+) exhibited similar mitochondrial content to MPPs and, unlike adult BM 
HSCs, to the committed progenitors CMPs. In that regard, mitochondrial content in FL 
HSCs resembled CB hHSCs. However, compared to Lin+ mouse FL HSCs contained 
significantly higher mitochondrial mass (Fig. 14C and D). In spite of the differences 
detected in the different hematopoietic tissues, the mitochondrial content in HSCs was 
never significantly lower than in any other hematopoietic population we included in this 
study. 
 
 HSCs exhibit lower mitochondrial respiration than downstream progenitors 
Previous evidence of low mitochondrial content in HSCs has been supported by the 
presence of a predominantly glycolytic metabolism and reduced mitochondrial ATP 
production263,264,290. We used a Seahorse analyzer to compare the mitochondrial function 
of enriched HSCs, sorted as LSKCD48- cells, to MPPs, sorted as LSKCD48+ cells, and 
CMPs. Although HSCs and MPPs had comparable mitochondrial content, as assessed by 
several different approaches, their oxygen consumption rate (OCR) profile was distinct 
(Fig. 15A). The basal respiration of all populations included ATP-linked respiration since it 
was sensitive to the ATP synthase inhibitor oligomycin. However, mitochondrial respiration 
and consequent ATP production were significantly lower in HSCs (Fig. 15B). These 
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findings confirm that HSCs do not heavily rely on mitochondria for ATP production, 
warranting additional research into the significance of high mitochondrial content in HSCs 
(Fig. 15).  
 
Figure 15. Metabolic profile of adult BM HSCs. A. OCR profile after sequential injection of Oligomycin, 
FCCP and Rotenone/Antimycin in HSCs (LSKCD48-), MPPs (LSKCD48+) and CMPs (Lin-cKit+Sca1-) 
(n≥5, mean±sem). B. Basal respiration and C. ATP production inferred from the metabolic profile of 
HSCs, MPPs, and CMPs (n≥5, mean±sem). 
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 Discussion and future directions 
In this study we showed that detection of low MTG fluorescence in adult murine HSCs was 
a consequence of dye efflux rather than an indication of low mitochondrial content. The 
ability to efflux MTG can be prevented by the ABC transporter inhibitor, verapamil (VP). 
We detected high mRNA levels of ABC transporters Mdr1a, Mdr1b and Bcdrp1 in HSCs 
but we did not identify the specific transporter(s) responsible for MTG efflux. Interestingly, 
MTG has been proposed as a substrate for human MDR1291, making its mouse 
homologues strong candidates for a similar specificity in mice. To experimentally address 
this hypothesis, MTG assays could be performed in Mdr1a/b-/-BM280 or in the presence of 
inhibitors with different specificities. For example, cyclosporin A has been shown to inhibit 
MDR1 but not BCRP292. Although these experiments would provide insights into the 
substrate specificity of HSC transporters, this topic was beyond the scope of this study but 
is of future interest.  
 
In the presence of VP, HSCs were phenotypically and functionally enriched in the highest 
MTG-fluorescence fraction of BM, indicating HSCs may be one of the hematopoietic 
populations with the highest mitochondrial content. However, using a qPCR assay to 
measure the ratio of mtDNA:nDNA we observed that although VP improved the ability of 
MTG to report on mitochondrial content, it appeared insufficient to confidently detect 
differences in relative mitochondrial mass between hematopoietic populations. We 
hypothesized the use of MTG may have misled the field regarding mitochondrial content 
in adult murine HSC for several years. To definitively clarify this matter, we employed dye-
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independent methodologies targeting different mitochondrial components to quantify 
mitochondrial content. 
  
First, the ratio of mtDNA:nDNA was highest in HSCs and MPPs and decreased with 
differentiation, suggesting mtDNA per cell was highest in the most primitive hematopoietic 
populations. Despite the convenience and quantitative value of this assay there are 
confounding variables that could skew the estimation of overall mitochondrial content from 
mtDNA quantification293. The copy number of nuclear-encoded genes can vary depending 
on the phase of the cell cycle. This is particularly relevant in this context since HSCs are 
mostly quiescent while committed progenitors and differentiated cells are more 
proliferative. Moreover, each mitochondrion can harbor a variable copy number of 
mitochondrial genomes294. We did not exclude the possibility of that number varying 
between hematopoietic populations.  
 
Second, we determined the number of mitochondrial nucleoids as marked by TFAM per 
cell. The number of mitochondrial genomes per nucleoid is thought to be relatively 
constant (normally 1 or 2), and therefore nucleoid abundance directly reflects mtDNA 
content. Indeed, the highest mean number of nucleoids per cell was observed in HSCs 
and MPPs, reproducing our previous results. Of note, nucleoid quantification might be 





Third, we used a transgenic mouse with fluorescently labeled mitochondria (mitoDendra2 
mice) in which fluorescence intensity correlated with mtDNA:nDNA ratio. We showed this 
was specific to the MTS-fused fluorescent protein since fluorescence from an unfused 
GFP driven by the same promotor in the same locus, did not correlate with mtDNA:nDNA 
ratio. We were thus able to utilize the mitoDendra2 mice to both visualize and quantify 
mitochondria. In line with our previous observations, phenotypic and functional analysis of 
HSCs showed stem cells were enriched in the fraction of BM with the highest mitochondrial 
content (highest mitoDendra2 fluorescence). Recently, Vannini and colleagues performed 
similar experiments using a mito-EGFP reporter mouse296 but concluded HSCs had low 
mitochondrial mass265. We speculate the discrepancy in conclusions between this study 
and our own could be explained by a less stringent definition of phenotypic HSCs and 
distinct experimental approaches. In Vannini et al, measurement of mitochondrial mass 
was heavily based on confocal microscopy in a necessarily small number of cells. 
Quantification of mitochondria by microscopy is notoriously difficult to do in HSCs - a small, 
round, and non-adherent heterogeneous cell population with highly fused mitochondria89. 
In addition, the authors did not correlate the mito-EGFP fluorescence measurements with 
an alternative mitochondrial component.  
 
When investigating mitochondrial content in CB-derived hHSCs we discovered the human 
population of stem cells was similarly capable to efficiently efflux MTG. Inhibition of efflux 
during MTG staining positioned hHSCs at an average mitochondrial content within the 
hematopoietic populations of the CB, a finding further validated by the mtDNA:nDNA 
assay. These data indicated relative mitochondrial content in CB hHSCs was not as low 
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as previously reported262, but it was not as high as in adult murine HSCs. This conclusion 
would require additional functional validation in long-term cultures or transplantation in 
humanized mice. This is of particular importance in human studies where the human 
hematopoietic populations are not yet precisely defined based on the expression of 
surface markers. Furthermore, for direct comparison of our mouse studies to human, the 
ideal source of hHSCs would be adult human BM. Since we lacked access to such 
samples, as an alternative we measured mtDNA content in the more developmentally 
closer murine FL-HSCs. Indeed, we observed the relative mitochondrial content in FL-
HSCs was not significantly different than committed progenitors, in contrast to their adult 
counterparts but similarly to CB hHSCs. Taken together, these results indicate 
mitochondrial content in HSCs might vary with the developmental stage or the species but, 
importantly, it was never lower than differentiated cells. MTG staining was not performed 
in FL because it has been described FL-HSCs do not efflux Hoechst 33342 or Rho-123297. 
In retrospect, this experiment would have been valuable to test in an inhibitor-independent 
manner if MTG would be an indicator of mitochondrial content in HSCs if not effluxed. 
 
In addition to uncovering a basic aspect of HSC biology, our study is of technical relevance 
to the field. We highlighted the importance of considering expression and activity of efflux 
pumps in hematopoietic populations when using live-cell dyes for comparative analysis. In 
this context, staining protocols should include efflux inhibitors and results should be further 
validated with additional independent assays. Alternatively, the use of ratio-metric 
fluorescent dyes should be preferred, if available. Interestingly, the requirement of ABC 
transporter inhibition for correct assessment of mitochondrial metabolism by mitochondrial 
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probes has been shown in glioma stem cells, which also efflux298. Efflux inhibition revealed 
glioma stem cells had higher mitochondrial content than initially thought but the readout 
for mitochondrial activity remained reduced. Similarly, in 1998 Kim et al observed HSCs 
were Rho-123Lo even in the presence of verapamil278, indicating low mitochondrial activity 
was an accurate assessment in HSCs. As discussed in Section 3.1.1, several groups have 
shown ATP production in HSCs originates from glycolysis rather than mitochondrial 
respiration. Our Seahorse data confirmed HSCs are less oxidative than more differentiated 
progenitors, including their immediate downstream progenitor population of MPPs. These 
findings raise questions regarding the evolutionary pressure driving HSCs to maintain high 
mitochondrial mass. A few studies have provided valuable insights to lead the path in 
addressing this matter. 
 
In recent years it was discovered that mutations causing mitochondrial dysfunction 
negatively impacted hematopoiesis. Deletion of the metabolic sensor Lsk1 (liver kinase 
B1) 299, the electron transport chain component SdhD (succinate dehydrogenase complex 
subunit D)300 or the relatively unknown Ptpmt1 (Pten-like mitochondrial phosphatase 1) 
caused decreased mitochondrial activity and correlated with loss of quiescence and 
dysfunctional HSCs which expanded but failed to differentiate. However, it remained 
unclear if the differentiation defects originated from HSCs or progenitors, which rely on 
oxidative phosphorylation for ATP production. More convincingly, conditional deletion of 
the electron transport chain component Riske iron-sulphur protein (RISP)301, directly 
linked mitochondrial dysfunction to HSCs. Moreover, Risp-/-HSCs exhibited an increase 
in DNA and histone methylation, suggesting mitochondria may play a role in epigenetics 
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of HSCs. A notion further supported by the observation of altered histone acetylation and 
methylation in hematopoietic populations with deletion of mitochondrial Tfam302 and 
mitochondrial fumarate hydratase (Fh1)303, respectively. The discovery that enhanced 
mitochondrial respiration, as well as dysfunctional mitochondrial respiration, were 
detrimental to HSC function is likely a reflection of a tightly regulated balance of 
mitochondrial metabolism in HSCs. 
 
Beyond generating ATP for cellular energy, mitochondria are required for other cellular 
processes that have been recently investigated in HSCs: fatty acid oxidation (FAO) and 
intracellular calcium buffering. Ito et al discovered chemical or genetic inhibition of the 
FAO pathway decreased the frequency of proper asymmetric division causing loss of 
HSC self-renewal and maintenance304. Our lab showed buffering of intracellular calcium 
(iCa2+) in HSCs likely via Mitofusin 2-mediated ER-mitochondria interactions was 
necessary to maintain CD150Low HSCs with extensive lymphoid potential89. More 
recently, Umemoto and colleagues confirmed the regulation of the Ca2+-mitochondria 
pathway was necessary to maintain HSCs in vivo305. These studies provided the first 
examples of an ATP-independent role for mitochondria in determining HSC homeostasis 
and cell fate. 
 
The mechanisms underlying maintenance, quiescence, renewal and multilineage 
differentiation potential of HSCs are still not understood. The present study of 
mitochondrial content in HSCs has revealed a previously unrecognized feature of these 
stem cells. Given the critical role of mitochondria for cellular homeostasis it is likely that 
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our finding has functional implications. As the role of mitochondrial function in HSCs 




4. Mitochondrial degradation by autophagy in HSCs 
 Background 
Mitochondria are maintained by synchronized cycles of degradation and biogenesis 
(mitochondrial turnover) which function together to ensure mitochondrial content remains 
stable and function of mitochondrial network is preserved (section 2.5). Previous 
observations of low mitochondrial mass in HSCs were linked to elevated mitochondrial 
degradation by autophagy. The proposed model implies an unusual imbalance between 
biogenesis and degradation that would ultimately lead to depletion of mitochondria in stem 
cells. In light of our findings showing high mitochondrial mass in adult HSCs, we revisited 
this issue. To provide context to our results we have summarized the current scientific 
evidence for the role of autophagy in unselective and selective mitochondrial clearance in 
HSCs.  
 
 Autophagy-mediated mitochondrial clearance 
Macroautophagy, commonly referred to as autophagy, is a highly conserved catabolic 
process whereby cytosolic components are degraded within lysosomes. Degradation of 
mitochondria by the autophagy machinery can occur in a stochastic or selective manner306. 
Non-selective autophagy degrades bulk cytosolic components, including mitochondria, 
and is typically induced in response to challenging conditions (e.g. starvation) to provide 
cells with essential nutrients. In contrast, selective autophagy of mitochondria (mitophagy) 
occurs to remove superfluous or damaged organelles. In both cases the cargo to be 
digested is contained in an autophagosome which subsequently fuses with the lysosome 
to form the autolysosome, where degradation occurs. In mitophagy, specific components 
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of the autophagy machinery must be targeted to mitochondria. In most mammalian cells 
this is thought to be mediated by the Ser/Thr kinase PINK1 and the E3 ubiquitin ligase 
Parkin. In healthy mitochondria, PINK1 is imported and proteolytically degraded in the 
mitochondrial matrix. Loss of mitochondrial membrane potential prevents import of PINK1, 
resulting in its accumulation in the OMM. PINK1 then recruits Parkin to the mitochondria 
where it ubiquitinates mitochondrial proteins. Hyper-ubiquitination of the mitochondrial 
surface is then recognized by ubiquitin-binding autophagy adaptors, thus promoting 
degradation by autophagy. In addition, ubiquitination by Parkin targets proteins involved 
in mitochondrial fusion307-310 and motility311 to promote separation of mitochondria to be 
removed from the mitochondrial network.  
 
Both selective and unselective mitochondrial autophagy are critical to maintain cellular 
homeostasis under normal and stress conditions and, not surprisingly, have been 
investigated in HSCs. 
 
 The role of non-selective autophagy in HSCs 
Investigation of autophagy in HSCs has largely relied on the use of mouse models with 
conditional deletion of key components of the autophagy machinery including the 
autophagy related gene (Atg) 7, Atg12 and Fip200. Loss of Atg7 resulted in loss of HSCs, 
myeloproliferation, decreased survival and reduced HSC function in Atg7-/-BM 
transplants268. Interestingly, Atg7-/-FL HSCs had a milder functional phenotype312, 
indicating autophagy could have different roles in fetal and adult HSCs. Atg12-/- HSCs also 
showed reduced regenerative function in transplants and myeloid-biased differentiation, 
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but the number of HSCs was unchanged and the mice survived269,287. Finally, deletion of 
FIP200, a component of the autophagy-initiation complex270, caused myeloid expansion 
and severely depleted the HSC pool and their reconstitution capacity. The phenotype of 
autophagy-deficient mutants was not completely overlapping but the requirement of 
autophagy for HSC maintenance and normal hematopoiesis was clear. In its absence the 
hematopoietic system of mutant mice was highly dysfunctional and resembled that of aged 
animals (myeloid-biased HSC output and decreased reconstitution capacity). At different 
levels of HSC purification, the same studies found increased mitochondrial mass, ROS 
levels, proliferation and apoptosis in mutant cells. This led the authors to conclude the 
phenotype of autophagy-deficient HSCs was likely a result of accumulation of superfluous 
or defective mitochondria. However, mitochondria were the only cytosolic component 
monitored and therefore these studies provide a narrow view of what other cellular 
elements could contribute to the detected functional defects.  
 
In addition to genetic ablation of autophagy components, the importance of autophagy in 
HSCs has been studied in steady state and in the more physiological context of starvation. 
A transgenic mouse overexpressing GFP-fused LC3b, a marker of the autophagosome, 
was used to visualize autophagy vesicles in HSCs269. Upon blockage of autophagosome 
degradation or cytokine withdrawal, LC3b-GFP punctae were readily observed in HSCs, 
indicating these stem cells had ongoing autophagy and could mount a robust autophagic 
response in starving conditions. Prevention of such response by autophagy inhibitors or 
in autophagy-deficient Atg12-/- HSC, showed autophagy was necessary to maintain HSC 
function and survival upon nutrient depletion.  
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Currently, the only known mechanism for ongoing autophagy in HSCs is a FOXO3A-driven 
pro-autophagy gene expression program269. Deletion of the transcription regulator 
FOXO3A in HSCs downregulated expression of pro-autophagy genes and decreased the 
ability of stem cells to recover from starvation.  
 
 Pink and Parkin-mediated mitophagy in HSCs 
The role of targeted degradation of mitochondria in HSCs has been directly addressed in 
two independent studies with conflicting conclusions. In 2016, Ito and colleagues identified 
upregulation of mitophagy via the FAO pathway as a key mechanism to maintain a top 
hierarchical HSC population (Tie2+HSCs)313. These stem cells exhibited high 
colocalization of the mitophagy-related Parkin and the mitochondria marker Tom20. 
Genetic abrogation of the FAO pathway or silencing of Parkin (Park2) caused a decrease 
in mitophagy and loss of Tie2+HSC maintenance. The authors concluded HSCs were able 
to, and relied on, specific targeting of mitochondria for degradation. In 2018 the first genetic 
model of hyperactivation of mitophagy in mice was developed and its impact was 
investigated in the hematopoietic system314. In this study the ATPase ATAD3a was 
identified as a mitophagy suppressor by facilitating import of PINK1 into the mitochondria 
for consequent degradation. In its absence, PINK1 accumulated on the mitochondria and 
triggered mitophagy. This genetic model provided a novel approach to specifically target 
mitophagy, instead of bulk autophagy, and to determine the consequences of inducing, 
rather than inhibiting, mitochondrial clearance. Atad3a-/- mice displayed reduced survival, 
decreased BM cellularity, anemia and lymphopenia. Although purified HSCs were not 
analyzed, Atad3a-/- BM exhibited reconstitution defects in transplants, a measure of HSC 
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function. Using different experimental approaches, these studies showed hematopoietic 
homeostasis was severely affected by both suppression and induction of mitophagy, 
leaving the field with unanswered questions on the importance of mitophagy in HSCs and 
their progeny.  
 
 mtDNA mutations in HSCs 
Understanding the consequences of mitochondrial damage to HSC function could provide 
insights into the level of requirement for mitochondria quality control mechanisms in these 
stem cells. In 2010, Inoue and colleagues used a mouse model of mitochondrial disease 
in which mice carry a pathogenic 4696bp deletion in approximately 80% of the mtDNA 
copies (ΔmtDNA)315. This study showed BM from ΔmtDNA mice had decrease 
reconstitution capacity likely due to impairment in differentiation of lineage-committed 
progenitors, which were expanded whereas terminally differentiated cells were decreased. 
However, the effect of ΔmtDNA mutation in HSCs remained unclear because experiments 
were performed in the heterogenous LSK population. A year later, Norddahl et al analyzed 
the hematopoietic function of the mitochondrial mutator mouse, which carries a 
proofreading-defective mitochondrial DNA polymerase316,317. HSCs exhibited similar 
mutation burden to downstream progenitors. However, the accumulation of mtDNA 
mutations caused severe functional defects in lymphoid and erythroid progenitors but did 
not affect the HSC pool. This study indicated HSCs and progenitors had different 





 Project rationale 
Although the scientific evidence supporting an important role for general autophagy in 
HSCs was convincing, the hypothesis that observed defects were driven by defective 
mitochondrial clearance was insufficiently verified. Furthermore, the concept that 
increased autophagy was required to maintain low mitochondrial content in HSCs was 
conflicting with our findings on mitochondrial mass. Nevertheless, the discovery of high 
mitochondrial content in HSCs only made investigating mitochondrial turnover and quality 
control more pertinent. On one hand, failure to eliminate defective mitochondria could 
negatively impact the HSC or its progeny, as shown in the mitochondrial mutator mouse. 
On the other hand, if high mitochondrial content was essential for HSC function or health, 
loss of mitochondria could be disruptive to hematopoietic homeostasis. In the next section 
we report our experimental evidence for unselective and selective autophagy of 





 Mitochondrial degradation by autophagy is lower in HSCs than in other 
hematopoietic populations 
Mitochondrial clearance by autophagy was 
the most accepted mechanism for 
maintenance of low mitochondrial content 
in HSCs. This model implied the rate of 
degradation was superior to biogenesis 
and over time stem cells would lose their 
mitochondria. We analyzed the relative 
mtDNA:nDNA ratio in purified HSCs (Lin-
cKit+Sca1+Flt3-CD48-CD150+), MPPs (Lin-
cKit+Sca1+Flt3+CD48+), CMPs (Lin-cKit+Sca1-), and cells with expression of markers of 
terminal differentiation (Lin+) isolated from the BM of 2 months-old (young) and 24 months-
old (old) mice. The mitochondrial content of the long-lived HSC population of old mice was 
unchanged, suggesting that HSCs do not feature imbalanced mitochondrial degradation 
versus biogenesis (Fig. 1). We concluded that the rate of mitochondrial turnover in these 
hematopoietic populations maintained a stable mitochondrial mass over time. However, 
this assay only monitored the quantitative aspect of mitochondrial content and as a result 
we were not able to infer if mitochondrial turnover was high or low.  
 
To determine the rate of mitochondrial turnover we monitored mitochondrial content in 
cells treated with chloroquine (CQ), an autophagy inhibitor which blocks autophagosome 
Figure 1. Mitochondrial mass in young and old 
mice. Relative mtDNA:nDNA ratio in 
hematopoietic populations HSCs (Lin-
cKit+Sca1+Flt3-CD48-CD150+), MPPs (Lin-
cKit+Sca1+Flt3+CD48+), CMPs (Lin-cKit+Sca1-) 
and Lin+ sorted from the BM of 2-months old 
(young) and 24-months old (old) mice (n=3, 
mean±sem), normalized to young HSCs. 
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fusion with the lysosome318 (Fig. 2A). Prevention of lysosomal degradation causes the 
accumulation of vesicles containing cargo that would have been otherwise cleared by 
autophagy, including mtDNA. Therefore, the extent of the increase in mtDNA after 
treatment is a reflection of mitochondrial turnover – the higher the increase in 
mtDNA:nDNA, the higher the mitochondrial turnover rate. Since HSCs are highly capable 
of xenobiotic efflux we assessed if treatment with CQ inhibited autophagy in HSCs. Indeed, 
6h and 24h post-treatment we observed the accumulation of autophagy vesicles marked 
by LC3b in both HSCs and MPPs (Fig. 2B). This observation validated the use of CQ as 
a general autophagy inhibitor in HSCs and confirmed previous observations of active 
autophagy in HSCs. In addition to HSCs, we examined mitochondrial content in MPPs, 
CMPs, and macrophages (Mac, Mac1+), a terminally differentiated population with high 
autophagy flux associated with its immune role in fighting pathogens319. Prevention of 
lysosomal degradation caused a significant accumulation of mtDNA in all populations 
except for HSCs (Fig. 2C), indicating steady-state mitochondrial turnover was lower in the 
Figure 2. Effect of autophagy inhibition on mitochondrial mass. A. Damaged or superfluous 
organelles are isolated from the mitochondrial network and surrounded by an isolation membrane to 
give rise to the autophagosome which fuses with the lysosome to form the autolysosome, where cargo 
is degraded. The autophagosome marker LC3b is shown in green. Chloroquine (CQ) is an inhibitor of 
general autophagy that prevents lysosomal fusion and is shown in grey. [Figure adapted from 242] B. 
Representative microscopy images of LC3b immunofluorescence in HSCs and MPPs after CQ. C. 
Relative mtDNA:nDNA ratio after treatment with CQ in HSCs, MPPs, CMPs and macrophages (Mac). 
Data normalized to the respective untreated sample (n≥3 mean±sem) 
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stem cells. However, due to the inability of maintaining HSC ex vivo this experimental 
approach targeted only one mitochondrial component (mtDNA) over a short period of time. 
 
To complement this assay, we acquired mito-Keima (mt-Keima) mice, a recently 
developed in vivo model to measure mitophagy320. Keima is a coral-derived protein with a 
bimodal excitation spectrum that changes according to pH321. In this transgenic mouse 
Keima has been fused to a mitochondria targeting sequence (MTS) allowing for 
discrimination of its location in the mitochondria (pH≈8) or in the lysosomes (pH≈4.5). As 
Keima is resistant to lysosomal proteases its signal is accumulated over time. Given these 
properties, Keima fluorescence reflects the level of mitochondrial degradation in a cell. 
Using flow cytometry, we determined mt-Keima fluorescence after excitation at a 
Figure 3. Mitochondrial autophagy in vivo. A. Schematic of gating strategy of the acidic, intermediate 
(Mid), and neutral fractions based on mt-Keima fluorescence. B. Proportion of each fraction in individual 




wavelength predominantly exciting the protein in a neutral environment (440nm) and a 
wavelength predominantly exciting in an acidic environment (586nm). Based on the 
fluorescence profile, we subdivided mt-Keima fluorescence in three fractions: most acidic, 
intermediate (Mid) and most neutral (Fig. 3A). The acidic and neutral fractions comprised 
the top 20% BM with the most and least mitochondrial autophagy, respectively. Based on 
cell surface marker expression profiles we determined the proportion of each fraction in 
HSCs, MPPs, CMPs and Lin+. All BM populations were represented in the three fractions 
but in different proportions (Fig. 3B). Whereas the percentage of cells with high 
mitochondrial autophagy was similar across all cell types, committed progenitors and 
differentiated cells were enriched in the mid fraction and HSCs and MPPs in the most 
neutral fraction (Fig. 3B, 3C and 3D).  
 
To functionally validate these results we performed competitive transplants, a measure of 
HSC activity. Purified acidic and neutral BM fractions were transplanted into lethally 
irradiated recipient mice (Fig. 4A) and donor reconstitution was determined by PB analysis 
16 weeks post-transplant (Fig. 4B). As predicted by the phenotypic analysis, the neutral 
BM fraction displayed significantly higher regenerative capacity than the acidic fraction 
(Fig. 4C). To assess the multilineage differentiation potential of each fraction we further 
analyzed donor cells for expression of pan-myeloid markers (Gr1 and Mac1), pan-
lymphoid markers (CD3 and CD19 for T and B cells, respectively). All lineages were found 
at similar frequencies in both fractions, showing the reconstitution capacity increased in 
the neutral fraction displayed normal multilineage potential (Fig. 4D and E).  
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Altogether, both in vitro monitoring of mtDNA and in vivo analysis of mt-Keima 
fluorescence indicated steady-state mitochondrial degradation by autophagy in HSCs was 
significantly lower than in CMPs and terminally differentiated cells.  
  
Figure 4. HSC activity in mt-Keima BM fractions. A. Experimental design and time line for isolation 
and transplant of mt-Keima BM fractions. B. Representative flow plots of PB analysis in recipients of 
mt-Keima+ donor BM. C. Percentage of mt-Keima+ donor cells. D. Percentage of lymphoid (Gr1-Mac1-) 
in the donor compartment. E. Ratio of T cells (CD3+) to B cells (CD19+) in the donor lymphoid 
compartment. Data was obtained from the PB of recipient mice 16 weeks post transplantation (n≥4 
mean±sem, from 1 independent transplant). 
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 CCCP-induced mitophagy is reduced in HSCs 
In most cell types mitochondrial degradation and biogenesis increase in response to injury 
to replace damaged mitochondria with healthy organelles. We investigated mitochondrial 
turnover in the context of mitochondrial damage by treating cells with CCCP, a 
mitochondrial uncoupler commonly used to induce PINK and Parkin-mediated mitophagy 
(Fig. 5A). To confirm the effect of CCCP we stained cells with TMRE, a positively-charged 
fluorescent dye which readily accumulates in mitochondria due to their negative charge. 
As expected, treatment with CCCP resulted in loss of mitochondrial membrane potential 
and consequent loss of TMRE fluorescence (Fig. 5B). Cell viability was similar in CCCP-
treated samples and thus excluded as a factor in the interpretation of results (Fig. 5C). 
 
Figure 5. Induction of mitophagy. A. Schematic representation of mitophagy modulation by the 
mitochondrial uncoupler CCCP (yellow) and the general autophagy inhibitor CQ (grey) [Figure adapted 
from 242]. B. Representative TMRE fluorescence histograms in untreated (grey) and CCCP-treated (red) 




Mitochondrial mass, measured by mtDNA content, was unchanged in all CCCP-treated 
populations (Fig. 6A). We hypothesized this was the result of high but balanced 
mitochondrial degradation and biogenesis. Indeed, simultaneous treatment with CCCP 
and the autophagy inhibitor CQ revealed a strong increase (5-20 fold) in mitochondrial 
content in all populations, except for HSCs where this increase was much less pronounced 
(≈1.7 fold) (Fig. 6A). Looking at an earlier step in the degradation process, we measured 
mitochondrial length in untreated and CCCP-treated samples. Mitochondrial damage, as 
induced by CCCP, typically triggers mitochondrial fragmentation to facilitate the process 
of removal. Interestingly, we detected an increase in shorter mitochondrial fragments in 
MPPs, but not in HSCs (Fig. 6B). Moreover, culture of HSCs in the presence of CCCP did 
Figure 6. Effect of mitophagy induction. A. Relative mtDNA:nDNA ratio after treatment with CQ and 
CCCP in HSCs, MPPs, CMPs and Mac. Data normalized to the respective untreated sample (n≥3 
mean±sem). B. Experimental design and timeline of HSC transplants after CCCP treatment. C. 
percentage of donor cells and D. lymphoid donor cells in the PB of recipient mice 16 weeks post-
transplant (n≥4±sem, from 1 independent transplant). 
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not affect their in vivo long-term multilineage reconstitution capacity (Fig. 6C and 6D). 
These data indicated the mitophagic response of HSCs to mitochondrial damage was less 
robust than other populations, including their immediate downstream progenitor population 
(MPPs). Even so, HSC in vivo function after depolarization was normal leading us to 
speculate stem cells might be more tolerant to mitochondrial damage and/or upon 
differentiation progenitors are equipped to efficiently remove damaged organelles, 
resulting in normal hematopoietic function. In the next sections we summarized our efforts 





 Parkin is dispensable for HSC function 
We hypothesized decreased mitochondrial degradation in HSCs could be caused by 
decreased expression of the key mitophagy mediators PINK1 and Parkin. Surprisingly, the 
mRNA levels for their coding genes, Pink1 and Park2, was preferentially expressed in 
HSCs (Fig. 7A). To determine the functional relevance of this observation we acquired 
mice with global deletion of Park2322 (Fig. 7B). Flow cytometric analysis of myeloid and 
lymphoid lineages in the PB of Park2-/- mice was normal, indicating Parkin is dispensable 
for steady-state hematopoiesis (Fig. 7C and 7D).  
Figure 7. Characterization of Parkin-deficient mice. A. Relative mRNA levels of Parkin (Park2) 
and Pink (Pink1) in purified hematopoietic populations (n≥2, mean±sem), normalized to HSCs. B. 
Western blot for Parkin and Gapdh in brain, liver, and heart lysates of WT and Park2-/- mice. C. 
Percentage of lymphoid and myeloid lineages in the PB of Park WT (Park2+/+), heterozygous (Park2-
/+) and KO (Park2-/-) mice (n=5, mean±sem). D. Representative flow plots of PB analysis.  
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The BM compartment of Park2-/-mice appeared normal, with the exception of a slight 
decrease in the number and frequency of Park2-/-HSCs (Fig. 8).  
Transplantation of equal numbers of WT and Park2-/-BM showed equivalent multi-lineage 
long-term reconstitution capacity (Fig. 9), indicating Parkin is dispensable for HSC 
regenerative capacity.  
Figure 8. Frequency and number of HSCs in the BM of Parkin-deficient mice. A. Representative 
flow plots of gating strategy to identify HSCs. B. Frequency and C. Number of HSCs Park2+/+ and 
Park2-/- BM (n=10, mean±sem). 
Figure 9. HSC activity of Parkin-deficient BM in competitive transplantation assays. A. 
Experimental design and time line of transplant assay. B. Representative flow plots of PB analysis. 
C. percentage of donor cells and D. lymphoid donor cells in the PB of recipient mice. E. Percentage 
of T and B cells in the lymphoid donor compartment. Data was obtained from the PB of recipient mice 
16 weeks post transplantation (n=13 mean±sem, from two independent transplants). 
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 Parkin deletion decreases mitochondrial turnover but hematopoiesis is 
unaffected 
While Parkin is best recognized for its role in mitophagy, it has also been linked to 
mitochondrial biogenesis249. Indeed, in comparison to WT, Park2-/- cells showed a smaller 
increase in mtDNA accumulation after treatment with CQ (Fig. 10A). However, 
mitochondrial turnover was still detected in all cell-types and was sufficient to maintain 
stable mitochondrial mass (Fig. 10B). 
 
Parkin is thought to be a negative regulator of the cell cycle as its deletion, silencing, or 
mutation has been linked to increased proliferation and tumorigenesis323-325. To determine 
if Parkin deletion affected progression of the tightly regulated cell cycle in HSCs, we 
performed an in vivo Edu cell proliferation assay (Fig. 11A). As expected, proliferation of 
WT HSCs was lower than progenitors. Surprisingly, proliferation was further reduced in 
Park2-/-HSCs, perhaps a contributing factor to their decrease in frequency and number. In 
Figure 10. Mitochondrial content in Parkin-deficient mice. A. Relative mtDNA:nDNA ratio after CQ 
treatment in Park2+/+ and Park2-/- hematopoietic populations, normalized to untreated (n=1, mean±sd). 




alignment with our observations in HSCs, we consistently detected a small decrease in 
the percentage of Edu+ in other BM cells (Fig. 11B and C). 
Finally, lack of Parkin has been linked to both an increase and decrease in mitochondrial 
length, depending on the cell type326,327. Our lab has previously shown mitochondrial 
Figure 11. Effect of Park2 deletion on cell proliferation. A. Experimental design and timeline of Edu 
proliferation assay. B. Representative flow plots of Edu+ gates in one control mouse injected with PBS 
and Edu-injected Park2+/+ and Park2-/- mice. C. Percentage of Edu+ in each population of Park2+/+ and 
Park2-/-  mice (n=2, mean±sem).  
Figure 12. Effect of Park2 deletion in mitochondrial morphology. A. Representative fluorescence 
microscopy images of Mitotracker Red (MTR) staining in Park2+/+ and Park2-/- KO HSCs and MPPs. B. 
Quantification of mitochondrial length in Park2+/+ and Park2-/- HSCs and MPPs (n≥15, mean±sem). 
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fusion was an important feature of BM HSCs89. Measurement of mitochondrial length in 
WT and Park2-/-HSCs and MPPs indicated mitochondrial morphology was unaffected by 
Parkin (Fig. 12).  
 
In conclusion, although we detected a role for Parkin in mitochondrial turnover and 
proliferation, in its absence hematopoiesis proceeded normally. Our findings suggest 
Parkin, and the degree to which these processes were affected in mutant mice, has no 
major functional consequences in HSCs.  
 
 Mitochondrial fusion does not explain low mitochondrial turnover in HSCs 
Mitochondrial length is a limiting factor of mitochondrial degradation by autophagy as the 
autophagosomes have a diameter of approximately 1μM328. Mitochondrial length is 
determined by the balance between cycles of mitochondrial fusion and fission (section 
2.4). Increased mitochondrial fusion results in more elongated mitochondria which have 
been shown to be spared from autophagy329. In 2016 we showed HSCs, in particular HSCs 
expressing low levels of the surface marker CD150 (CD150LowHSCs), displayed increased 
expression of Mitofusin 2 (Mfn2) and exhibited a highly fused mitochondrial network89. We 
hypothesized mitochondrial fusion could be a contributing factor to low mitophagy in HSCs 
and, if so, CD150Low HSCs would have lower mitochondrial turnover than CD150High HSCs. 
We repeated the CQ and CCCP experiments in HSCs purified based on CD150 
expression and MPPs, used as control for detectable mitochondrial turnover and 
fragmentation. Autophagy inhibition with CQ caused a minor accumulation of mtDNA in 
CD150HighHSCs, indicating this population of stem cells could have increased 
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mitochondrial turnover (Fig. 13C). The frequency of shorter mitochondrial fragments 
increased in CCCP-treated CD150High HSCs but not in CD150Low HSCs (Fig. 13A and 
13B). However, regardless of CD150 levels, mitochondrial turnover upon damage was 
undetected (Fig. 13C). Because both populations of HSCs have longer mitochondria than 
other progenitors, we wondered if the difference between the two subsets was too minor 
to impact mitochondrial clearance. 
 
We isolated HSCs, progenitors and macrophages from animals with conditional 
hematopoietic deletion of Mfn2. Adult Mfn2-/-HSCs exhibit a collapse of the mitochondrial 
network and loss of the CD150Low population89, two features which would theoretically 
make them more amenable to mitochondrial degradation by autophagy. Mitochondrial 
content, measured by mtDNA, was unchanged in all populations (Fig. 14A). Importantly, 
Figure 13. Mitochondrial turnover in CD150High and CD150Low HSCs. A. Quantification of 
mitochondrial length after CCCP treatment (n≥15, mean±sem). B. Representative fluorescence 
microscopy images of CCCP-treated cells purified from MitoDendra2 mice. White arrows identify 
examples of fragmented mitochondria. C. Relative mtDNA:nDNA ratio after treatment with CQ and/or 
CCCP, normalized to untreated (n=3, mean±sem). 
99 
 
the accumulation of mtDNA in CQ-treated Mfn2-/-HSCs was not significantly different than 
WT (Fig. 14B). Taken together we concluded mitochondrial fusion was not the major 
mechanism by which mitochondrial degradation was lower in stem cells. 
 
  
Figure 14. Mitochondrial turnover in Mfn2-/-hematopoietic populations. A. Relative mtDNA:nDNA 
in freshly isolated cells, normalized to WT (n≥3, mean±sem). B. relative mtDNA:nDNA after treatment 
with CQ, normalized to untreated (n≥4, mean±sem). 
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 Discussion and future directions 
It was previously thought HSCs displayed low mitochondrial content in an autophagy-
dependent manner. Studies of mice with deletion in pro-autophagy genes described an 
increase in mitochondrial mass, ROS, and hematopoietic defects. However, the 
housekeeping functions of autophagy include not only degradation of mitochondria but of 
proteins, protein aggregates, pathogens, lipid droplets, peroxisomes, and ribosomes. 
Accumulation of such dysfunctional components, like mitochondria, have been associated 
with several physiological disorders. Although these cytosolic elements were plausible 
contributors to the hematopoietic defects observed in autophagy deficient mice, they were 
never analyzed. 
 
The causative relation established between an increase in mitochondrial mass in 
autophagy-deficient mice and HSC dysfunction presented a reductive view of the 
importance of autophagy in cellular homeostasis. Nonetheless, this evidence established 
the belief that maintaining low mitochondrial content via autophagy was a requirement for 
HSC function. We reexamined this notion for several reasons. First, the concept of biased 
mitochondrial degradation to promote their elimination over time was in direct conflict with 
our findings of high mitochondrial content in HSCs. Second, the increase in mitochondrial 
mass in autophagy-deficient mice was moderate and heavily based on mitochondrial dyes, 
which we showed are unreliable in HSCs. Third, mitochondrial autophagy is a mechanism 
by which mitochondrial health is preserved. The discovery of high mitochondrial mass in 
HSCs, which give rise to all blood cell lineages, made the investigation of mitochondria 
quality control mechanisms of high relevance. 
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We first observed mitochondrial mass, measured as mtDNA content per cell, was 
unchanged in young and old HSCs. This finding alone refuted the idea that mitochondrial 
degradation by autophagy promoted elimination of mitochondria in HSCs. Since HSCs are 
long-lived cells, if mitochondria were preferably degraded in stem cells the organellar 
content would decrease over time, which was not observed. Moreover, we found this to 
be an unlikely scenario conceptually as mitochondrial biogenesis and degradation 
(turnover) are coordinated processes that together maintain mitochondrial content stable. 
The only established exceptions to this equilibrium are the reticulocytes in which 
unbalanced mitochondrial degradation occurs in the final maturation step of red blood 
cells330, and the fertilized oocytes in which paternal mitochondria are selectively 
eliminated331. However, limitations inherent to the mtDNA assay could bias the 
interpretation of results as it relied on the assumption of equal mitochondrial genome 
integrity in young and old HSCs. Although we cannot conclusively exclude this variable, 
the region targeted for determining mtDNA copy number (Cytb) falls outside of the 
common 3867bp deletion described to accumulate in aged mice332.  
 
Next, we set out to investigate mitochondrial turnover in steady-state and upon induction 
of damage. Defining the turnover rate of mitochondria is challenging for several reasons. 
First, mitochondria do not generally exist as isolated organelles but as interconnected 
structures continuously merging their content through cycles of fusion and fission. Second, 
turnover assays focus on one mitochondrial component (proteins, lipids or mtDNA), and 
the extension to which the turnover rate of one component reflects that of the whole 
organelle is uncertain. Therefore, the interpretation of these data must proceed with 
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caution. In our experiments mitochondrial turnover was assessed by monitoring two 
independent targets with distinct methodologies. We determined the accumulation of 
mtDNA after inhibition of autophagy by qPCR and the proportion of mt-Keima in the 
lysosome. The lack of accumulation of mtDNA in CQ-treated HSCs reflected undetectable 
mitochondrial biogenesis and degradation, which was observed in all other hematopoietic 
populations. In accordance with this finding, both phenotypic HSCs and HSC activity were 
enriched in the fraction with the lowest mitochondrial autophagy as evaluated by the mt-
Keima reporter.  
 
Although we are encouraged by the alignment of two independent methodologies, neither 
approach is without shortcomings. First, the targeted region of mtDNA is inferior to 100bp 
and we were unable to discriminate between detection of degraded and whole genomes, 
due to its small size. This may be relevant in discriminating between degradation and 
biogenesis, respectively. Even so, the unchanged mtDNA content in HSCs still indicated 
neither biogenesis, nor degradation were ongoing. In addition to inhibiting autophagy, CQ 
has been described to induce autophagy-independent disorganization of the Golgi and 
endosomes, aspects we did not account for in interpreting the response of HSCs and other 
populations to CQ318. Finally, mt-Keima fluorescence reports on mitochondria, or 
mitochondrial components, delivered to the lysosome. Although this in vivo model is a 
powerful tool to measure mitophagy, it does not report on biogenesis. Despite the technical 
limitations, using two independent assays we showed HSCs have ongoing autophagy but 
mitochondrial degradation by autophagy was lower than more differentiated populations, 
both ex vivo and in vivo.  
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Next, we determined the ability of HSCs to target defective mitochondria for degradation 
by autophagy (mitophagy). Depolarization of mitochondria with the uncoupler CCCP has 
been reported to induce PINK1-Parkin mediated-mitophagy242,333-335. In response to 
CCCP, and confirmed depolarization, HSCs increased mitochondrial turnover but to a 
lesser extent than any other population. We cannot exclude that other damaging agents 
could have triggered a more robust response from stem cells. However, attempts to 
promote mitochondrial degradation in HSCs with the autophagy inducer rapamycin and 
mtDNA depletion with ethidium bromide were unsuccessful (data not shown). Based on 
these findings, we questioned whether mitochondria were less susceptible to autophagy 
in HSCs than in other populations. We pursued two distinct avenues to address this 
question.  
 
First, we focused on characterizing the best known mitophagy-mediator Parkin. Despite 
the low mitochondrial turnover in response to CCCP, Pink1 and Park2 mRNA levels were 
upregulated in HSCs indicating expression of these genes was not the limiting factor. We 
were unable to validate these results at the protein level as we were not confident in the 
antibody specificity in immunofluorescence experiments (data not shown). Deletion of 
Park2 caused a mild decrease in mitochondrial turnover and proliferation in all 
hematopoietic cells. Although its expression was the highest in HSCs these cells seem to 
be the least affected population. Importantly, the changes observed in Park2-/- mice did 
not affect steady-state hematopoiesis or HSC activity in transplants. Discovering Parkin 
was dispensable for maintaining stable mitochondrial content and normal HSC function 
was in agreement with previous work287 but in striking disagreement with a study showing 
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silencing of Park2 affected HSC maintenance313. We speculated that differences in 
experimental approaches (global deletion vs acute silencing) could contribute to the 
inconsistencies observed. In fact, the timeline of deletion of Parkin in cardiomyocytes was 
shown to be relevant and determinative with respect to mouse survival336, suggesting 
unknown mechanisms of mitochondrial plasticity likely exist. Nonetheless, our studies 
propose Parkin-dependent mitophagy is dispensable for normal hematopoiesis and not 
required to maintain stable mitochondrial content and steady-state mitochondrial turnover 
in all hematopoietic populations. As other E3 ubiquitin ligases have recently begun to be 
identified as regulators of mitophagy337,338 we cannot exclude that Parkin-independent 
mitophagy pathways could affect HSC function.  
 
In a second avenue of research into the mechanisms by which mitochondrial degradation 
by autophagy could be low in HSCs, we focused on the role of mitochondrial fusion. 
Elongated mitochondrial networks, as observed in HSCs, do not favor engulfment by the 
isolation membrane of the autophagosome230. However, CQ treatment of HSC subsets 
with different mitochondrial lengths or Mfn2-/-HSCs with fragmented mitochondria did not 
show a significant change in mtDNA accumulation. The interpretation of the Mfn2 data 
was convoluted as MFN2 has been identified as receptor of Parkin339 in addition to its role 
in mitochondrial fusion. In theory, its deletion could both favor mitochondria engulfment by 
bulk autophagy and limit Parkin-mediated mitophagy, an interpretation we rejected since 
the evidence for Parkin-mediated mitophagy in HSCs was unconvincing. Fused 
mitochondrial morphology was excluded as a mechanism by which mitochondria in HSCs 
were less degraded by autophagy than committed progenitors or differentiated cells. 
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Additional validation could be obtained by performing these experiments in fission-
deficient cells and determining if the elongation of mitochondria would reduce 
mitochondrial degradation in progenitors to the level of HSCs. 
 
In short, we assessed mitochondrial degradation via autophagy in HSCs by combining 
distinct experimental approaches and including progenitors and differentiated populations. 
We discovered HSCs had the lowest rate of mitochondrial degradation in both steady-
state and upon mitochondrial damage. The relevance and mechanisms underlying this 
discovery remain unknown and leave many unanswered questions.  
 
We found mt-Keima mice to be perhaps the best tool to study the mitophagic response 
process in HSCs since it is amenable to flow cytometric analysis of a small number of 
cells. Additional experiments of interest would be to transplant equal numbers of HSCs 
isolated from the most neutral and the most acidic fraction and compare their regenerative 
capacity to directly assess the impact increased mitophagy may have on reconstitution. If 
we observe a difference in HSC function between the subsets, we can perform RNA 
sequencing and gain insight into how or why mitophagy was triggered in HSCs. In addition, 
we can determine if the mitochondrial content of HSCs with higher mitophagy is reduced 
or if, alternatively, higher mitophagy is balanced with biogenesis. The mt-Keima mice can 
also be a useful quantitative tool to test the response to different mitochondrial damaging 
agents. Finally, these animals can be crossed to other transgenic mice of interest such as 
the mutator mouse and the Atad3a-/- mice to drive mitophagy in the hematopoietic system 
and compare the mitophagic response of HSCs to progenitors in those scenarios. 
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As for the discovery of mechanisms maintaining low mitochondrial autophagy in HSCs, we 
can assess the role of mitochondria motility. Arrest of mitochondrial movement is thought 
to facilitate clearance. In accordance, proteins involved in mitochondria motility such as 
Miro are specifically targeted for degradation by the PINK1/Parkin pathway311. Live cell 
imaging of hematopoietic populations isolated from mitoDendra2 mice revealed 
mitochondria are highly motile in HSCs compared to committed progenitors (unpublished 
data). Moreover, HSC [iCa2+] is low89 and required to be maintained low for self-renewal 
division305, a feature linked to high mitochondrial motility340. To investigate if this was a 
limiting step in mitochondrial autophagy in HSCs, we may acquire mice with deletion of 
key modulators of mitochondrial motility. A prime candidate for this purpose would be the 
adaptor Miro which anchors the organelle to microtubules (section 2.4.3.) in a Ca2+ 
dependent manner340-342. 
 
To look at the other arm of mitochondrial turnover, mitochondrial biogenesis, we 
considered introducing an inducible Tet-ON system into HSCs to express the molecular 
clock MitoTimer343, a mitochondrially targeted modified fluorescent protein that is 
produced as green and shifts irreversibly to red as it matures. Changes in green:red 
fluorescence reports differences in mitochondrial degradation and mitochondrial protein 
synthesis, import, and biogenesis. This system would require extensive optimization and 
experimental controls but could be an elegant in vivo model to define mitochondrial 




Finally, mitochondrial quality control mechanisms comprise a network of pathways that 
work together to ensure mitochondrial health. Autophagy is only one of these pathways. 
Other mitochondrial quality control mechanisms that may be of interest in HSCs include 
content mixing and separation by mitochondrial fusion and fission, mtDNA repair 
pathways, refolding of misfolded proteins by chaperones (Hsp60, Hsp70, and others), 
induction of the mitochondrial unfolded protein response (UPRmt), and proteolysis (Lon, 
AAA proteases). Of these, only UPRmt has been investigated in the hematopoietic system. 
In 2015, Mohrin et al activated the UPRmt in HSCs through deletion of the histone 
deacetylase SIRT7261. Sirt7-/- HSCs showed loss of quiescence and functional defects 
associated with aged HSCs. Consistent with studies in Atad3a-/- mice314, in which 
mitophagy was hyperactivated, this study provided genetic evidence for a link between 
activation of mitochondrial quality control pathways and loss of stemness. These findings, 
together with our own, suggest mitochondrial quality control mechanisms might be overall 
reduced in HSCs. HSCs have a predominantly glycolytic metabolism and their 
mitochondria might be protected from damage, in which case quality control mechanisms 
would be superfluous. Alternatively, HSCs could be more tolerant to mitochondrial damage 
resulting in a reduced response in comparison to progenitors when challenged with similar 
damage. It could also be that these mechanisms are repressed in HSCs and only activated 
upon exit of quiescence and differentiation, as has been described for UPRmt344 and for 




In conclusion, the regulation of mitochondria in HSCs remains puzzling and with each 
study new questions arise in what is becoming an exceedingly interesting and complex 




5. Deletion of Mitofusin 1 and 2 in the hematopoietic system 
 Background 
Mitochondrial dynamics (section 2.4) determine morphology, distribution and activity of 
mitochondria. Their regulation appears cell-type specific and can quickly change in 
response to cues from the intra- and extracellular environments. The tightly controlled 
balance between fusion and fission has been shown to modulate a variety of processes 
including metabolism, apoptosis, cell cycle, autophagy and calcium homeostasis. The 
physiological role of mitochondrial dynamics in a particular system can be studied by 
directly disrupting that balance. This can be accomplished by deletion or overexpression 
of the core components of the fusion and fission machinery: Mfn1, Mfn2, Opa1 and 
Drp1221. In the present study we have conditionally deleted the two regulators of OMM 
fusion (Mfn1 and Mfn2) in the hematopoietic system. To provide context to our findings we 
reviewed our current knowledge of the role of mitofusins in regulating mitochondrial 
function.  
 
 Regulation of mitochondrial function by MFN1 and MFN2  
Modulation of mitochondrial dynamics by deletion or overexpression of Mfn2 has been 
shown to modify the metabolic profile of various cell-types. This effect is associated with 
MFN2-induced changes in the expression levels of subunits of oxidative phosphorylation 
complexes and is independent of the pro-fusion function of MFN2348. However, the exact 
mechanism by which MFN2 affects metabolism remains unclear and is further complicated 




Depending on the environmental cue, mitofusins have been described to either protect or 
promote mitochondrial elimination by autophagy. In starving conditions mitochondria are 
protected from degradation by fusion-dependent elongation329. In damaged or superfluous 
mitochondria, MFN2 acts as a Parkin receptor in the early steps of mitophagy339 and both 
MFN1 and MFN2 are targeted for degradation, ultimately causing mitochondria to become 
shorter and facilitating subsequent removal310.  
 
During cell cycle progression mitochondrial morphology changes continuously. During 
G1/S phase, mitochondria elongate to meet the ATP requirements of this energy-
demanding process351. When cells divide during G2/M, mitochondria fragment to ensure 
equal distribution to daughter cells. Unsurprisingly, mitofusins have been shown to be 
important for the restructuring mitochondrial networks undergo during this process. Park 
and colleagues observed that mitochondrial fragmentation during G2/M was mediated by 
targeted degradation of MFN1352. The concept of MFN2 as a regulator of cell cycle is 
widely accepted, but whether MFN2 is a negative or positive regulator is still up for debate 
and may vary across cell-types. For example, Mfn2 deletion increased proliferation in 
MEFs353, but repressed proliferation in smooth muscle cells354. 
 
The mitochondrial network becomes severely fragmented during apoptosis via DRP1-
mediated fission355. MFN2 has been implicated in regulation of programmed cell death in 
several instances but discrepancies are found between studies. In hypoxia-induced 
neuronal apoptosis, Mfn2 expression was decreased. If overexpressed, MFN2 would 
attenuate the apoptotic phenotype, suggesting that MFN2 has anti-apoptotic functions356. 
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In contrast, MFN2 promotes apoptosis in smooth muscle cells357, embryonic stem cells358, 
HeLa359 and T cells360. 
 
While it is clear that mitochondrial dynamics modulate mitochondrial function in diverse 
cellular processes, major discrepancies exist between studies. The use of different cell-
types and experimental approaches (knockdown, knockout, mutation or overexpression) 
are likely contributors to the observed inconsistencies. Still, variability in results might 
simply reflect the complexity of this process – the perceived role of mitochondrial dynamics 
may be specific to both the celltype and experimental conditions. 
 
The majority of these studies implicated MFN2 as a key modulator of mitochondrial 
function. Whether or not MFN1 had similar roles would require further investigation. In the 
next sections we categorized aspects of the two GTPases as redundant and non-
redundant.  
 
 Redundant properties of MFN1 and MFN2 
Mitofusins are nuclear-encoded mitochondrial proteins that belong to the transmembrane 
GTPase protein family. Homologues have been identified in eukaryotes, from yeast to 
humans. MFN1 and MFN2 share a similar amino acid sequence and the same relevant 
structural domains: one cytosolic GTPase domain, a first coil heptad-repeat (HR1) domain, 
two transmembrane (TM) domains, and a second HR domain (HR2). Their role in 
mitochondrial fusion is indisputable as single deletion of either Mfn1 or Mfn2 causes a 
collapse of the mitochondrial network. Their pro-fusion function is thought to significantly 
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overlap since mitochondrial fragmentation in mitofusin-deficient mouse embryonic 
fibroblasts (MEFs) could be rescued by overexpression of the undeleted mitofusin217.  
 
 Non-redundant properties of MFN1 and MFN2 
Several key studies have demonstrated that depending on the cellular process, the cell-
type or the developmental stage, MFN1 and MFN2 could be functionally distinguished, 
including in regard to mitochondrial fusion. In 2003, Chen and colleagues observed Mfn1-
/-MEFs exhibited small and spherical mitochondria, while Mfn2-/-MEFs exhibited enlarged 
and irregular mitochondria217. One year later it was shown that in addition to its role in 
OMM fusion, MFN1, but not MFN2, was required to mediate OPA1-driven IMM fusion in 
MEFs226.  
 
Generation of mice with genetic ablation of either mitofusin, showed that MFN1 and MFN2 
are essential for survival and that deletion of either causes lethality in mid-gestation. Mfn1-
/- Mfn2-/- double knockout (DKO) died earlier than either single mutants217, leading the 
authors to propose mitofusins might not be completely redundant. Later, the same 
investigator generated a transgenic mouse with Cre-mediated deletion of Mfn1 or Mfn2 
that bypassed embryonic lethality of the single mutants361. This study revealed MFN2, but 
not MFN1, was required for normal development of the cerebellum, indicative of a MFN2-
specific role in neurodegeneration. Notably, one allele of Mfn1, but not Mfn2, was sufficient 
to rescue the embryonic lethality of Mfn1-/-Mfn2-/- conditional DKO mice. Otherwise, Mfn1-
/-Mfn2-/+ or DKO mice die at P0 which is indicative of a cardiac, circulatory or pulmonary 
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developmental defect. Altogether, these studies demonstrated MFN1 and MFN2 are not 
entirely redundant in vivo either. 
 
Several factors might contribute to the differential effects of deletion of Mfn1 and Mfn2. 
First, the relative abundance of each mitofusin appears to be specific to the celltype and 
developmental stages362,363. The vulnerability of cells to a mutation in either mitofusin is 
thought to be determined by which mitofusin is predominantly expressed364. In agreement, 
MFN2 is expressed at higher levels in the cerebellum than MFN1361. Second, MFN2 
contains a unique proline rich domain (PR) between HR1 and the TM domains, which is 
not present in MFN1. This region is likely responsible for MFN2-specific interactions with 
other proteins. Third, MFN1 exhibits approximately an eight-fold higher GTPase activity 
than MFN2365, tethering mitochondrial membranes with higher efficiency than MFN2. 
Fourth, in contrast to MFN1, MFN2 is found in the ER at the regions where ER and 
mitochondria are juxtaposed, termed mitochondria-associated membranes (MAMs). 
Although controversial, it has been proposed that MFN2 mediates ER-mitochondria 
membrane tethering, establishing an interface between the two organelles and promoting 
Ca2+ exchange366.  
 
 The study of mitochondrial dynamics in HSCs 
Our lab generated mice with conditional hematopoietic deletion of Mfn289. To our 
knowledge, this has been the only protein directly involved in mitochondrial dynamics that 
has been studied in HSCs. Luchsinger et al found MFN2 was necessary for maintenance 
of HSCs with extensive lymphoid potential (enriched in CD150LowHSCs) but not myeloid-
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dominant HSCs (enriched in CD150High HSCs). As a consequence, Mfn2-/-HSCs exhibited 
a functional defect in long-term lymphoid reconstitution in competitive repopulation 
studies. At the cellular level, Mfn2-/-HSCs exhibited fragmented mitochondrial morphology 
and an increase in intracellular Ca2+ levels. Rescue experiments identified repression of 
the nuclear factor of activated T cells (NFAT) activity, via maintenance of low intracellular 
Ca2+, as the mechanism by which MFN2 maintain CD150Low HSCs. These findings 
provided a novel mechanism by which mitochondria can determine HSC heterogeneity. In 
addition to this discovery, it was observed that mitochondria were longer, or more fused, 
in HSCs than in more differentiated populations including immediate progenitors MPPs, 
lineage-committed progenitors CMPs and CLPs, and Lin+ cells. This finding indicated 
HSCs have unique mitochondrial dynamics. The functional implications of increased 
mitochondrial fusion remained unclear as the effect of MFN2 in HSC maintenance was 
independent of its GTPase activity.  
 
 Project rationale 
Properties of HSCs that change with differentiation are of great interest as they may 
provide insights into the mechanisms that determine stemness. A high mitochondrial 
content and a highly fused mitochondrial network are two of such properties, as recently 
identified by our lab 89,367. These findings showed HSCs have unique mitochondrial 
dynamics, likely associated with particular roles for mitochondria. In the present study we 
aimed to investigate the function of mitochondria in HSCs by direct disruption of 
mitochondrial dynamics. To do so we generated mice with conditional deletion of both 
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Mfn1 and Mfn2. Deletion of both mitofusins excluded the possibility of compensatory 





 Hematopoietic deletion of Mfn1 and Mfn2 is incompatible with life 
Mfn1 and Mfn2 transcripts were ubiquitously detected in the hematopoietic system but 
whereas Mfn1 was expressed at similar levels across hematopoietic populations, Mfn2 
was more selectively expressed in HSCs (Fig. 1A and 1B). These experiments were 
performed in fetal liver (FL) hematopoietic populations and matched what we had 
previously observed in adult bone marrow (BM) populations89. To investigate the role of 
mitofusins, we generated mice with hematopoietic deletion of both Mfn1 and Mfn2 (DKO). 
To do so, we crossed floxed animals for both mitofusins (Mfn1fl/flMfn2fl/fl)361 with transgenic 
Figure 1. Generation of mitofusins-deficient mice. A. mRNA levels of Mfn1 and Mfn2, normalized to 
HSCs (n=6, mean±sem). B. Relative abundance of Mfn2 to Mfn1 transcripts in each hematopoietic 
population (n=3). C. Schematic representation of the Mfn1, Mfn2 and Vav loci in DKO mice. LoxP sites are 
represented as arrowheads flanking exons 4 (Mfn1) and 6 (Mfn2). Primers designed to detect excision are 
represented as black arrows flanking excision sites. D. Excision amplicon for Mfn1 (top) and Mfn2 (bottom) 
in bulk hematopoietic cells isolated from floxed Cre- and Cre+ DKO mice.  
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Vav-Cre mice368 (Fig. 1C). Genomic excision was confirmed by PCR amplification of the 
region flanking the LoxP sites at each locus and detection of a shorter amplicon in Cre+ 
hematopoietic cells (Fig. 1D).  
 
Mice with deletion of the four alleles (DKO) were found at Mendelian ratios during 
development but died perinatally (Fig. 2A). Interestingly, the viability of mice with deletion 
of three alleles was dependent on which allele was present. Mice with one allele of Mfn1 
(3R) survived to adulthood while mice with one allele of Mfn2 (3W) died perinatally (Fig. 
2A). To further investigate the factors contributing to the lethality of 3W and DKO 
genotypes, we continued our studies in mouse embryos. During development, expression 
of the Vav gene, and consequently Cre expression, is first detected at E11.5 and begins 
Figure 2. Hematopoietic deletion of Mfn1 and Mfn2 in mice. A. Expected and observed Mendelian 
ratios in adult and fetal mice. Adult mice were generated by crossing Mfn1fl/wtMfn2fl/wt Cre- with 
Mfn1fl/wtMfn2fl/wt Cre+. Embryos were generated by crossing Mfn1fl/flMfn2fl/fl Cre- with Mfn1fl/wtMfn2fl/wt Cre+. 
B. Total FL cellularity (n≥4, mean±sem). C. Mfn1 and D. Mfn2 mRNA levels in HSCs and MPPs isolated 
from the FL of mutant embryos at E15, normalized to WT littermates (n=3, mean±sem) 
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to peak at E1442. Therefore, we isolated FLs from mouse embryos at E14-E18, the primary 
site of hematopoiesis at this developmental stage (section 1.4). Analysis of Mfn1 and Mfn2 
mRNA levels in HSCs and MPPs from mutant FLs isolated at E15 confirmed the expected 
expression profile. Cell heterozygous for one mitofusin displayed intermediate expression 
levels between the WT and the KO cells (Fig. 2C and 2D). The number of cells in whole 
FL was not significantly affected in the mutants, indicating that differences in frequency of 
hematopoietic populations reflect differences in their absolute numbers (Fig. 2B). 
 
 Fetal erythropoiesis is altered in 3W and DKO mutants 
Although all embryos were found at expected frequencies, we immediately observed 
differences in their appearance. While 3R embryos were indistinguishable from WT, DKO 
and 3W embryos were pale in appearance (Fig. 3A). Based on the number of Mfn1/2 
Figure 3. Embryo appearance and erythroid differentiation. A. E15 embryos. B. Representative flow 
plots of subdivision of erythroid progenitors based on CD71 and Ter119 expression. C. Percentage of 
R1 in FL (n≥1, mean±sem). D. Percentage of AnnexinV+ cells in each erythroid subset of WT and DKO 
FL (n≥3, mean±sem). E. Representative hematoxylin and eosin-stained sections of WT and DKO 
embryos, black arrows point to red blood cells. 
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alleles deleted (3) and on their appearance (red or white) we termed embryos with one 
allele of Mfn1 as 3R and embryos with one allele of Mfn2 as 3W. The pale appearance of 
3W and DKO is strongly associated with anemia (lack or insufficient number of 
erythrocytes), a common cause of lethality. Since the FL is a major site for maturation of 
erythroid cells at this developmental stage369, we investigated whether the frequency of 
erythroid progenitors was altered. Using the cell surface markers CD71 and Ter119370 we 
subdivided the FL in four erythroid subsets, R1 being the most immature subset and R4 
the most mature subset (Fig. 3B). Based on this analysis, the pale embryos (3W and DKO) 
showed a 2 to 3 fold increase in the most primitive erythroid progenitors R1 (Fig. 3C) and 
a consequent decrease in more differentiated subsets. The increase in frequency of R1 
was not explained by cellular death of more mature populations as the percentage of 
AnnexinV, an apoptotic marker, was not significantly increased in any of the populations 
of the pale DKO embryo (Fig. 3D). Moreover, we were able to detect less frequent, but 
seemingly normal, red blood cells in hematoxylin and eosin stained sections of DKO 




The process of red blood cell maturation is complex and involves several morphological 
changes which include removal of the nucleus (enucleation) to generate reticulocytes and, 
among other steps, elimination of mitochondria through NIX-mediated mitophagy330,371 
(Fig. 4A). The decrease in mitochondrial mass in the later erythroid stages was determined 
by mtDNA:nDNA ratio and confirmed in WT cells (Fig. 4B). Although mitofusins have not 
been studied in this context, they have been implicated in other mitophagy 
processes310,339,372. We thus investigated whether the absence of mitofusins could 
interfere with this critical step. Although we found a significant increase in mitochondrial 
content in R3 of DKO mutants and R4 of 3W mutants (Fig. 4C), these changes were not 
extensive or consistent across both mutants. We conclude that decreased mitochondrial 
clearance could be a contributing factor but is unlikely to be the sole explanation for the 
likely anemia present in pale embryos.  
 
As an alternative hypothesis, we investigated if erythropoiesis could be affected as a result 
of a block in the differentiation of more primitive progenitors. Specifically, we focused on 
the megakaryocyte-erythroid progenitors (MEP), the progenitors that give rise to 
Figure 4. Mitochondrial content in late erythropoiesis. A. Schematic representation of the terminal 
steps of erythropoiesis (enucleation in erythroblasts and mitochondrial clearance in reticulocytes) B. 
mtDNA:nDNA ratio in WT FL erythroid populations normalized to R1 (n≥3 mean±sem). C. mtDNA:nDNA 
ratio in FL R3 and R4 populations normalized to WT (n≥3, mean±sem). 
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erythrocytes. These can be identified by flow cytometry based on their surface marker 
profile along with the other myeloid progenitors CMPs (common myeloid progenitor) and 
GMPs (granulocyte-macrophage progenitor) (Fig. 5A). We observed an increase in the 
broad progenitor compartment as shown by the increase in the percentage of cells 
negative for surface markers of terminally differentiated cells (Lin-). Within the myeloid 
progenitor compartment (cKit+Sca1-), the expression of CD16/32 and CD34 showed CMPs 
and GMPs were significantly increased in frequency in the pale mutants (Fig. 5B and 5C). 
Importantly, the frequency of MEPs was not altered (Fig. 5B and 5C). Altogether our 
results indicate that erythropoiesis is not affected at this point in differentiation, although 
we cannot exclude the presence of a defect in MEPs that could subsequently affect the 
function and survival of their progeny later in differentiation. 
Figure 5. Myeloid progenitors in the FL. A. Gating strategy of myeloid progenitors. B. Frequency of 
gated populations (n≥1, mean±sem). C. Representative flow plot of the cKit+Sca1- population based on 
expression of CD16/32 and CD34.  
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 Frequency of 3W and DKO HSCs is increased but in vitro function is impaired 
HSCs are the founder cells of the hematopoietic system and abnormalities in these stem 
cells can compromise all blood cell lineages. To investigate if the 3W and DKO mutations 
affected the top cells of the hematopoietic hierarchy, we determined FL HSC frequency by 
flow cytometry (Fig. 6A). FL HSCs were defined as Lin-cKit+Sca1+CD48-Mac1+CD150+ 
and were found at 2 to 3-fold higher frequency in 3W and DKO than in WT or 3R. In 
addition to HSCs, 3W and DKO FLs presented a statistically significant increase in the 
overall frequency of immature cells (Fig. 6A and 6B). 
 
An increase in the frequency of HSCs is often associated with enhanced proliferation, a 
phenomenon that has been observed in other mitofusin-deficient cell types. To measure 
proliferation we assessed the expression of Ki-67, an intracellular marker of proliferation 
only absent in G0/quiescent cells. Unlike BM HSCs, FL HSCs proliferate extensively and 
approximately 60% of the WT HSC pool was Ki-67+ (Fig. 7A and 7B). On the other hand, 
more than 90% of 3W and DKO HSCs were proliferating, suggesting an almost complete 
Figure 6. HSC frequency in the FL. A. Gating strategy and representative flow plots of FL HSCs. B. 
Frequency of gated populations (n>7, mean±sem).  
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absence of quiescent HSCs. Interestingly, the proliferation of the Lineage- compartment, 
frequency of which was also increased in 3W and DKO FLs, was not altered in the mutants. 
This finding suggests mitofusins may act as suppressors of cell cycle progression 
specifically in FL HSCs. When analyzing specific populations of progenitors (MPPs and 
CMPs) we were unable to detect an increase in proliferation since most progenitor cells 
were Ki-67+ in WT FL. 
 
To test HSC function, we performed a methylcellulose assay with 100 sorted phenotypic 
HSCs isolated from E15-E19 FL (Fig. 8A). After 10-12 days in culture, colonies were 
observed under the microscope (Fig. 8B) and manually counted (Fig. 8C). When 
compared to WT and 3R, HSCs from DKO and 3W mutants were severely impaired in 
Figure 7. Expression of intracellular Ki-67 in 3W and DKO. A. Representative flow plots of 
intracellular Ki-67 expression in control conditions and stained HSCs. B. Percentage of Ki-67+ cells 
in progenitors and HSCs (n>1 mean±sem). 
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their ability to form colonies. However, DKO HSCs never gave rise to visible colonies while 
3W HSCs exhibited an intermediate phenotype between WT and DKO.  
 
Although the methylcellulose assay is a limited method to measure HSC function, it 
revealed a clear functional defect in the DKO and 3W mutants but not in 3R, indicating 
one allele of Mfn1 was sufficient for normal colony formation capacity (although colony 
morphology was not analyzed).  
 
  
Figure 8. Colony forming capacity of 3W and DKO HSCs. A. Schematic representation of 
methylcellulose assay experimental design and timeline. B. Representative tile scan of an assay well 
10-12 days after seeding. C. Number of colonies observed after 10-12 days in culture (n≥2 mean±sem 
from 2 independent HSC isolations). 
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 3W and DKO FL fail to normally reconstitute recipients in primary transplants 
To study both long-term multilineage and self-renewal capacity of HSCs we performed 
competitive transplants with whole FL hematopoietic cells at 1:1 ratio with competitor BM 
(Fig. 9A). Over the course of 16 weeks we monitored the peripheral output from donor FL 
and competitor BM in recipient mice by flow cytometry (Fig. 9B). WT FL is known to 
outcompete WT BM in competitive transplantation373, a phenomenon we observed not 
only in WT but also in 3R donors. In alignment with the phenotype observed in the 
methylcellulose assay, DKO FL cells completely failed to repopulate recipient mice and 
3W donor-derived cells were significantly less frequent than WT or 3R (Fig. 9C and 9D). 
This result was due exclusively to differences in the repopulating capacity between donor 
and WT competitor, since recipient chimerism was comparable across all groups (Fig. 9E). 
Figure 9. Donor chimerism in primary competitive transplant. A. Schematic representation of 
primary competitive transplant timeline and experimental design. B. Gating strategy based on 
expression of CD45.1 and CD45.2. C. Percentage of total CD45.2 donor cells (n≥9, mean±sem). D. 
Representative flow plots and E. compiled data of donor, competitor and recipient chimerism (n≥9, 
mean±sem). Data was obtained from the PB of recipient mice 16 weeks post transplantation.  
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Our results show the hematopoietic function of 3W and DKO FLs was diminished despite 
an increase in the frequency of phenotypically defined HSCs.  
 
To assess differences in lineage potential, we used pan-lymphoid and myeloid lineage 
markers within the donor compartment of repopulating mutants, thus excluding DKO (Fig. 
10A). Compared to WT, both 3R and 3W FL HSCs exhibited a statistically significant 
decrease in lymphoid output (Gr1-Mac1-), a phenotype that has been described in adult 
mice with single hematopoietic deletion of Mfn289. However, while the decrease in 
lymphoid cells observed in the 3R mutant was minor, 3W lymphoid reconstitution was 
Figure 10. Donor lineage reconstitution in primary competitive transplant. A. Gating strategy 
based on lymphoid and myeloid markers in the PB of recipient mice. B. Percentage of lymphoid cells 
(Gr1-Mac1-) in the CD45.2 donor compartment (n≥8, mean±sem). C. Representative flow plots 
highlighting the lymphoid population of each mutant in the PB of recipient mice based on myeloid 
markers (top) or scatter (bottom). D. Percentage of lymphoid and myeloid populations in the 3W donor 
compartment of each recipient of 3W FL (n=17). The dashed line shows the average percentage of 
lymphoid cells in WT donors. E. Frequency of lymphoid and myeloid cells prevenient from donor in PB 
of recipient mice (n≥8, mean±sem). Data was obtained from the PB of recipient mice 16 weeks post 
transplantation from a minimum of 3 independent transplants.  
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more profoundly impaired (Fig. 10B and 10C). Within the 3W donor compartment of 17 
recipients, more than half had lymphoid reconstitution below 5% in comparison to the WT 
average of 75% (Fig. 10D). Next, we determined the lymphoid and myeloid frequency in 
the recipient factoring in both the donor chimerism and the respective percentage of 
lymphoid and myeloid cells. As expected, the abundance of 3W lymphoid cells in the 
periphery was drastically reduced. Interestingly, the change in frequency of 3W donor 
myeloid cells in the periphery was minor, but significant, compared to WT (Fig. 10E). This 
finding indicated lymphoid and myeloid lineages could be differentially affected by ablation 
of mitofusins.  
 
We investigated the nature of the Gr1-Mac1- lymphoid cells detected in recipients of mutant 
FL cells by further analysis of the expression of the pan-T cell marker CD3 and the pan-B 
cell marker CD19 (Fig. 11A). This analysis revealed that, despite the minor reduction in 
lymphocyte reconstitution, 3R lymphoid populations were present in the same proportion 
as WT. However, in addition to the major overall lymphoid defect, the few 3W Gr1-Mac1- 
lymphoid cells found in the periphery exhibited an abnormal CD19/CD3 distribution of 
expression (Fig. 11B and 11C).  
 
Analysis of the Gr1-Mac1- population excludes the lymphocyte population of mature 
natural killer (NK) cells which express Mac1374. To account for this less abundant 
population we performed a complementary analysis of surface markers defining mature 
NK cells as CD3-NKp46+DX5+374 (Fig. 11D). The percentage of WT NK cells from either 
the WT donor or the competitors comprised 1-2% of the lymphocyte population. However, 
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the percentage of 3W NK cells was approximately 5-fold higher in the 3W lymphocyte 
compartment (Fig. 11E). When considering this percentage and the total frequency of 
donor cells, 3W NK cells were found at a similar frequency in the PB of recipient mice as 
WT NK cells (Fig. 11E). Although preliminary, these results might reflect differential roles 
for mitofusins in lymphocyte development.  
 
 
In concordance with the PB phenotype, the percentage of 3W donor cells in the BM, spleen 
and thymus of recipients was negatively correlated with the abundance of Gr1-Mac1- 
lymphoid cells in each tissue. In the predominantly lymphoid organs such as spleen and 
thymus, 3W donor cells were almost undetectable. 3W chimerism was observed to be the 
Figure 11. Analysis of lymphocytes in competitive transplantation. A. Representative flow plots of B 
and T lymphocyte analysis. B. Percentage of B (CD19), T (CD3) and other (CD3-CD19-) within the donor 
lymphoid population (n≥8 mean±sem, from three independent transplants). C. Representative flow plot of 
donor lymphoid B and T populations in each mutant. D. Representative flow plots of mature NK lymphocyte 
analysis. E. Percentage of mature NK cells in lymphocytes (left) and overall donor NK cell frequency(right) 
(n=6 mean±sem, from 1 independent transplant). Data was obtained from the PB of recipient mice 16 
weeks post transplantation. 
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highest in the BM, the tissue with the highest percentage of myeloid cells included in this 
analysis (Fig. 12A and 12B).  
 
 
Taken together these results indicate that MFN1 was both sufficient for virtually normal 
repopulation and required for T and B reconstitution upon transplantation in a DKO genetic 
background. In addition, myeloid lineages did not appear to have a strong requirement for 
either mitofusin. The reconstitution of the myeloid compartment from mutant FLs with one 
allele of Mfn1 or Mfn2 was nearly normal. In the absence of both mitofusins, however, the 
ability of FL HSCs to reconstitute either lineage was lost.  
  
Figure 12. Donor chimerism in recipient hematopoietic tissues. A. Percentage of WT (top) and 3W 
(bottom) CD45.2 donor cells in the PB, BM, spleen (S), and thymus (T) (n≥3 mean±sem) B. 
Representative flow plots of WT (top) and 3W (bottom) CD45.2 donor chimerism and donor lymphoid 
gate in four hematopoietic locations. Data was obtained from recipient mice 16 weeks post 
transplantation, from one independent transplant. 
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 Development of lymphoid lineages appears normal in 3W FLs 
We wondered whether the dramatic defect in lymphoid potential was present in the 3W FL 
or if it was precipitated by exposure to a different niche (BM) and/or stress (transplant), 
both encountered in lethally irradiated recipient mice. To address this question, we have 
performed a preliminary analysis of the lymphoid development in 3W FLs. As previously 
observed for HSCs and myeloid progenitors, we detected a slight increase in the frequency 
of CLPs, defined as Lin-cKitloSca1loFlt3+IL7Rα+ (Fig. 13A and 13B). These results 
indicated the presence of all identifiable stem and progenitor subpopulations was 
increased in 3W FL. In addition, we detected CD19+CD43+ B cell precursors cells in 3W 
FL at the same frequency as WT (Fig. 13C and 13D), suggesting normal B cell 
development up to this point.  
 
Figure 13. Lymphoid progenitors in 3W FL. A. Gating strategy for CLPs. B. Frequency of Lin- and 
CLPs in WT and 3W FL (n≥4, mean±sem). C. Percentage of CD19+ cells in WT and 3W FL (n≥2, 




Similarly, the composition of double 
positive (CD4+CD8+) and double negative 
(CD4-CD3-CD25+/-CD44+/-) thymocytes in 
the fetal thymus of WT and 3W embryos 
appeared normal (Fig. 14). Although 
preliminary, this analysis suggested 3W T 
cell development was normal in the 
embryo. Single positive T cells were not 
detected in either thymus and hence we 
were not able to investigate this later stage 
of T cell development.  
 
Given the apparently normal B and T cell development in 3W embryos, we hypothesized 
that the reduction in lymphoid cells might be restricted to the recipient mice. Further 
investigation was required to determine if this observation was caused by the stress of 
transplantation or encounter with the adult niche. 
  
Figure 14. T cell development in 3W FL. Flow 
cytometric analysis of thymocyte composition in 
WT (top) and 3W (bottom) fetal thymus (n=1). DP: 
double positive, DN: double negative. 
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 The 3W HSC compartment is expanded in the BM of recipient mice 
To begin to understand the origin of the abnormal peripheral reconstitution of 3W FL, we 
performed a phenotypic analysis of the stem cell compartment in recipient BM. 
Interestingly, we observed an approximate 8-fold increase in LSKs and HSCs (Fig. 15A 
and 15B). Since the total donor chimerism of 3W in the BM was higher than in the PB and 
closer to WT (Fig. 15C), mutant HSCs were overall more frequent than WT HSCs in the 
BM of recipient mice (Fig. 15D). This was also true with respect to absolute numbers since 
BM cellularity was unchanged in recipients of WT and 3W FLs (Fig. 15E). Moreover, the 
frequency of competitor-derived HSCs was unchanged in both cohorts, indicating that this 
phenotype was caused by cell-intrinsic mechanisms (Fig. 15F).  
Figure 15. 3W donor HSC frequency in the BM of recipient mice. A. Representative flow plots of donor 
HSCs in the BM of recipient mice. B. Frequency of Lin-, LSK, and HSCs in the donor compartment of 
recipient BM (n=8 mean±sem, from two independent transplants). C. Donor chimerism in the PB and BM 
of recipient mice (n=8 mean±sem, from two independent transplants). D. Frequency of donor HSCs in the 
BM of recipient mice (n=8, from two independent transplants, mean±sem). E. BM cellularity in primary 
recipients (x106) (n=3 mean±sem, from one independent transplant). F. Frequency of competitor HSCs in 




The expansion of the 3W HSC compartment, the near absence of lymphoid lineages and 
virtually normal myeloid repopulation led us to hypothesize that myeloid-biased HSCs 
could be overrepresented within the HSC pool of 3W mutants. We isolated HSCs from the 
FL of embryos and the BM of recipient mice and determined the expression of markers 
reported to be enriched for myeloid-biased HSC compartments153,156,151,375,376. The mRNA 
levels of Mfn1 and Mfn2, included as controls, were the only transcripts significantly 
decreased in 3W HSCs from both sources (Fig. 16A). The surface marker CD150 was 
unchanged as shown by mRNA and protein (Fig. 16A and 16B). We found that the markers 
Cd41 and Vwf, were differently expressed in different sources of 3W HSCs. Cd41 
Figure 16. Expression of myeloid-bias HSC markers in 3W HSCs. A. normalized mRNA levels 
detected by RT-qPCR in HSCs isolated from (top) recipient bone marrow 16 weeks post-transplant and 
(bottom) from E14-E18 FL (bottom) n=3 mean±sem B. Representative histogram and normalized mean 
fluorescence intensity (MFI) of CD150 (n=5 mean±sem) in BM donor HSCs and C. FL HSCs. 
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expression in HSCs, which is associated with a myeloid-commitment377,378, was marginally 
increased in transplanted HSCs but not in FL HSCs. Whereas Vwf, expression of which in 
HSCs has been linked to a platelet-biased replenishment after transplantation151, was 
upregulated only in 3W FL HSCs. One caveat to consider is that the link between 
expression of Vwf and cd41 in HSCs and a myeloid output was identified at the protein 
level, which we have not analyzed here. Moreover, in our current experimental setting we 
were unable to track donor-derived platelets as they lack expression of CD45. Therefore, 




Next, we examined if 3W HSCs were present in other tissues, a phenomenon termed 
extra-medullary hematopoiesis (EMH), and often observed in hematopoietic disorders. As 
expected, the frequency of donor WT HSCs was highest in the BM of recipient mice and 
phenotypic HSCs were nearly undetected in the liver and spleen (Fig. 17A). In contrast, 
donor 3W HSCs were found in the spleen (Fig. 17B), although at a lower frequency than 
previously observed in the BM. 
 
Figure 17. 3W donor HSC frequency in the liver and spleen of recipient mice. A. Representative 
flow plots of WT (top) and 3W (bottom) donor HSCs in the liver and spleen of recipient mice. B. Donor 
HSC frequency in the liver and spleen of recipient mice (n=2 mean±sem, from one independent 
transplant). Data was obtained 16 weeks post transplantation.  
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 3W reconstitution is improved in secondary transplants 
To further challenge stem cells and assess their self-renewal capacity we performed 
secondary transplants. Whole BM cells isolated from primary recipients was injected into 
lethally irradiated secondary recipients. To analyze serial transplants we determined the 
ratio of donor to competitor (D:C), excluding the recipient population since it included cells 
from both the primary and secondary recipients which we were unable to distinguish. 
Suprisingly, we observed an increase in 3W donor chimerism compared to primary 
transplants, a phenomenon we did not observe in secondary recipients of WT FL (Fig. 
18A). Indeed, in secondary transplants the proportion of 3W donor cells was no longer 
significantly decreased compared to WT (Fig. 18B). Despite the overall increase in the 
Figure 18. Donor chimerism and lineage reconstitution in secondary transplant. A. Log ratio of 
donor to competitor in primary recipient and respective secondary recipients (n=9 from 3 independent 
transplants). B. Log ratio of donor to competitor in primary and secondary transplants (n=9 mean±sem, 
from 3 independent transplants. C. Percentage of lymphoid cells (Gr1-Mac1-) in the CD45.2 PB donor 
compartment of secondary recipients. D. Donor chimerism in the PB and BM. E. Frequency of HSCs in 
donor-derived BM cells. F. Images and weight of spleen isolated from secondary recipients. Data was 
obtained from secondary recipient mice 16 weeks post transplantation. 
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donor reconstitution, donor-derived cells in the periphery remained almost exclusively 
myeloid (Fig. 18C). Moreover, we continued to observe higher 3W chimerism in the BM 
than in the PB and, importantly, 3W HSC frequency remained significantly higher than WT 
(Fig. 18D and 18E).  
 
The phenotype observed in the secondary transplants of 3W mutants was reminescent of 
myeloproliferative diseases, which can be accompannied by splenomegaly and further 
exposed by tertiary transplantation. However, the spleens from 3W recipients were not 
enlarged (Fig. 18F) nor did the 3W donor chimerism in tertiary recipients increase 
compaired to their respective donor (Fig. 19A and 19B). Nonetheless, it is possible that 
HSC frequency and number continued to expand in the BM, a phenomenon that has been 




Figure 19. 3W chimerism in tertiary transplants. A. Log ratio of donor to competitor in secondary 
recipients and respective tertiary recipients of WT and B. 3W donor cells (n=8 from 4 independent 
donors). Data was obtained from the PB of recipient mice 16 weeks post transplantation. 
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 Mx1-Cre inducible mouse model bypasses perinatal lethality of 3W and DKO 
In the FL experiments we observed the lymphoid defect appeared restricted to the 
recipient mice. Here, we investigated whether this was strictly a result of challenges 
associated with transplantation or if mutant FL cells were unable to reconstitute the adult 
niche. To address this point and to study the effect of these mutations in adult mice, we 
generated animals in which excision of the Mfn1 and Mfn2 loci was driven by a Cre 
recombinase under the regulatory elements of Mx1 (Fig. 20A). The Mx1 promoter is 
activated in an interferon-dependent manner, which we accomplished in these 
experiments via injection of the synthetic analog of dsRNA Poly(I:C). As anticipated, 
without induction this model bypassed the perinatal lethality of 3W and DKO Vav-Cre mice. 
Mice from all genotypes survived to adulthood and were found at Mendelian frequencies 
(Fig. 20B). 
Figure 20. Inducible deletion of Mfn1 and Mfn2 in mice. A. Schematic representation of Mfn1, Mfn2 
and Cre loci in DKO mice. LoxP sites are represented as arrowheads flanking exons 4 (Mfn1) and 6 
(Mfn2). Primers designed to detect excision are represented as black arrows flanking excision sites. B. 




To drive Cre expression we injected adult mice with 3 doses of 400μg of Poly(I:C), every 
other day for 5 days. After 14 weeks all animals were still alive, possibly indicating that the 
effect of mitofusins deletion was less pronounced in unperturbed adult hematopoiesis (Fig. 
21A). However, inducible models can lead to misinterpretation of results if excision is not 
evaluated. Therefore, at 8 weeks post-induction we sacrificed one WT and one DKO 
mouse to determine efficiency of excision in bulk BM cells. PCR on genomic DNA flanking 
LoxP sites confirmed the presence of a shorter amplicon in DKO BM but not in WT, 
suggestive of complete excision in mutant mice and absence of spontaneous excision in 
control mice (Fig. 21B). This mouse model was further validated by gene expression 
assays showing significantly decreased mRNA levels of Mfn1 and Mfn2 in DKO BM HSCs 
(Fig. 21C).  
 
We utilized these mice to determine the percentage of lymphoid and myeloid lineages in 
the PB, BM, spleen, and thymus. We did not observe changes in expression of lymphoid 
markers CD19 and CD3 in any of the DKO tissues (Fig. 22A). Interestingly, the frequency 
of DKO HSCs in the BM was increased by 2 to 3-fold (Fig. 22B and 22C), while total BM 
cellularity was unchanged (Fig. 22D), as previously observed in DKO Vav-Cre FL. 
Figure 21. Survival and excision post Poly(I:C) injection. A. Survival curve of three independent cohorts 
after injection with Poly(I:C). The number of animals in each group is in parenthesis. B. PCR amplification 
of Mfn1, Mfn2 and Mx1-Cre from tail genomic DNA (left), and of Mfn1 and Mfn2 excision flanking region 





As a possible explanation for the survival results and seemingly normal hematopoiesis up 
to 8 weeks post induction, we hypothesized the phenotype might originate from defective 
HSCs or early progenitors. If so, a defect in terminally differentiated cells would only be 
observed in long-term survival experiments or in challenging conditions such as 
transplantation. 
 
To assess HSC function in Mfn1 and Mfn2-deleted adult mice, we transplanted BM before 
and after induction of deletion. Injection of adult BM 12 weeks after Poly(I:C) into recipient 
mice provided a direct comparison with the FL transplants (Fig. 23A). Efficiency of excision 
was assessed in LSKs sorted from donor BM by conventional PCR and qPCR. LSKs from 
3W and 3R showed the expected Mfn1 and Mfn2 profile of excision and expression, 
Figure 22. Analysis of adult DKO hematopoietic tissues. A. Expression of CD19 and CD3 in 
hematopoietic tissues. B. Flow cytometry analysis C. Number and D. Frequency of WT and DKO BM HSCs. 
Data collected 8 weeks post Poly(I:C) injections. 
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depending whether one or two alleles were deleted. Excision in DKO LSKs was also 
detected but appeared less efficient (Fig. 23B and 23C), highlighting the variability inherent 





Figure 23. Excision of Mfn1 and Mfn2 in Mx1-Cre donor BM. A. Experimental timeline and design 
of transplant assay. B. PCR amplification of Mfn1, Mfn2 and Mx1-Cre from tail genomic DNA (left) and 
of Mfn1 and Mfn2 excision region from BM genomic DNA (right) C. mRNA levels of Mfn1 and Mfn2 in 
sorted BM LSKs 12 weeks post induction (n=1, mean±sd). 
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Since HSC frequency was increased in 3W and DKO FLs, we performed a similar 
phenotypic analysis in Mx1-Cre BM from donor mice. Indeed, 3W HSCs were increased 
by frequency and number in 3W BM. However, in this particular DKO mouse, the 
frequency and number of HSCs were only marginally higher in the BM (Fig. 24A, 24B, and 
24C). Given our previous data (Fig. 22C) and the detection of both Mfn1 and Mfn2 
transcripts in the DKO LSKs (Fig. 24C), this discrepancy was likely a consequence of 
incomplete excision. Therefore, the lack of a functional phenotype in recipients of BM 
Figure 24. HSC frequency and numbers in the BM of Mx1-Cre donor mice. A. Flow plots of WT, 
3R, 3W and DKO HSCs in the BM of donor mice. B. Frequency and C. number of HSCs in the BM of 
donor mice (n=1). Data was obtained 12 weeks post Poly(I:C) injection. D. Experimental timeline and 
design of transplant assay. Red box highlights the timing of PB analysis. E. Percentage of total donor 
cells and F. lymphoid cells within the donor compartment 8 weeks post-transplant (n≥4 mean±sem, 
from one independent transplant).  
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isolated from this DKO mouse was not interpretable (Fig. 24D and 24E). On the other 
hand, the validated 3R and 3W donor populations appeared to be reproducing the 
phenotype observed in Vav-Cre FL transplants. Although preliminary, at 8 weeks post 
transplantation we detected a significant decrease in 3W donor chimerism (Fig. 24E). 
Furthermore, the percentage of donor-derived Gr1-Mac1- lymphoid cells was significantly 
decreased in 3R and 3W (Fig. 24F). As previously seen in FL transplants, this defect was 
more pronounced in 3W than in 3R.  
 
When transplanting undeleted cells, we waited approximately 8 weeks to begin Poly(I:C) 
injections and analysis of donor chimerism (Fig. 25A). Prior to deletion, the PB 
reconstitution of mutant donor cells was similar to WT. After 4 weeks the percentage of 
3W and DKO donor-derived cells decreased (Fig. 25B), indicating that deletion of 
mitofusins might affect short-lived cells in transplantation setting. However, the lymphoid 
reconstitution remained unchanged at 4- and 12-weeks post Poly(I:C) (Fig. 25B and 25C). 
To date, we have been unable to assess HSC function as these experiments are still on 
going and long-term reconstitution capacity cannot be determined before 16 weeks.  
  
Figure 25. Deletion of mitofusins in adult BM after transplant. A. Experimental timeline and design of 
transplant assay B. Donor chimerism and C. Percentage of lymphoid cells in the donor compartment in 
the PB of recipient mice (n≥10 mean±sem, from 3 independent transplants). 
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As discussed in section 1.7.5, recent studies have proposed that the involvement of HSCs 
in physiological hematopoiesis is significantly lower than in challenging situations, such 
as injury or transplantation. Our experiments in embryos and adult mice indicated the 
functional defects observed in lymphoid lineages were specific to transplants and not 
present in steady-state hematopoiesis. We thus hypothesized that this phenotype might 
be a consequence of the increased contribution of mutant HSCs to the hematopoietic 
reconstitution of recipient mice. In the subsequent experiments we investigated possible 




 Loss of mitofusins differentially impacts mitochondrial morphology and 
content in HSCs 
Previous work published by our lab has revealed the existence of a highly fused 
mitochondrial network in adult BM HSCs. In the same study it was shown Mfn2-/-HSCs 
isolated from adult BM exhibit mitochondrial fragmentation89. Since 3R and 3W mutants 
are single KO for Mfn2 and Mfn1, respectively, we expected to observe mitochondrial 
fragmentation in all mutants. However, compared to WT HSCs, only DKO cells exhibited 
clear mitochondrial fragmentation (Fig. 26A). This finding points to differential 
requirements for the individual mitofusins in the regulation of mitochondrial dynamics in 
adult and fetal HSCs.  
 
Figure 26. Mitochondrial morphology and content in FL HSCs. A. MTR-stained HSCs isolated from 
FL. B. relative mtDNA:nDNA ratio in FL HSCs (n>2 mean±sem). 
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As covered in Chapters 3 and 4, high mitochondrial content appears to be a consistent 
feature of HSCs. To determine if mitochondrial mass was affected by deletion of 
mitofusins, we measured the mtDNA:nDNA ratio in FL HSCs as well as MPPs, CMPs and 
Lin+ (Fig. 26B). We found 3W and DKO HSCs and their immediate progenitors MPPs 
showed a 50% decrease in mass compared to WT cells. The combined analysis of 
mitochondrial morphology and content revealed a distinct profile for the three mutant 
populations of HSCs: 3R HSCs were indistinguishable from WT in both aspects, 3W HSCs 
had normal mitochondrial network but decreased mitochondrial mass, and DKO HSCs 




 MFN1 and MFN2 are not required to maintain iCa2+ levels in the HSC and 
progenitor compartment of the FL 
To begin exploring the functional implications of mitochondrial shape and number in the 
mitofusin mutants we determined the cytosolic intracellular calcium (iCa2+) levels in FL 
LSKs. Studies from our lab linked MFN2 with maintenance of low iCa2+ in adult HSCs 89, 
which has been recently proposed to be important to suppress mitochondrial metabolism 
and promote BM HSC quiescence 305. The involvement of these pathways in FL HSCs has 
yet to be established. To determine iCa2+ levels we stained sorted FL LSKs with the 
fluorescent calcium indicator Indo-1. Using flow cytometry, we measured Indo-1 
fluorescence at two wave lengths as its emission shifts depending upon binding to calcium. 
To calculate iCa2+ concentration we treated each sample with the chelator EGTA or the 
Figure 27. Intracellular calcium concentration in FL LSKs. A. Schematic representation of Indo1-AM 
assay. B. Representative flow plots of Indo1-stained LSKs treated with EGTA (blue) or ionomycin (red), 
and untreated (black) before and after ATP C. Intracellular calcium concentration overtime before and after 
stimulation with ATP. D. Basal intracellular calcium concentration in LSKs, n>2 (mean±sem). 
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ionophore ionomycin to establish the minimum and maximum binding of Indo-1, 
respectively (Fig. 27A and 27B). The concentration of iCa2+ was between 20 and 30nM in 
all mutant LSKs and it increased similarly upon addition of ATP, an internal control which 
induces a transient increase (Fig. 27C and 27D). These data show, that not only calcium 
dysregulation can be excluded as a mechanism, but also that the role of mitochondrial 
dynamics is distinct in fetal and adult hematopoietic populations. 
 
 3W and DKO progenitor cells are operating at maximum respiratory capacity 
Next, we assessed the metabolic function of mitochondria using Seahorse assays. In brief, 
mitochondrial function is measured by the changes in oxygen consumption rate (OCR) 
upon injection of modulators of the electron transport chain (ETC). These metabolic 
studies require a large number of cells, hence, given the low frequency of HSCs and 
limited availability of embryos, experiments were performed in sorted Lin- cells. The OCR 
profile (Fig. 28A) showed an increase in basal respiration in 3W and DKO mutant cells 
(Fig. 28B). The decrease in OCR after addition of the ATP synthase inhibitor oligomycin 
is a measure of mitochondrial ATP production. Mitochondrial ATP production was 
significantly increased in 3W and DKO cells, indicating that the elevated basal respiration 
in both mutants was used in part to produce ATP (Fig. 28C). Furthermore, the basal OCR 
in cells isolated from the pale embryos also included elevated oligomycin-insensitive 
respiration, interpreted as an increase in proton leakage (Fig. 28D). Addition of the 
uncoupler FCCP collapses the proton gradient, allowing for unrestricted flow of electrons 
through the ETC and measurement of the maximal respiration of cells. In response to 
FCCP the OCR increased in WT as well as 3R cells compared to basal OCR. This result 
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indicated WT and 3R had spare respiratory capacity to respond to an increase in ATP 
demand by the cell. In contrast, the maximum respiration was similar to basal respiration 
in 3W and DKO, indicating these mutant cells were operating at maximum respiratory 
capacity (Fig. 28A, 28B and 28E). The basal extracellular acidification rate (ECAR), a 
measure of glycolytic activity, was also higher in 3W and DKO (Fig. 28F). However, since 
we did not perform experiments in the presence of glycolytic modulators, we cannot 
exclude that acidifying reactions from other cellular processes could be responsible for 
this finding. Even so, treatment with oligomycin led to an increase in ECAR, strongly 
suggesting that all mutants could increase glycolysis in response to inhibition of oxidative 
phosphorylation. The altered metabolic phenotype of 3W and DKO was indicative of a 
stressed/energetic state characterized by an increase in basal levels of both OCAR and 
ECAR (Fig. 28G) 
Figure 28. Metabolic profile of FL Lineage- cells. A. OCR profile after sequential injection of 
Oligomycin, FCCP and Rotenone/Antimycin (n≥4 mean±sem). B. Basal respiration, C. ATP, D. Proton 
leak, and E. Maximal respiration inferred from the metabolic profile of Lin- FL cells (n≥4 mean±sem). F. 
ECAR profile during Seahorse Mitostress test (n≥4 mean±sem). G. Energy map based on basal levels 
of OCR and ECAR (n≥4 mean±sem). 
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Next, we assessed changes in mitochondrial membrane potential (ΔΨ) using TMRE, a 
positively-charged dye which is readily accumulated in mitochondria due to their negative 
charge. Depolarized mitochondria fail to sequester TMRE and a reduction in fluorescence 
can be observed, as shown by treatment with mitochondrial uncoupler FCCP (Fig. 29A). 
Since Seahorse experiments were performed in Lin- cells, we sorted HSCs along with 
progenitors MPPs and CMPs from WT and 3W FL. Compared to WT, 3W populations 
showed a decrease in TMRE fluorescence, reflective of a reduction in ΔΨ (Fig. 29B). The 
reduction of ΔΨ was strikingly higher in FCCP-treated samples, indicating 3W cells were 
only slightly altered (Fig. 29B and 29C). Detection of non-ATP generating respiration in 
the Seahorse assay together with a reduction in ΔΨ was indicative of mitochondrial 
uncoupling. Depending on the cellular context, increased proton leak in 3W HSCs could 




Figure 29. Mitochondrial membrane potential. A. Representative flow plot of TMRE fluorescence in 
unstained, untreated and FCCP-treated WT FL MPPs. B. TMRE fluorescence in WT and 3W FL sorted 
cells from two independent experiments. C. TMRE fluorescence in untreated and FCCP-treated cells 




 Gene expression in mitofusin-deficient HSCs 
To identify additional genes, pathways, or cellular processes differentially affected in the 
3W and DKO mutants we performed RNA sequencing (RNASeq) in HSCs isolated from 
the FL of E18 embryos. Gene expression analysis was performed by Dr. Larry Luchsinger. 
 
As expected, mRNA counts of Mfn1 and Mfn2 were significantly decreased in 3W HSCs 
(Mfn1-/-Mfn2-/+) and DKO HSCs (Mfn1-/-Mfn2-/-). In WT HSCs Mfn2 mRNA was more 
abundant than Mfn1, confirming previous RT-qPCR results (Fig. 1A and 30A). To analyze 
the variation across samples we performed principal component (PCA) and a t-distributed 
stochastic neighbor embedding (t-SNE) analyses. Both techniques showed a distinction 
between WT and mutant samples, which appeared to cluster together (Fig. 30B and 30C). 
Figure 30. Sample variation in 3W and DKO HSCs. A. Mfn1 and Mfn2 RPKM values in HSCs isolated 
from WT, 3W and DKO FLs (n≥3±sem). B. Principal component analysis (PCA) and C.t-distributed 
stochastic neighbor embedding (t-SNE) of individual samples. 
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Unsupervised hierarchical clustering of samples was performed using the top 1000 
differentially expressed genes as determined by ANOVA analysis using a threshold of 
expression of 0.1 RPKM. This analysis was represented in a heatmap which showed the 
individual samples from each group clustered together and clear distinctive patterns of 
gene expression between WT and mutant HSCs (Fig. 31A). Next, we examined 
differentially expressed genes between the three groups. We identified only 5 genes that 
were differently expressed between 3W and DKO, none of which have been investigated 
in HSCs (Fig. 31B). When comparing WT and mutant HSCs, we found a total of 351 
significantly changed genes, with 280 being upregulated and 71 downregulated. The 251 
Figure 31. Differently expressed genes in 3W and DKO FL HSCs. A. Heatmap of the 1000 most 
significant genes B. Volcano plot of differentially expressed genes in 3W and DKO. Genes were colored 
in red if the log2 fold change (log2fc) was >2 or <-2. C. Overlap of differently expressed genes between 
3W and DKO HSCs. D Volcano plot of differentially expressed genes in 3W (left) and DKO (right) 
compared to WT HSCs. 
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genes identified in 3W HSCs completely overlapped with DKO, which in addition displayed 
100 uniquely changed genes (Fig. 31C and 31D).  
 
To determine if these genes were associated with particular biological processes or 
functions, we performed pathway analysis using the DAVID algorithm with a cut-off gene 
count greater than 5. First, we analyzed the 251 genes overlapping between 3W and 
DKO compared to WT (Fig. 32A). The 227 genes upregulated in both 3W and DKO were 
enriched for mitochondria-associated processes such as oxidative stress, apoptosis, lipid 
metabolism, and ion transport (Fig. 32B). Interestingly, the most commonly upregulated 
pathways were related to inflammation and immune activation (Fig. 32C), strongly 
indicative of an inflammatory signature in 3W and DKO HSCs. Pathway analysis of the 
Figure 32. Upregulated pathways in 3W and DKO HSCs. A. Number of significantly upregulated 
(red) and downregulated (green) genes in 3W and DKO HSCs. B. Fold enrichment of gene ontology 
(GO) pathways significantly upregulated in 3W and DKO HSCs. C. Statistical significance and gene 
count in each significantly upregulated pathway. quantity of related genes upregulated. Pathways 
associated with inflammation and/or innate immunity are highlighted in red. 
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24 genes downregulated in both mutants did not show a significant enrichment for any 
cellular process or function. 
 
To gain insight into mechanisms underlying the phenotypic and functional differences 
between 3W and DKO HSCs, we performed the same analysis within the 100 genes 
significantly changed only in DKO (Fig. 33A). The most upregulated pathways were again 
immune-related, indicating that the previously detected signature in 3W HSCs was further 
pronounced in DKO HSCs (Fig. 33B). Downregulated genes were not highly enriched for 
any particular gene set. Despite this, cell differentiation and multicellular organism 
development pathways were 2-fold enriched in DKO HSCs (Fig. 33C).  
 
While pathway analysis can be extremely informative in providing biological meaning to 
different expression profiles, its relevance can be limited by challenges such as 
annotation inaccuracies and the lack of consideration of cell-specific gene functions. To 
complement this approach, we generated a list of the genes with the top 50 most 
significant changes in expression (Fig. 34 and 35) and an appendix with the complete 
gene list. The implications of particular genes will be further discussed in the next section. 
Figure 33. DKO-specific pathway analysis. A. Number of significantly upregulated (red) and 
downregulated (green) genes exclusively in DKO. B. Fold enrichment of gene ontology (GO) 




Figure 34. Heatmap of differently expressed genes in 3W and DKO HSCs. A. List of the 
genes significantly downregulated in 3W and DKO HSC. Mfn1 is highlighted in bold. B. List of 




Figure 35. Heatmap of differently expressed genes uniquely in DKO HSCs. A. List of the genes 
significantly downregulated and B. upregulated exclusively in DKO HSCs.  
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 Discussion and future directions 
In the present study we investigated the role of mitofusins in HSCs by conditionally 
deleting Mfn1 and Mfn2 in vivo both during development (Vav-Cre) and in adult mice 
(Mx1-Cre). We showed mitofusins were important for normal hematopoiesis in steady-
state and upon transplantation. The extent of hematopoietic dysfunction in mitofusin-
deficient cells depended on several factors: the number and which alleles of mitofusin 
genes were deleted, the developmental stage at which deletion occurred, and the context 
of hematopoiesis (steady-state versus transplantation). These observations emphasized 
the complexity of mitochondrial function in hematopoiesis.  
 
The importance of mitochondrial dynamics in the hematopoietic system was directly 
supported by the fact that DKO Vav-Cre mutants did not survive after birth. The pale 
appearance of embryos is indicative of anemia and is the likely cause of death. In addition 
to our studies, two other mitochondrial proteins have been reported to cause lethality 
when conditionally deleted in the hematopoietic system via Vav-Cre-mediated excision: 
the mtDNA binding protein TFAM and the subunit of the mitochondrial complex III RISP 
(Rieske iron-sulfur protein)301. These mice also died before completion of gestation and 
displayed pale appearance due to severe anemia. Despite this similarity, the phenotype 
observed in OXPHOS-deficient Risp-/- cells was strikingly different than 3W and DKO. Of 
note, the frequency and number of Risp-/- HSCs was unchanged and their regenerative 
capacity was particularly affected in myeloid reconstitution301. In contrast, in our model 
we observed an increase in DKO HSCs and a complete impairment in reconstituting 
lymphoid and myeloid lineages.  
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Interestingly, one allele of Mfn1 (3R), but not of Mfn2 (3W), was sufficient to rescue 
lethality and most phenotypes observed in DKO. Similar reports were made in mice with 
Meox2-Cre and MLC-Cre mediated excision of mitofusins in epiblast-derived tissues and 
muscle cells, respectively361,380. These findings showed that in the absence of Mfn2, Mfn1 
heterozygous mice could maintain nearly normal tissue homeostasis. Indeed, 3R FL and 
3R BM were indistinguishable from WT on every parameter we analyzed, except in 
reconstitution of recipient mice. Both fetal and adult sources of 3R excised cells showed 
a slight but consistent decrease in lymphoid reconstitution. 
 
Understanding why one allele of Mfn1, but not Mfn2, was sufficient for virtually normal 
hematopoietic function in 3R mice is a question yet to be addressed. In section 5.1.3 we 
reviewed non-redundant properties of MFN1 and MFN2 that might explain this finding. 
Intriguingly, we found that Vav-Cre Mfn1-/-mice survive, their hematopoietic tissues 
appear normal and we only detected a slight defect in lymphoid reconstitution post-
transplantation (data not shown). This observation rejected the idea that MFN1-unique 
functions were necessary for normal blood development.  
 
In addition, the observed survival of 3R and lethality of 3W mice was inconsistent with the 
notion that the vulnerability of cells to a mutation in either mitofusin is determined by which 
mitofusin is predominantly expressed364. According to this theory, we would expect 3W 
(Mfn1-/-Mfn2-/+) mice to do better than 3R (Mfn1+/-Mfn2-/-) since expression of Mfn2 in both 
fetal and adult89 hematopoietic populations was equally or more abundant than Mfn1. 
Further complementary experiments are necessary to formally disprove this hypothesis. 
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Firstly, expanding the analysis of Mfn1 and Mfn2 expression to the specific mature 
lineages that were most affected in 3W reconstitution such as B and T cells. Secondly, 
determining whether mRNA levels match protein expression. If MFN1 expression is not 
higher than MFN2 we would conclude MFN1 has superior compensatory capacity than 
MFN2. It is possible that unique properties of MFN1 such as higher GTPase activity may 
be responsible for this phenomenon. However, MFN1 GTPase activity is associated with 
its role in membrane tethering during mitochondrial fusion, which appeared unaffected in 
both 3W and 3R. 
 
The majority of our functional studies focused on 3W mutant cells which exhibited an 
intermediate phenotype between WT and DKO cells. As in DKO mice, the frequency of 
3W HSCs in the FL and the BM was increased and their function impaired. However, 
while DKO FL failed to reconstitute all hematopoietic lineages in recipient mice, 3W FL 
functional defects were mostly restricted to the B and T cell reconstitution, which was 
nearly absent. The absence of myeloid reconstitution in recipients of DKO but not of 3W 
might be associated with the expression of the neutrophil elastase Elane. Elane has been 
recently identified as a negative regulator of neutrophil production in fetal HSCs and 
progenitors381 and was significantly upregulated by 10-fold only in DKO FL HSCs.  
 
Preliminary results showed normal reconstitution of 3W donor-derived lymphoid NK cells 
in the PB of recipient mice. The observation that not all lymphoid lineages were decreased 
in recipients of 3W FL suggests that the lymphoid defect originated after the differentiation 
path of NK cells diverged from B and T cells. However, identifying the step of commitment 
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to NK differentiation that was driving normal NK, but not B and T, reconstitution from 3W 
FL may prove challenging. Although NK cells are commonly described to arise from 
common progenitors of B and T cells (CLP), it has been shown they can share progenitors 
with myeloid cells, including dendritic cells and monocytes382. Since the myeloid branch 
of hematopoiesis in 3W transplants appeared functional, it is possible that 3W NK cells 
derived from a common myeloid progenitor. Therefore, based on this finding alone we 
were unable to identify or narrow down the hierarchical origin of the 3W lymphoid defect. 
 
While conclusively demonstrating that a hematopoietic phenotype originates from the 
stem cell compartment allows for further advancement of our understanding of HSCs, 
these experiments are challenging and frequently not performed. Detection of changes 
at the HSC level, such as reduced mitochondrial content and increased oxidative 
metabolism, does not prove that abnormal differentiation of mature cells was directly 
caused by stem cell dysfunction. In support of a stem cell defect we only detected B and 
T cell defects in transplantation, a condition in which HSC contribution to hematopoiesis 
increases. However, the biased myeloid output of 3W FL did not correlate with expression 
of genes in HSCs that are associated with myeloid-biased reconstitution. This result 
indicated, but did not exclude, that the biased output of the periphery was not pre-
determined at the HSC level. Importantly, the decrease in lymphoid reconstitution can be 





To assess the contribution of progenitors we propose three experiments. First, in-depth 
phenotypic analysis of donor-derived precursors of B and T cell in recipient mice. This 
would be a rapid and appropriate strategy to detect a block in lymphoid maturation. 
Second, induction of Cre-mediated excision after transplantation of progenitor 
populations isolated from uninduced Mx1-Cre 3W BM. If the phenotype is caused by 
progenitor dysfunction alone, then 3W progenitors originated from undeleted HSCs would 
have impaired B and T cells reconstitution. Third, generation of mice with Cre-mediated 
excision of Mfn1 and Mfn2 under the regulatory elements of genes that are not expressed 
in HSCs but are in downstream progenitors such as GMPs (LysM-Cre), T cell progenitors 
(LCK-Cre) and B cell precursors (CD19-Cre). If ablation of mitofusins in these mice did 
not disrupt normal reconstitution in vivo, we would infer that the phenotype likely 
originated from defective HSCs. If so, it would be interesting to perform single-cell 
transplants and begin assessing HSC heterogeneity in 3W HSCs.  
 
Phenotypic analysis of 3W HSCs in the BM of recipient mice revealed drastic 
abnormalities, as the HSC pool was increased in frequency and number by approximately 
8-fold. This finding excludes defects in BM engraftment while pointing to other possible 
explanations. We hypothesized 3W HSCs might be increased due to proliferation, as 
seen in 3W FL HSCs. As HSCs divide, they gradually lose regenerative capacity62 and 
as such we investigated if 3W HSCs isolated from the BM of primary recipients would fail 
to reconstitute secondary recipients. Altogether, the increased number of HSCs, the 
myeloid-biased differentiation and the reduced self-renewal, would be evocative of an 
aging phenotype. Surprisingly, serial transplantation data excluded this hypothesis by 
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revealing an increase in donor reconstitution compared to primary transplants, while 
remaining exclusively myeloid. A similar phenotype has been observed in pre-leukemic 
HSCs with ablation of two proteins with a role in epigenetic control of gene expression: 
the methyltransferase DNMT3A and the methylcytosine dioxygenase TET2.  
 
As observed in serial transplantation of 3W HSCs, Dnmt3a-/-HSCs and Tet2-/-HSCs 
simultaneously displayed impaired differentiation and increased self-renewal95,98. Tet2-/-
mice developed myeloid malignancies, died by 1 year of age383 and displayed extra-
medullary hematopoiesis, a phenomenon we observed in recipients of 3W. The 
oncogenic phenotype of Dmnt3a-/-HSCs was revealed by decreased survival of recipient 
mice 200-400 days after receiving Mx1-Cre deleted Dnmt3a-/-HSCs109. Interestingly, our 
RNAseq analysis revealed an approximate 10-fold increase in Dnmt3l mRNA in 3W and 
DKO, which has been shown to regulate DNMT3A activity384 and is not expressed in WT 
HSCs96.  
 
Using the Mx1-Cre model we would be able to compare if 3W HSCs exhibit additional 
pre-leukemic phenotypes in transplantation and steady-state. 100 days post-induction of 
deletion, 3W adult mice are alive but their long-term survival will continue to be monitored 
and PB isolated for analysis of any signs of malignancy. In addition, we could assess if 
the epigenetic landscape of HSCs is altered in mitofusin-deficient mice. We hypothesize 
this is likely the case given the similarity of 3W phenotype with Tet2-/- and Dnmt3a-/- mice, 
the upregulation of Dnmt3l, and the role of mitochondria in providing the intermediate 
metabolites to generate epigenetic marks. 
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Finally, in support of the hypothesis that 3W HSCs might be pre-leukemic was the 
detection of an inflammatory signature by RNAseq. Multiple studies have linked 
inflammatory signaling with HSC progression into preleukemic stem cells and myeloid 
oncogenesis385. Upregulated inflammatory genes in 3W HSCs included s1008, s1009, 
Hck, and Mac1. Recently, our lab found that a similar signature was linked to the faster 
development of leukemia in mice injected with MLL-AF9 HSCs overexpressing the short 
isoform of the transcription factor Prdm16 (s-Prdm16)88. s-PRDM16 binds to the promoter 
of Mfn2 but not Mfn1 and regulates its transcription89. Since MFN2 is the only mitofusin 
present in 3W it would be interesting to further explore this connection. We could begin 
by transducing WT and 3W Mx1-Cre HSCs with the MLL-AF9 gene and determine if the 
progression of leukemia was accelerated in mice that received MLL-AF9 3W HSCs. This 
experiment would not provide mechanistic proof of a link between the s-PRDM16 studies 
and ours, but it would be valuable in determining if deletion of mitofusins can predispose 
HSCs to malignant transformation. 
 
Next, we aimed to identify the mechanisms by which mitofusins regulated hematopoiesis, 
in particular HSCs. We discovered mtDNA content, proliferation and metabolism were 
altered in 3W and DKO HSCs and/or progenitors. Interestingly, mitochondrial morphology 
was only altered in DKO HSCs and iCa2+ levels were unchanged in all mutants. Notably, 
hematopoietic populations from 3R mice were not significantly different than WT by any 




The discovery that mitochondrial morphology was not altered in either 3R or 3W was 
puzzling. Deletion of either Mfn1 and Mfn2 in a variety of cell-types has been shown to 
consistently lead to mitochondrial fragmentation, including in murine BM HSCs89. 
Remarkably, it has been shown that in starving conditions Mfn2-/-MEFs were able to 
elongate mitochondria to spare them from degradation, demonstrating that mitochondria 
can fuse in mitofusin-deficient cells in response to cues from the cellular environment329. 
It is therefore possible that regulation of mitochondrial fusion in FL HSCs is distinct from 
BM HSCs. This hypothesis could be tested by visualizing mitochondria in 3W and 3R 
HSCs isolated from the BM of Mx1-Cre adult mice as well as recipient mice transplanted 
with FL HSCs. Nonetheless, collapse of the mitochondrial network was a distinctive 
feature of DKO FL HSCs that could possibly account for the total compromise of their 
regenerative capacity. To this point, it would be interesting to assess if a similar phenotype 
would be found in HSCs lacking the core component of inner mitochondrial membrane 
fusion OPA1. In MEFs, both Mfn1-/-Mfn2-/- and Opa1-/- cells were unable to elongate 
mitochondria during starvation329, showing a complete impairment in fusion capacity even 
in challenging conditions. 
 
Previous reports from our lab showed Vav-Cre Mfn2-/- mice failed to maintain lymphoid-
balanced CD150Low HSCs as a result of an increase in iCa2+. We anticipated that Mfn2-
deleted 3R and DKO LSKs would have a similar phenotype. However, neither iCa2+ levels 
were changed in LSKs, nor was CD150 expression altered in mutant HSCs. The GO 
pathway for ion transport activity was enriched due to upregulation of genes involved in 
transport of iron (Ltf, Lcn2), copper (Slc31a2), sodium (Scnn1a) and protons (Atp6v1c2, 
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Cybb, Hvcn1), but not calcium. These results indicated calcium homeostasis was 
unaffected in mutant FL LSKs. We speculate that the role of MFN2 in maintaining iCa2+ 
levels might depend on the developmental stage of hematopoiesis. In agreement, 
Umemoto and colleagues have recently showed that the Ca2+-mitochondria pathway is 
important for maintenance of HSC quiescence305, a state characteristic of adult BM HSCs 
but not of FL HSCs. This hypothesis may be tested by performing Indo-1 experiments in 
adult Mx1-Cre mutant LSKs. Nevertheless, based on our findings we excluded 
intracellular calcium regulation as a mechanism by which MFN1 and MFN2 regulate 
hematopoiesis in the FL. 
 
In contrast, altered proliferation of 3W and DKO HSCs might be a contributing factor to 
their hematopoietic dysfunction. In our studies, 3W and DKO HSCs were more 
proliferative than WT, as shown by the presence of Ki-67 in nearly all mutant HSCs. Since 
Ki-67 is only absent in G0 cells, complementary experiments would have to be performed 
to determine the specific state of cycling cells. In adult murine HSCs acceleration of cell 
proliferation is often associated with functional exhaustion of HSCs in vivo. However, this 
relation does not necessarily apply to FL HSCs, which actively cycle to expand the HSC 
pool.  
 
Indeed, as previously discussed, 3W HSCs did not exhaust and their self-renewal 
capacity seemed enhanced. In contrast, DKO FLs were unable to reconstitute recipients. 
RNA seq analysis showed two cell cycle regulators were upregulated uniquely in DKO 
HSCs: Cdkn3, Cdkn2c (p18). CDKN3 prevents CDK2 activation and p18 regulates G1 
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phase by inhibiting CDK4/6. While the role of CDKN3 in hematopoiesis is unclear, p18 
has been established as a negative regulator of self-renewal divisions in HSCs386. In its 
absence, p18-/-HSCs did not exhaust in serial transplantations over the course of 3 
years387. Consistently, p18 expression is reduced in actively cycling FL HSCs388, where 
self-renewal divisions and expansion of the HSC pool take place. We speculate that the 
upregulation of p18 in DKO HSCs may have the opposite effect, favoring differentiation 
cell divisions and rendering them unable to sustain blood cell production. If p18 
upregulation is independently validated in RT-qPCR assays, it would be interesting to test 
if DKO HSCs regenerative capacity would improve upon treatment with recently 
developed small molecules to inhibit p18386. 
 
An increase in HSC proliferation presents an increase in metabolic demands which is 
addressed in adult HSCs by a metabolic switch to oxidative phosphorylation. FL HSCs 
are already predominantly oxidative and exhibit an increase in expression of genes 
involved in DNA repair and antioxidant pathways389. Seahorse assays detected an 
increase in oxidative phosphorylation and proton leak in the more proliferative 3W and 
DKO FL Lin- cells. Since Lin- comprise a very heterogenous population of immature cells, 
extrapolation of this observation to HSCs requires further investigation. To this point we 
performed TMRE stain in purified populations and detected a decrease in mitochondrial 
membrane potential (ΔΨ) in 3W HSCs. Uncoupling of the ETC and ΔΨ dissipation results 
in proton leak, which is in line with our Seahorse results. Proton leak minimizes the 
production of mitochondrial ROS and protects cells from oxidative damage. Since 
RNAseq revealed an upregulation of pathways involved in response to oxidative stress, 
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it would be interesting to determine if ROS levels are elevated in 3W and DKO HSCs. An 
increase in proliferation, oxidative metabolism and ROS levels are commonly observed 
in defective adult HSCs and could be contributing to the hematopoietic impairment of 
these mutants, particularly if we observe similar results in adult 3W and DKO HSCs. 
 
To conclude, we propose additional research into important aspects of this project that 
remain unclear. Fetal HSCs are distinct from their adult counterparts in many aspects. 
Our findings strongly suggest that this is also the case with respect to mitochondrial 
dynamics. In the future we will use the recently generated and validated Mx1-Cre mice to 
carefully compare the effect of 3R, 3W and DKO mutations in adult hematopoiesis and 
HSCs. While 3W and DKO embryos die perinatally with an apparent anemic phenotype, 
DKO and 3W Mx1-Cre mice have survived for more than 100 days post-induction of 
deletion. We have yet to determine if Mx1-Cre mutants are deficient in red blood cell 
production, if they will develop malignancies over time or, alternatively, if they are 
unaffected. These experiments might elucidate different mechanisms by which fetal and 
adult hematopoiesis are regulated.  
 
A significant drawback of this study was the inability to track erythrocytes and platelets in 
transplants, particularly since 3W and DKO FLs exhibited a defect in erythropoiesis. Since 
these cell-types lack expression of CD45, in the future we will transition to transgenic 
mouse models stably expressing a fluorescent marker in all hematopoietic-lineages45 
(section 1.3.6). These experiments will allow us to expand our studies of HSC multi-
lineage potential in vivo to erythrocytes and platelets.  
168 
 
The main goal of this project was to understand the importance of mitofusins in regulating 
HSC function. We showed Mfn1 and Mfn2 deletion can cause a drastic reduction in 
hematopoietic function and disturb various cellular processes known to be tightly 
regulated in HSCs. RNAseq pointed to additional processes that might be altered in 3W 
and DKO HSCs such as apoptosis, inflammation and lipid metabolism. In the future we 
will investigate the extent to which these processes are altered in mutant HSCs and 
further explore the role of upregulated genes such as p18 and Dnmt3l. However, MFN1 
and MFN2 are mitochondrial GTPases and, unlike transcription factors, they are not 
known to directly regulate genetic transcription. The transcriptional signature of mitofusin-
deficient HSCs was most likely the result of widespread indirect changes. As recently 
shown by Jassinskaja and colleagues, mass spectrometry-based quantitative proteomics 
can be an extremely useful approach to expand our mechanistic studies beyond gene 
expression381. Employing a similar strategy, one could define the protein landscape of 






Our findings show that staining 
with MTG, a commonly used dye 
to measure mitochondrial 
content, leads to artefactually low 
fluorescence in HSCs because of 
dye efflux, an oversight that led to 
misinterpretation of a basic 
aspect of HSC biology (Fig. 1). 
Using mtDNA quantification, 
enumeration of mitochondrial 
nucleoids, and fluorescence 
intensity of a genetically encoded 
mitochondrial reporter, we show here that adult murine BM HSCs and MPPs have higher 
mitochondrial mass than lineage-committed progenitors and mature cells. Despite similar 
mitochondrial mass, the respiratory capacity of MPPs exceeds that of HSCs, suggestive 
of an ATP-independent role for mitochondria in these stem cells. Furthermore, although 
elevated mitophagy has been invoked to explain low mitochondrial mass in HSCs, using 
an autophagy inhibitor, a mitophagy inducer, and a mitophagy reporter mouse, we 
consistently observed that mitochondrial turnover is comparatively low in HSCs. 
 
Disruption of mitochondrial function in the hematopoietic system by genetic deletion of 
Mfn1 and Mfn2 is incompatible with life, highlighting the importance of mitochondrial 
Figure 1. Graphical summary I. Mitochondrial content 
and turnover in hematopoietic populations. 
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dynamics for normal blood production. FL DKO HSCs and progenitors are increased in 
both frequency and absolute numbers and, except for intracellular calcium levels, they 
exhibit several abnormalities including low mitochondrial mass, mitochondrial 
fragmentation, increased oxidative metabolism, and increased proliferation. When put to 
the test, DKO FL exhibits a complete impairment of its regenerative capacity by failing to 
repopulate both myeloid and lymphoid lineages in competitive transplantation assays (Fig. 
2). Interestingly, one allele of Mfn1 (3R) is sufficient to rescue lethality of DKO mice and 
its phenotypes, except for a mild defect in lymphoid repopulation, as previously observed 
in Mfn2-/-HSCs89. On the other hand, one allele of Mfn2 (3W) rescues myeloid 
reconstitution in vivo to virtually normal levels whereas lymphoid reconstitution remains 
severely reduced. Among the mutants, 3W HSCs displayed the unique property of 
expanding in the BM of recipients over serial transplantation, an indication that 
mitochondria may be linked to HSC self-renewal capacity. 
Figure 2. Graphical summary II. Deletion of Mfn1 and Mfn2 in the hematopoietic system 
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We have yet to determine if our findings are exclusively due to HSC dysfunction, if these 
phenotypes will replicate in adult HSCs, or what mechanisms underly the different 
functional defects of the mitofusin mutants. In the future, we hope to answer these 
questions by using the adult mouse model we have generated and by testing the 
hypotheses we have proposed based on our gene expression data and the current 
understanding of HSCs. 
 
In conclusion, despite the inherent challenges in studying such rare cells, it is imperative 
that we further our understanding of HSC biology to better utilize them for research and 
therapeutic purposes. Altogether, our data strongly suggest that the established belief in 
the disposability of mitochondria for HSC function is misguided and we are confident that 




7. Materials and Methods 
 Experimental Models  
 Mice 
C57BL/6J mice (CD45.2) and B6.SJL-PtprcaPep3b/BoyJ (CD45.1) were purchased from The 
Jackson Laboratory (West Grove), while CD45.1+CD45.2+ F1 (CD45.12) mice were 
generated in house by crossing CD45.2 and CD45.1 mice. For mitochondrial content 
studies, mice with ubiquitous expression of the mitoDendra2 reporter were obtained by 
crossing conditional mitoDendra2 transgenic mice (B6;129S-Gt(ROSA)26Sortm1(CAG-
COX8A/Dendra2)Dcc/J) with E2A-Cre mice (B6.FVB-Tg(EIIa-cre)C5379Lmgd/J)89,286,390. For 
mitophagy studies, we used mice with global deletion of Parkin (Park2) (B6.129S4-
Prkntm1Shn/J) and mito-Keima reporter mice (FVB.129(Cg)-Igs2tm1(CAG-mt-
Keima)Fink/J)320,322. To generate conditional mitofusin knockouts we crossed Mfn1loxP 
(B6.129(Cg)-Mfn1tm2Dcc/J) and Mfn2loxP (B6.129(Cg)-Mfn2tm3Dcc/J) mice to Vav-Cre 
(B6.Cg-Commd10Tg(Vav1-icre)A2Kio/J) or Mx1-Cre (B6.Cg-Tg(Mx1-cre)1Cgn/J) 
mice36,361,368. The transgenic mice mentioned above were purchased from the Jackson 
Laboratory. Map17 Cre-ER animals were obtained from the Reizis lab47. All experimental 
mice were used at age 8–16 weeks, except for 2-year-old mice, and both genders were 
included in experiments. In fetal liver experiments mouse embryos were dissected from 
pregnant females at E14-E18. Animals were housed in a specific pathogen-free facility. 
Experiments and animal care were performed in accordance with the Columbia University 





 Human cord blood  
De-identified cord blood was obtained from the New York Blood Center and experiments 
were performed in accordance with protocol approved by Columbia University Institutional 
Review Board protocol number AAAR0324. 
 
 Cells 
NIH-3T3 cells were purchased from ATCC. Hematopoietic populations were isolated from 
mouse bone marrow, mouse fetal liver, and human cord blood.  
 
 Cell culture 
NIH-3T3 cells were cultured in 10% FCS/DMEM at 37ºC. Hematopoietic cells were 
cultured in complete media using StemPro34 (Invitrogen), 100 ng/mL SCF, 100 ng/mL 
TPO, 50 ng/mL IL-6 (Peptrotech) in 5%O2 at 37ºC. When indicated, cells were cultured 
overnight in the presence of 50μM Chloroquine (Sigma) or/and 10μM CCCP (Sigma).  
 
 Mouse genotyping 
Tails from anesthetized adult mice or isolated embryos were clipped and incubated in 
300uL of 50mM NaOH at 90°C for 1h. To neutralize 1M Tris pH=8 was added 1:10, mixed, 
and 1μL used as input for each PCR reaction. The genotyping primers are listed in Table 






 Cell isolation and preparation 
 Mouse bone marrow and tissues  
Bone marrow isolation was prepared by crushing the tibia, femur, and pelvis of each mice 
in 1XPBS. Fetal liver was isolated by dissection of mouse embryos and dissociated by 
grinding through a 20μM cell strainer in 1XPBS. Spleen, liver and thymus were dissected 
and dissociated as previously described. Cell suspensions were centrifuged at 450g for 
5min at 4ºC and pellet re-suspended in 1XACK lysis buffer (Gibco) and incubated for 5 
min at RT. After washing in 1XPBS (Corning) the cells were filtered through a 40µm cell 
strainer, centrifuged, and the pellet re-suspended in buffer only, complete media, or 
staining mix (Tables 5, 6 and 7).  
 
 Mouse peripheral blood  
Peripheral blood was collected by submandibular vein puncture with a sterile disposable 
lancet. Red blood cells were lysed two times with 1XACK lysis buffer, washed in 1XPBS, 
and centrifuged at 450g for 5min at 4ºC. The pellet was re-suspended in staining mix 
(Table 5). 
 
 Human cord blood  
De-identified CB units were diluted at a 1:1 ratio with Iscove’s MEM (IMEM, Gibco) and 
layered in a 2:1 ratio on Histopaq-1077 (Sigma). Samples were centrifuged at 450g for 
30min at 25ºC without breaking. Mononuclear cells were collected at the plasma:Histopaq 
interface and washed in IMEM followed by red blood cell lysis with 1XACK lysis buffer. 
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After washing in 1XPBS, cells were centrifuged at 1200rpm for 5min at 4ºC and the pellet 
re-suspended in staining mix (Table 7).  
 
 FACS sorting and analysis 
Live cells were incubated with the appropriate antibody mix targeting cell surface markers 
(Tables 5, 6 and 7) in MACS buffer for at least 30min at room temperature, followed by a 
washing step with MACS buffer or 1XPBS. Flow cytometry analysis was performed on 
LSR II and Fortessa flow cytometers (Becton Dickinson). Cell sorting was performed in an 
influx cell sorter (Becton Dickinson). Data were analyzed using FlowJo 9.9.3 (TreeStar). 
The experiments in which cell surface marker staining was performed in combination with 
mitochondrial dyes or with intracellular staining are described below. 
 
 Mitrotracker Green 
For experiments using MitoTracker Green (Invitrogen), 3x106cells/mL of isolated bone 
marrow or cord blood were incubated with the dye at a final concentration of 30nM and 
200nM, respectively, in the presence or absence of verapamil (50µM, Sigma) at 37ºC for 
20-30min, washed in 1XPBS and centrifuged at 1200rpm for 5min at 4ºC. For flow 
cytometric cell sorting of bone marrow fractions based on MTG and mitoDendra2 
fluorescence, cells were re-suspended in MACS buffer and the top and bottom 10-15% 
cells of the fluorescence distribution were isolated. For analysis of specific populations, 
MTG-stained cells were further re-suspended in antibody mix (Tables 7) and sorted 





3-5x103 sorted cells were incubated in 10μM of FCCP or DMSO for 10min at 37°C followed 
by incubation with TMRE (Abcam) at 200nM for 30min at 37°C. Cells were washed in 
PBS/0.2%BSA and analyzed in a Fortessa flow cytometer in the PE channel. 
 
 Ki-67 intracellular staining 
Following staining of cell surface markers, 10x106 bone marrow cells or 5x106 fetal liver 
cells were washed and fixed in 4%PFA/PHEM for 10min. Fixed cells were washed two 
times in 1xPBS and permeabilized in 0.1%Triton-X 100/PBS for 10 min on ice. After 
permeabilization and three washing steps samples were incubated with conjugated Ki-67 
antibody (eBioscience) in 0.1%Triton-X 100/PBS for 1h, at 4°C, in the dark, washed and 
analyzed (Table 7). Ki-67+ cells were determined using unstained and isotype controls as 
reference.  
 
 Edu proliferation assay 
Bone marrow was harvested 16h post injection of 1.3mg of Edu or equivalent volume of 
1XPBS. 10x106 bone marrow cells were stained for cell surface markers (Table 7) and 
Edu incorporation was detected using the Click Click-iT™ Plus EdU Alexa Fluor™ 647 







Sorted hematopoietic populations (2-5x103 cells) were collected in complete media and 
plated on MicroWell 384-well glass-bottom plates (Thermo) previously coated with 1µg/mL 
poly-D-lysine (Sigma) overnight. Cells were spun at 30g for 5min and fixed with 4%PFA 
for 10min at room temperature (RT). Cells were then permeabilized with 0.1% TritonX-
100/PBS for 10min and blocked with 1% BSA/0.1% TritonX-100/PBS for 1h at RT. Cells 
were incubated in 50µL of primary antibody (1:200) in blocking solution overnight at 4ºC 
in a humidified chamber, washed three times with 1XPBS and incubated with appropriate 
AlexaFluor secondary antibody (Invitrogen) 1:500 for 1h in blocking solution. After washing 
three times with 1XPBS cells were mounted with fluorescent mounting media (Vector 
Labs). Confocal images were acquired with a Leica SP8 mutli-photon confocal microscope 
or a Leica DMi8 inverted microscope (Leica Microsystems). For quantification confocal z-
stacks were projected as a z-project and analyzed in ImageJ (NIH, Bethesda, MD, USA). 
Primary and secondary antibodies are listed in Table 4. 
 
 Mitochondrial morphology 
To visualize mitochondria we imaged cells from MitoDendra2 mice or live cells stained in 
200nM of MitoTracker Red (Invitrogen) for 30min at 37°C. Seeding and fixation protocols 
were performed as previously described. Images were acquired with a Leica DMi8 inverted 
microscope, deconvoluted and processed with Leica AF6000 software package. For 
mitochondrial length measurements, individual z-stacks were projected as a z-project in 
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ImageJ (NIH) and individual mitochondria were manually traced, binned into length 
categories expressed as percent of cellular mitochondria.  
  
 RNA extraction for RNA sequencing and RT-qPCR 
Sorted cell populations (5x103 cells) in 0.25mL of complete media were added to 0.75mL 
of Trizol LS Reagent (Invitrogen) and RNA was isolated according to the manufacturer’s 
instructions. RNA was dissolved in 0.012mL of water and used to synthesize cDNA using 
Superscript III Reverse Transcriptase (Invitrogen) or submitted for sequencing. For RNA 
sequencing mRNA from total RNA samples was enriched by poly-A pull down and libraries 
were prepared using a low input Clontech SmartSeq v4 chemistry. Sequencing using 
Illumina NS500 single-end 75bp (Illumina) and VIPER analysis were performed at the 
Dana Farber Cancer Institute. For RT-qPCR target Ct values were determined using 
inventoried Taqman probes (Applied Biosystems) listed on Table 2. Relative quantification 
was calculated by the ΔΔCt method normalized to actin (ActB) or Gapdh (Gapdh). 
 
 mtDNA:nDNA  
Sorted or cultured mouse and human hematopoietic cells (2-10x103) were washed with 
1X PBS, centrifuged at 450g for 5min at 4ºC and re-suspended in 70µl lysis buffer (10mM 
Tris-HCl pH7.5, 50mM NaCl, 6.25mM, 0.045% NP40, 0.45% Tween20) with freshly added 
proteinase K (1mg/ml, NEB) followed by incubation for 2h at 56ºC and 15min at 95ºC in a 
PCR machine289. Quantification was performed by qPCR with SYBR green-based 
detection (Thermo Fisher Scientific) using 5µL of the lysate as input in each reaction. 
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Relative mtDNA:nDNA ratio was calculated by the ΔΔCt method upon targeting of 
mitochondria and nuclear-encoded genes (oligonucleotides listed in Table1).  
 
 Methylcellulose assay 
HSCs sorted from fetal liver were plated at a density of 100 cells per well in a 35-mm non-
tissue culture plates in semi-solid methylcellulose IMDM-based medium supplemented 
with SCF, IL-6, IL-3,TPO and GM-CSF (50ng/mL, PeproTech). The number of colonies 
was counted after 10-12 days and a tile scan of each well acquired using a Leica DMI 
6000B. 
 
 Competitive transplant 
Donor cells together with WT competitor bone marrow were transplanted by tail vein 
injection into recipients lethally irradiated with two doses of 478 cGy over 3h using a Rad 
Source RS-2000 X-ray irradiator (Brentwood). In all transplants, cells were counted 
manually, and viability assessed by trypan blue staining. For two weeks after injection 
recipient mice were given antibiotics via drinking water. At indicated timepoints post-
transplantation, PB of recipients was collected for analysis of donor and competitor 
populations which were distinguished by targeting of CD45 alleles and/or presence of a 
fluorescence reporter (mitoDendra2 and mt-Keima transplants).  
 
 Mitochondrial content transplants 
5x104 45.1donor bone marrow cells sorted based on MTG or MitoDendra2 fluorescence 
were transplanted together with 20x104 45.12 competitor bone marrow cells. 
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 Mt-Keima transplants 
1x104 donor bone marrow cells sorted based on the acidic:neutral ratio of mt-Keima 
fluorescence were transplanted together with 20x104 FVB mt-Keima-/- competitor bone 
marrow cells. 
 
 Mutant bone marrow and fetal liver transplants 
50x104 WT and mutant 45.2 donor cells were transplanted together with 50x104 45.1 
competitor bone marrow cells. 
 
 Serial transplants 
50x104 bone marrow cells from primary or secondary recipients were injected into lethally 
irradiated secondary or tertiary recipients, respectively, with the same CD45 allele as the 
primary recipients. 
 
 Induction of Mfn1 and Mfn2 deletion in adult mice 
To induce expression of Mx1-Cre recombinase mice were injected intraperitoneally with 
400ug of low molecular weight Poly(I:C) (InvivoGen) in 1XPBS every other day for five 
days (total of 3 injections per mouse). In survival experiments mice were monitored for 
health and survival over time. Transplants were performed using bone marrow from donor 
mice before or after Poly(I:C) administration. When donor cells were injected before 
Poly(I:C) injection, induction protocol was initiated on the recipient mice 10-16 weeks after 
transplantation. When donor cells were injected after induction of deletion, bone marrow 
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was isolated 60 days post Poly(I:C) from donor mice. Deletion efficiency was analyzed via 
PCR and RT-qPCR (Tables 1 and 2). 
 
 Seahorse metabolic assay  
Prior to experiments DMEM media was neutralized to pH 7.4 at 37 C and XFp flux 
cartridges were hydrated in XF Calibrant overnight. Bone marrow HSCs (LSKCD48-) 
MPPs (LSKCD48+) CPs (Lin-Sca1-cKit+) cells were isolated from 6 mice while fetal liver 
Lin- were isolated from one embryo. Sorted cells were manually counted and ≥50,000 cells 
were plated onto one well of a Seahorse XFp culture plate coated overnight with Cell-Tak 
reagent. Cells were immobilized by centrifugation at 200g for 3min at RT, washed three 
times with DMEM and equilibrated in a humidified non-CO2 37°C incubator until the start 
of the assay. Flux cartridges were loaded with drugs prepared with DMEM according to 
manufacturer’s instructions. Oxygen consumption and extracellular acidification rate 
values were obtained using the Seahorse XFp Analyzer and metabolic parameters were 
derived from calculations based on manufacturer’s instructions. Due to feasibility of cell 
number isolation, experiments are represented as one or two technical replicates per cell 
type, per condition over a minimum of three independent experiments. 
 
 Indo-1-AM calcium flux 
15x103 sorted fetal liver LSKs (Lin-Sca1+cKit+) were cultured at 37° for 30min in complete 
media in the presence of 2μM Indo-1 (Life Technologies) previously prepared in 20% (w/v) 
Pluronic-F127 and FCS. After staining, each sample was divided into three tubes each 
used to determine Rmin, Rmax or baseline. The Rmin tube was washed in 1XPBS without 
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calcium and the Rmax and baseline tubes were washed in 1XPBS with calcium. Rmin and 
Rmax samples were incubated in 10mM EGTA for 10min or stimulated with 1μM ionomycin 
for 10sec, respectively. Data for the baseline tube was collected for 30 seconds before 
adding ATP at 25μM concentration to induce calcium transients. FACS tubes were kept at 
37°C before and during acquisition in an LSRII equipped with a 355nm excitation laser. 
Calcium concentration was calculated using the ratio of bound/free Indo-1 (R) in the three 
conditions for each sample assuming an Indo-1 dissociation constant (Kd) of 237nM at 
37°C, following the equation: 
 
 Western blot 
Mouse tissues were lysed in RIPA buffer in the presence of protease inhibitors (Roche). 
After protein quantification, 30μg from each lysate was denatured in 4x sample buffer at 
95°C and loaded onto 4–12% Bis-Tris SDS–PAGE gradient gels (Invitrogen). Gels were 
transferred onto 0.22μm nitrocellulose membranes and blocked with 3% BSA in 
0.1%Tween-20/TBS for 1h at room temperature. After overnight incubation at 4°C with 
primary antibody anti-Parkin (1:200, Cell Signaling) and anti-β-actin (1:5000, Abcam), 
membranes were washed three times and incubated with HRP-conjugated secondary 
antibodies for 1h at room temperature (Table 4). Exposition was done onto X-ray film 






 Statistical Analysis 
For statistical comparison of two groups, unpaired two-tailed Student’s t test was used. 
When more than two groups were compared, one-way ANOVA followed by multiple 
comparisons test was performed. To calculate deviation from Mendelian ratios Chi-Square 
test was used. All statistical analyses were done using Prism version 7.00 for Windows 
(GraphPad). Differences among group means were considered significant when the 
probability value, p, was less than 0.05 (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). 
Sample size (n) represents biological replicates. Results are represented as mean ± sem. 
No statistical methods were used for exclusion of outliers and no outliers were excluded. 
The experiments were not randomized, and we were not blinded to allocation during 









Table 2. Taqman probes used for RT-qPCR 
 
Table 3. Reagents 
 




Table 5. Antibody panels for analysis of peripheral blood 
 
Table 6. Antibody panels for analysis of lineage development  
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Appendix. List of differentially expressed genes in 3W and/or DKO FL HSC 
Genes highlighted in grey are only differentially expressed in DKO HSC 
    
 mean Z-score 
GeneID WT 3W DKO 
SVA -3.32193 1.61265 1.42267 
HAS2OS -3.32193 -1.10178 -0.52673 
AI463170 -3.32193 -0.97228 -1.40315 
4931428L18RIK -3.32193 -1.48564 -1.13502 
1Mar -3.32193 -2.18277 -1.30889 
GLT28D2 -3.32193 -1.94004 -1.60528 
PCDH8 -3.32193 -1.84806 -1.50484 
PROK2 -3.27197 -1.69554 -0.01581 
LYVE1 -3.26139 -2.26628 -1.43597 
TTC21A -3.24828 -2.33644 -1.57757 
HAS2 -3.23537 -1.21112 -1.22010 
MYBPH -3.21707 -1.67094 -1.54224 
MMP25 -3.18585 -0.59525 0.42174 
CSTA1 -3.18194 -1.93848 -1.46279 
4930431P03RIK -3.15070 -1.72426 -0.86356 
GM11149 -3.13442 -1.69554 -0.77256 
SERPINB1B -3.13092 -2.43304 -0.68491 
IFIT1BL2 -3.09610 -0.81287 -0.09099 
CHST13 -3.04116 -1.72049 0.07272 
CLEC4B1 -3.03363 -1.31930 -0.65216 
IFNLR1 -2.99204 -0.48693 -0.16715 
DNMT3L -2.98650 -0.18721 0.27819 
SPATC1 -2.95665 -1.34650 -0.77701 
FCRL1 -2.94844 -1.27274 -0.29782 
ALDH3B3 -2.93239 -0.27937 0.12855 
LIN28A -2.92493 -1.09893 -0.64707 
IFITM10 -2.92053 -1.01785 -0.15379 
BC049730 -2.91879 -0.26095 0.11253 
IRGC1 -2.89350 -0.46358 0.32623 
MAP6 -2.88700 -1.21405 -0.25536 
PANCT2 -2.86727 -1.20552 -0.37986 
NTNG2 -2.85367 -1.00918 -1.23060 
ATP6V1C2 -2.85169 -0.17160 -0.54652 
GM1604B -2.84432 -0.54711 0.36441 
CHDH -2.83785 -0.93273 -0.21979 
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SLC6A12 -2.80820 0.28359 0.52571 
AMER2 -2.78459 0.15706 1.31647 
C130060C02RIK -2.76527 -0.81811 -0.03163 
GRAMD2 -2.75004 -1.37935 -0.61437 
KLRA17 -2.73957 0.74968 1.08504 
ADTRP -2.73346 -0.71416 -0.13251 
PLET1 -2.67791 -1.26170 -0.12361 
NT5E -2.66101 -0.40007 0.24929 
RPL3L -2.60112 -0.69547 -0.06657 
SIGLECF -2.53152 0.08754 0.47937 
GM4763 -2.53037 0.44841 0.71339 
SH2D1B1 -2.52655 -1.28936 0.51909 
ALDH3B2 -2.52184 0.11588 0.36776 
GM21188 -2.51183 -0.69584 -0.20373 
9830107B12RIK -2.47447 0.99389 1.44000 
RAPSN -2.43576 -0.43676 0.28643 
RAP1GAP2 -2.39210 -0.15813 -0.14457 
EVI2 -2.34641 -1.08283 0.78279 
SLFN1 -2.28177 1.08499 1.53198 
TADA2B -2.22851 0.04681 -0.28030 
CES1D -2.20451 0.96323 1.00693 
NRP1 -2.20356 -0.27732 0.26694 
DHRS9 -2.15484 0.08443 0.45893 
KRT83 -2.12645 1.27107 2.14587 
F830208F22RIK -2.11451 -0.59331 0.12177 
OLR1 -2.08959 0.93120 1.63828 
NLRP12 -2.08497 0.06036 1.01440 
9830166K06RIK -2.01667 -0.27920 -0.15909 
GAS7 -1.90213 0.12415 0.21393 
BAIAP3 -1.88351 -0.23501 -0.04703 
PTGER2 -1.84829 -1.12176 0.02517 
LHFPL2 -1.83561 0.35347 1.13169 
A530064D06RIK -1.83450 1.29216 2.22658 
IL1RN -1.83039 1.02404 0.80550 
ATP8A2 -1.80474 0.06312 0.54277 
CD300LD -1.77333 0.37032 0.95620 
1700047M11RIK -1.76603 1.52002 1.08991 
RHOU -1.73959 0.99942 1.07487 
CLEC4A4 -1.66829 1.12510 2.05772 
BCL6 -1.59770 0.45855 0.91475 
SCRG1 -1.57410 2.11849 2.19574 
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PPP1R42 -1.47255 0.55066 1.09057 
BMX -1.45481 1.59374 2.53961 
CEACAM2 -1.42364 0.97632 1.56250 
MREG -1.42062 1.43221 2.75199 
SLCO4C1 -1.38931 1.54324 1.96228 
B430010I23RIK -1.37922 0.32408 0.81580 
YAP1 -1.36081 -2.68193 -3.32193 
TGFB3 -1.33661 -2.97167 -3.32193 
PILRB2 -1.28621 2.38114 2.75740 
MYRF -1.26390 -2.18560 -2.92371 
RPS6KA2 -1.23619 0.52527 0.50835 
ANKRD22 -1.23100 1.77174 2.17648 
CYP4F18 -1.21030 1.37388 1.76743 
E230016M11RIK -1.13006 0.25248 0.80158 
KBTBD11 -1.12267 -2.19998 -2.84708 
1700020L24RIK -1.12037 0.39728 1.20118 
MEIS3 -1.10714 -2.11036 -3.14820 
NOTCH3 -1.09292 -2.33549 -3.04893 
KDF1 -1.08510 -2.74148 -3.09383 
ZKSCAN7 -1.08102 -1.12578 -2.56791 
AATK -1.04358 1.06382 1.43647 
PLEKHB1 -1.02317 -2.16529 -2.72546 
NRN1 -1.00700 -2.70696 -3.32193 
FPR1 -0.98596 2.81868 3.31897 
TMC7 -0.97228 0.62592 1.00223 
SGMS2 -0.95854 1.21668 1.44407 
CLDN15 -0.92381 1.65818 2.53021 
TUBB1 -0.89682 -1.80194 -2.88196 
STAP2 -0.88328 0.65428 0.93310 
CYR61 -0.87238 -2.71104 -2.72654 
GM9733 -0.86282 1.03812 1.46574 
SCNN1A -0.85684 1.28171 1.96016 
GM19705 -0.77582 1.68781 1.88808 
MGLL -0.76265 0.40756 1.22124 
IL1F9 -0.70609 2.93723 3.26968 
MIRT2 -0.70147 2.54112 3.00293 
INPP5J -0.65973 1.54552 2.11861 
SERPINB10 -0.65624 0.26063 1.78879 
GM14207 -0.63978 -2.57542 -2.82909 
GAB3 -0.63926 0.72504 1.19703 
BST1 -0.62694 1.67737 2.52058 
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MYO15 -0.62401 -1.83165 -2.62071 
TMCC1 -0.62309 0.86513 1.09184 
SUSD5 -0.61951 -2.58709 -3.22496 
LEPR -0.60911 -2.72660 -2.60533 
TLR7 -0.60734 0.73570 1.62607 
CDKN2C -0.60110 1.22603 1.83397 
SLC22A4 -0.55855 0.95536 1.12605 
ATP7B -0.45779 -1.90203 -2.17317 
CEACAM10 -0.45501 3.42136 4.00745 
ZBP1 -0.45178 -2.35313 -3.07195 
ZFP354C -0.43570 -1.25646 -2.34813 
PILRB1 -0.43199 2.77153 3.37682 
B430306N03RIK -0.42558 2.16141 2.61997 
SLFN5 -0.42225 -1.53952 -2.51320 
NCAM1 -0.40993 1.30964 1.85207 
AIRN -0.38902 -2.38499 -3.18839 
CD300LB -0.37461 1.67747 2.49953 
5Sep -0.32475 2.37569 2.81467 
CEP112 -0.29939 -0.96034 -2.83713 
GBP9 -0.29932 -1.59145 -2.16500 
RET -0.29437 -1.87984 -2.70939 
ETNK2 -0.23979 -2.30910 -2.62780 
PROSER2 -0.21363 -1.71543 -1.97681 
SHROOM4 -0.19202 -1.09392 -2.15723 
MEGF9 -0.17055 1.47163 1.45312 
LAMA5 -0.16618 -0.88618 -2.33102 
LRRK2 -0.16394 2.35981 2.51867 
HCAR2 -0.13863 1.07109 2.32019 
GPR160 -0.13849 1.12312 1.70713 
GM4489 -0.12923 -0.65688 -1.94942 
FPR2 -0.12242 3.15137 3.45168 
BC016579 -0.10116 -1.39060 -2.60866 
EDA2R -0.08189 -1.16114 -2.21558 
SIGLECE -0.05340 2.18568 2.62924 
MRGPRA2A -0.04478 2.59723 2.71644 
TREM1 -0.03608 2.38475 2.87328 
DDAH1 -0.01956 -1.23581 -2.04437 
DACT3 -0.01920 -0.73824 -2.06861 
FCGR4 0.01130 2.13817 2.34873 
TACSTD2 0.03666 1.48876 2.05521 
PRSS57 0.09806 1.50130 2.67198 
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FBXO44 0.12958 0.48790 -3.04428 
UTF1 0.15450 -1.51399 -2.22104 
PROM1 0.15937 2.12206 3.00896 
GDA 0.17115 2.17907 3.06652 
FXYD2 0.18179 -1.82634 -2.27063 
B230208H11RIK 0.18236 2.84730 3.22082 
PKP2 0.21137 -0.95105 -2.39903 
APLN 0.21792 -1.30987 -1.50010 
SIPA1L3 0.23194 -0.32253 -1.17695 
AOAH 0.23719 2.59548 3.77142 
G0S2 0.23887 2.71173 4.20232 
CLEC5A 0.29979 2.56661 3.17993 
MRGPRA2B 0.38056 2.91023 3.15871 
MMP2 0.39999 -0.31145 -1.68001 
ARHGEF10 0.40613 -0.26205 -1.51029 
TMEM45A 0.40792 -1.20088 -1.94684 
DAPK2 0.40809 2.53540 3.19249 
CLDN1 0.43064 3.54242 4.50436 
TLR13 0.46468 1.95221 2.27399 
INSL3 0.47245 -1.71760 -2.32540 
CRISPLD2 0.50747 2.75375 3.59137 
PXDN 0.52917 -0.34285 -2.11940 
PILRA 0.54059 3.00280 3.25269 
MMP9 0.54581 4.53785 5.09618 
CLEC12A 0.56847 3.28905 4.50992 
CHIL4 0.60011 3.77497 4.29606 
HK3 0.63563 2.65247 3.21500 
TCTN1 0.65883 2.02166 2.65309 
WDR19 0.65945 0.09730 -1.22214 
SYNE1 0.67601 2.29392 2.34002 
CD300C2 0.69561 2.73764 2.85432 
CARD9 0.70042 2.03370 2.45362 
EPHB2 0.74538 -0.22726 -1.50182 
SCD1 0.76353 -0.44966 -1.27942 
CXCR2 0.76738 3.08616 3.51213 
OLFML2B 0.78045 3.04292 3.63823 
SEMA4A 0.78315 3.27855 3.86009 
MZB1 0.79458 -0.89632 -1.88121 
NKG7 0.83447 2.42863 3.55640 
XDH 0.85276 2.99050 3.11670 
CEACAM1 0.87454 3.36271 4.11951 
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ABCB4 0.87773 -0.15122 -0.95109 
ABCD2 0.88165 2.30374 2.83752 
6430548M08RIK 0.88856 2.84422 3.25153 
DRAM1 0.93634 2.08404 2.74806 
ATP8B4 0.97933 2.76226 3.45326 
HIST3H2BB-PS 1.00083 -0.19064 -0.86753 
PLBD1 1.00987 4.46857 4.91363 
ACPP 1.01440 2.78493 3.42760 
GPR141 1.03558 3.15304 4.02179 
GCA 1.05035 2.58798 3.23104 
H2-OB 1.05421 0.34971 -0.69101 
RANBP9 1.06408 3.59649 2.98579 
MOCOS 1.07642 2.97557 3.46232 
RUSC2 1.15650 -0.10455 -0.97495 
C1QTNF4 1.18792 -0.41500 -0.57642 
KLF5 1.19955 2.32164 3.22377 
CLEC4A2 1.24367 3.74544 4.51721 
LPCAT2 1.26832 2.82054 3.10000 
GAPT 1.27003 2.77362 3.30415 
HSD11B1 1.35263 4.20917 4.88563 
ALDH3B1 1.37179 3.51813 4.28048 
RAB44 1.37365 3.49709 4.05747 
NEDD9 1.38369 2.90534 3.30621 
3830403N18RIK 1.41822 0.59880 -1.19567 
F630028O10RIK 1.45254 3.17626 3.45718 
GPX3 1.48666 3.06217 4.19486 
CEBPE 1.49528 4.18146 5.02977 
FGR 1.49573 3.32468 3.91369 
GPC1 1.52651 3.27748 3.80296 
TNFAIP8L2 1.53992 3.12455 3.93326 
PRAM1 1.54663 4.48553 4.98308 
RGS14 1.55100 2.64309 3.37380 
AB124611 1.56009 3.87840 4.61725 
HCK 1.62094 3.65348 4.34183 
ASPRV1 1.63738 4.33271 4.79585 
KRT7 1.67114 0.28586 -1.00254 
PFKFB4 1.67547 3.02712 3.46221 
C5AR1 1.69261 4.22304 4.77385 
CCDC125 1.69964 3.13199 3.69174 
GIPR 1.70964 0.11267 -2.07223 
ARL11 1.73728 3.30936 3.48099 
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NDUFA4L2 1.74248 -1.06200 -1.15297 
PRKCB 1.74682 3.31709 4.04826 
ALOX5 1.75358 4.45500 4.99789 
MOGAT2 1.76938 4.21777 5.28219 
LRG1 1.81372 3.54261 4.32677 
PI16 1.83057 3.63095 3.86124 
MTUS1 1.83634 3.32721 3.90217 
HVCN1 1.86124 3.66997 4.33208 
SLPI 1.89833 4.87510 5.47580 
CPNE2 1.92726 3.54793 3.86043 
SLC40A1 1.94551 4.01652 4.23017 
RNF208 1.95505 1.35202 0.12945 
TREM3 1.95620 4.84481 5.22878 
EPHX1 1.95656 0.60140 -0.80208 
MS4A3 1.98402 4.18536 5.34304 
NYNRIN 1.98567 1.26117 0.01549 
LY6C1 1.98915 3.65190 4.11186 
GADD45A 1.99984 3.30322 4.00372 
PSTPIP2 2.02850 3.34699 3.92089 
DOK3 2.04636 4.46927 5.29290 
CYBB 2.04797 4.63717 4.85543 
IL20RA 2.07498 0.89682 0.36283 
RFLNB 2.09751 3.54100 3.93038 
ESPN 2.12810 0.93351 0.10994 
ADGRG3 2.15103 3.89623 4.46762 
ADGRE5 2.16189 3.99215 4.58238 
CCR1 2.16894 3.41574 4.06890 
ITGB2L 2.19061 5.15156 5.85513 
CD177 2.23784 5.73812 5.96539 
FCGR2B 2.25351 3.84925 4.44201 
GSTP3 2.31401 4.14503 4.11391 
ADM 2.33198 -0.37764 -1.59329 
SP140 2.35640 3.63698 4.10283 
CTSG 2.51709 4.71968 6.09376 
F10 2.65522 4.59829 5.30006 
MFN1 2.69619 -0.36775 -0.26592 
C3 2.71753 4.89270 4.97079 
THBS1 2.73281 4.77622 4.81105 
IGSF6 2.77655 5.19035 6.00258 
ACSL1 2.79250 4.16476 4.46606 
SLC31A2 2.80949 4.16343 4.77067 
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PIRB 2.83083 4.38291 4.66968 
SNORD23 2.83543 -3.32193 -3.32193 
CDKN3 2.95114 4.03703 4.63910 
NFAM1 2.99188 4.39534 4.70134 
LPIN1 2.99651 1.70159 0.96228 
MGST2 3.06020 5.32410 5.90174 
CD300LF 3.08170 4.77279 5.30779 
CITED1 3.09380 1.66892 0.40556 
DGAT2 3.10905 4.89337 5.65744 
MAPK13 3.10975 4.65774 5.40194 
ABTB1 3.11855 4.53925 5.08977 
STOM 3.13089 4.34519 5.03239 
LTB4R1 3.13627 5.48216 6.36750 
MCEMP1 3.19362 5.89111 6.50934 
CSF2RA 3.23195 4.44908 5.28302 
ANXA3 3.23662 5.06503 5.59304 
P4HA2 3.38188 2.43582 1.61620 
MSRB1 3.39271 4.90636 5.25788 
MGARP 3.45308 2.21205 1.01496 
FCGR3 3.57355 5.52151 6.41795 
2310003N18RIK 3.57756 0.95027 0.69478 
ADPGK 3.75782 5.12328 5.40413 
LY6C2 3.83428 6.13546 6.72557 
SNORD35B 3.88916 -3.32193 -3.32193 
MPP1 3.89019 5.07809 5.67959 
CHIL1 3.89739 6.57086 7.40041 
GM5416 3.99325 7.05069 7.21340 
PLAUR 4.02635 5.28689 6.12952 
IFITM6 4.05430 6.80636 7.26320 
RETNLG 4.06363 7.09105 7.98473 
MIR19B-1 4.13326 -3.32193 -3.32193 
PADI4 4.20282 5.63779 6.04484 
ITGAM 4.21741 5.76978 5.87918 
SERPINB1A 4.29609 6.14743 7.28650 
PLAC8 4.31242 5.95238 6.61155 
NCF4 4.37009 5.72863 6.53210 
FCNB 4.41153 6.58841 7.19052 
PNKP 4.42798 5.67159 6.29097 
HP 4.43266 6.91342 7.59998 
LYZ1 4.48055 6.69663 7.27735 
MPO 4.64145 6.91846 8.46290 
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ELANE 4.66576 6.76499 7.71719 
CD52 4.74855 6.90957 7.19615 
ITGB2 4.77154 6.14447 6.56116 
OLFM4 4.79590 7.67323 8.10765 
CHIL3 4.84241 8.12373 8.60605 
MIR5125 4.84601 -3.32193 -3.32193 
NCF1 5.17369 6.68594 7.11413 
2010005H15RIK 5.42182 8.35752 8.65696 
UPP1 5.56304 4.32301 3.75737 
LTF 5.89228 9.10777 9.61642 
WFDC21 5.92911 8.83014 9.06987 
FCER1G 6.36231 8.20128 8.78369 
STFA2 6.38750 9.43590 9.89335 
TYROBP 6.44562 8.61244 9.15812 
PGLYRP1 6.52669 8.22666 8.62613 
ANXA1 6.54059 8.73533 9.34065 
STFA2L1 6.64525 9.69482 10.12475 
LCN2 6.74264 9.72992 10.27341 
STFA3 6.75761 9.75945 10.09306 
CAMP 7.13599 10.23357 10.95016 
BC117090 7.17836 10.04382 10.55790 
GM5483 8.10428 11.02591 11.40182 
MIR1906-1 8.19715 7.36315 -3.32193 
NGP 8.26440 11.23388 11.87840 
LYZ2 8.62182 10.81875 11.41002 
STFA1 8.69482 11.66626 12.14248 
BC100530 9.32063 12.19116 12.71544 
S100A9 10.36083 13.31622 13.59314 
S100A8 10.94213 13.93340 14.24683 
 
